 CTI BioPharma Corp.  
 
 
Protocol PIX306 
(PIX-R® Trial) 
 
A Phase 3 Clinical Study of Pixantrone  
  
A Randomized Multicenter Study Comparing Pixantrone + 
Rituximab with Gemcitabine + Rituximab in Patients with 
Aggressive B -cell Non- Hodgkin Lymphoma Who Have Relapsed 
after Therapy with CHOP -R or an Equivalent Regimen and are 
Ineligible for Stem Cell Transplant  
 
 
IND 62,678  
EudraCT: 2012 -001790-86 
 
Amendment 9 
July 10, 2017 
 
 
  
 
Sponsor:  
CTI BioPharma Corp. 
3101 Western Avenue, Suite 600 Seattle, WA 98121 
 
 
 
Jack W. Singer, MD Interim CMO, Global Head of Translational Medicine  
Medical Monitor  
206-272-4402 
 
  
©CTI BioPharma Corp., all rights reserved.  This document and its contents are the property of the confidential to CTI BioPha rma Corp.  
Unauthorized copying or use of this information is prohibited. This document or information within may not be used, divulged, published or 
otherwise disclosed without the written consent of CTI BioPharma Corp.  
Page 1 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
Table of Contents  
 
Synopsis ........................................................................................................................................................................ 8  
List of Abbreviations and Acronyms  ....................................................................................................................... 19 
1 Background and Rationale  ................................................................................................................................ 22 
1.1 Overview of Relapsed/Re fractory Aggressive NHL .................................................................................. 22 
1.2 Pixantrone  .................................................................................................................................................. 23 
1.2.1  Pixantrone Clinical Studies  ......................................................................................................... 24 
1.2.1.1  Pixantrone Efficacy: Study PIX301 ........................................................................... 24 
1.2.1.2  Pixantrone Safety in Clinical Studies  ........................................................................ 25 
1.2.2  Pixantrone Nonclinical Photosensitivity Study  ........................................................................... 26 
1.3 Rituximab  .................................................................................................................................................. 26 
1.4 Gemcitabine ............................................................................................................................................... 27 
1.5 Combination Chemoimmunotherapy ......................................................................................................... 28 
1.5.1  Rationale for Pixantrone + R Combination  ................................................................................. 28 
1.5.1.1 Potential for Drug -Drug Pharmacokinetics Interactions  ............................................ 29 
1.5.2  Rationale for Gemcitabine + R Combination  .............................................................................. 29 
1.5.2.1  Potential for Drug -Drug Pharmacokinetics Interactions  ............................................ 30 
2 Study Objectives  ................................................................................................................................................. 30 
2.1 Primary Objective  ...................................................................................................................................... 30 
2.2 Secondary Objectives  ................................................................................................................................ 31 
2.3 Exploratory Objectives  .............................................................................................................................. 31 
3 Investigational Plan  ............................................................................................................................................ 32 
3.1 Overall Study Design  ................................................................................................................................. 32 
3.1.1  Participation in Treatment and Follow -up Periods  ...................................................................... 33 
3.1.2  Study Conduct  ............................................................................................................................. 34 
3.1.2.1  Independent Data Monitoring Committee  ................................................................. 34 
3.1.2.2  Study Steering Committee  ......................................................................................... 35 
3.1.2.3  Independent R adiology Committee  ........................................................................... 35 
3.1.2.4  Central Pathology Review  ......................................................................................... 36 
3.2 Discussion of Study Design  ....................................................................................................................... 36 
3.2.1  Choice of Endpoints  .................................................................................................................... 37 
3.2.2  Interim Analysis and OS Analysis  ............................................................................................... 37 
3.2.3  Choice of Dose and Schedule of Pixantrone  ............................................................................... 37 
3.3 Study Population  ........................................................................................................................................ 37 
3.3.1  Inclusion Criteria  ......................................................................................................................... 38 
3.3.2  Exclusion Criteria  ........................................................................................................................ 40 
Page 2 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
3.3.3  Completion and Discontinuation of Treatment  ........................................................................... 41 
3.4 Study Treatment ......................................................................................................................................... 42 
3.4.1  Treatment Assignment  ................................................................................................................. 42 
3.4.2  Treatment Blinding  ...................................................................................................................... 42 
3.4.3  Treatment Compliance  ................................................................................................................ 43 
3.4.4  Rituximab Preparation, Storage, and Handling  ........................................................................... 43 
3.4.5  Pixantrone Handling, Preparation, Administration, and Storage  ................................................. 43 
3.4.5.1  Handling of Pixantrone  .............................................................................................. 43 
3.4.5.2  Pixantrone Preparation and Administration  ............................................................... 43 
3.4.5.3  Storage of Pixantrone  ................................................................................................ 44 
3.4.6  Gemcitabine Preparation, Storage, Handling, and Administration  .............................................. 44 
3.5 Pixantrone Drug Accountability and Disposal  ........................................................................................... 45 
3.6 Study Drug Precautions, Dose Adjustments, and Delays  .......................................................................... 46 
3.6.1  Pixantrone Dose Modifications for Hematol ogic Toxicity  .......................................................... 47 
3.6.2  Gemcitabine Dose Modifications for Hematologic Toxicity  ....................................................... 47 
3.6.3  Gemcitabine and Pixantrone Dose Modifications for Nonhematologic Toxicity  ........................ 48 
3.6.4  Rituximab Precautions and Discontinuation  ............................................................................... 49 
3.6.4.1  Cytokine Releas e Syndrome  ...................................................................................... 49 
3.6.4.2  Hypersensitivity Reactions and Anaphylaxis  ............................................................ 50 
3.6.4.3  Progressive Multifocal Leukoencephalopathy  ........................................................... 50 
3.7 Concomitant Medications  .......................................................................................................................... 51 
3.8 Visit Schedule and Assessments  ................................................................................................................ 52 
3.8.1  Visit Schedule  .............................................................................................................................. 52 
3.8.1.1  Screening Period  ........................................................................................................ 52 
3.8.1.2  Treatment Period  ....................................................................................................... 53 
3.8.1.3  End of Treatment Visit  .............................................................................................. 54 
3.8.1.4  Follow-up Periods ...................................................................................................... 55 
3.9 Efficacy Assessment  .................................................................................................................................. 57 
3.9.1  Disease Assessment by Imaging  .................................................................................................. 57 
3.9.2  PET Scans .................................................................................................................................... 57 
3.9.3  Disease Assessment Definitions  .................................................................................................. 58 
3.9.3.1  Measurable Disease  ................................................................................................... 58 
3.9.3.2  Nonmeasurable Disease  ............................................................................................. 58 
3.9.4  Selection of Nodal and Extranodal Target Lesions  ..................................................................... 59 
3.9.5  Selection of Non -Target Lesions  ................................................................................................. 59 
3.9.6  Criteria for Response  ................................................................................................................... 59 
3.9.7  Bone Marrow Biopsy  .................................................................................................................. 62 
Page 3 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
3.9.8  Efficacy Endpoints  ...................................................................................................................... 62 
3.9.8.1  Primary Endpoint  ....................................................................................................... 62 
3.9.8.2  Secondary Endpoints  ................................................................................................. 63 
3.9.8.3  Exploratory Endpoints  ............................................................................................... 63 
3.10 Safety Assessments  .................................................................................................................................... 63 
3.10.1  Adverse Events  ............................................................................................................................ 63 
3.10.1.1  Definition of an Adverse Event  ................................................................................. 63 
3.10.1.2  Reporting Adverse Events  ......................................................................................... 64 
3.10.1.3  Criteria for Assessing Causality of Adverse Events  .................................................. 65 
3.10.2  Serious Adverse Events  ............................................................................................................... 66 
3.10.2.1  Definition of a Serious Adverse Event  ...................................................................... 66 
3.10.2.2  Reporting Serious Adverse Events  ............................................................................ 66 
3.10.3  Expedited Safety Reports  ............................................................................................................ 68 
3.10.4  Laboratory Evaluation  ................................................................................................................. 68 
3.10.4.1  Cardiac Assessment  ................................................................................................... 69 
3.10.5  Vital Signs and Physical Examination  ......................................................................................... 69 
3.10.6  ECOG Performance Status  .......................................................................................................... 69 
3.11 Pharmacokinetics Assessments (for participating sites)  ............................................................................ 70 
4 Data Management  .............................................................................................................................................. 70 
4.1 Data Collection  .......................................................................................................................................... 70 
4.2 Data Entry and Quality Control  ................................................................................................................. 70 
5 Statistical Analysis  .............................................................................................................................................. 70 
5.1 Hypotheses  ................................................................................................................................................. 71 
5.1.1  Primary Hypothesis  ..................................................................................................................... 71 
5.1.2  Secondary Hypotheses  ................................................................................................................. 71 
5.2 Variables/Time Points of Interest  .............................................................................................................. 71 
5.2.1  Primary E fficacy Variable ........................................................................................................... 71 
5.2.2  Secondary Efficacy Variables  ..................................................................................................... 71 
5.2.3  Exploratory Efficacy Variables  ................................................................................................... 72 
5.2.4  Safety Variables  .......................................................................................................................... 72 
5.3 Statistical Methods  ..................................................................................................................................... 72 
5.3.1  Analysis Populations  ................................................................................................................... 72 
5.3.1.1  Intent-To-Treat (ITT) Population  .............................................................................. 72 
5.3.1.2  Histologically Confirmed Population ........................................................................ 72 
5.3.1.3  Per-Protocol (PP) Population  ..................................................................................... 72 
5.3.1.4  Safety Population  ....................................................................................................... 72 
5.3.2  Efficacy Evaluation  ..................................................................................................................... 73 
Page 4 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
5.3.2.1  Progression -Free Survival ......................................................................................... 73 
5.3.2.2  Overall Survival  ......................................................................................................... 73 
5.3.2.3  Overall Response Rate (ORR) and Complete Response (CR) Rate  .......................... 74 
5.3.2.4  Exploratory Efficacy Variables  ................................................................................. 74 
5.3.2.5  Multiplicity  ................................................................................................................ 74 
5.3.2.6  Subgroup Analyses  .................................................................................................... 74 
5.3.3  Safety Evaluation  ........................................................................................................................ 74 
5.3.4  Pharmacokinetics Analysis  .......................................................................................................... 75 
5.4 Interim Analysis ......................................................................................................................................... 75 
5.5 Power and Sample Size Determination  ...................................................................................................... 75 
6 Ethical Considerations  ....................................................................................................................................... 76 
6.1 Informed Consent  ...................................................................................................................................... 76 
6.2 Institutional Review Board/Ethics Committee Approval  .......................................................................... 76 
6.3 Patient Privacy  ........................................................................................................................................... 77 
7 Study Administration  ......................................................................................................................................... 77 
7.1 Good Clinical Practice and Regulatory Requirements  ............................................................................... 77 
7.2 Quality Assurance Procedures  ................................................................................................................... 77 
7.3 Changes to the Protocol  ............................................................................................................................. 77 
7.4 Site Training and Monitoring Procedures  .................................................................................................. 78 
7.5 Record Retention  ....................................................................................................................................... 78 
7.6 Financing and Insurance  ............................................................................................................................ 78 
7.6.1  Financial Disclosure  .................................................................................................................... 78 
7.7 Publication Policy  ...................................................................................................................................... 79 
8 Appendices  .......................................................................................................................................................... 79 
8.1 International Prognostic Index (IPI) Score Calculation  ............................................................................. 79 
8.2 ECOG Performance Status Grades and Definitions ................................................................................... 80 
8.3 Ann Arbor Staging System  ........................................................................................................................ 80 
8.4 New York Heart Association Functional Classification  ............................................................................ 80 
8.5 Anthracycline/Anthracenedione Equivalent Doses .................................................................................... 81 
8.6 Evaluation of Target and Non -target Lesions  ............................................................................................ 81 
8.6.1 Baseline Target Lesion Evaluation  .............................................................................................. 81 
8.6.2  All Subsequent Target Lesion Evaluations  .................................................................................. 81 
8.6.3  Baseline and Post -Baseline Non -target Lesion Evaluations  ........................................................ 82 
9 Investigator Responsibilities, Required Documentation, and Signature  ....................................................... 83 
10 Document History  ............................................................................................................................................... 84 
11 References  ........................................................................................................................................................... 85 
12 Addendum: Pharmacokinetics Sub-Study ....................................................................................................... 87 
Page 5 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
12.1 Background  ................................................................................................................................................ 87 
12.2 Objective of Pharmacokinetics Sub -Study ................................................................................................ 87 
12.3 Pharmacokinetics Sub-Study Population  ................................................................................................... 88 
12.4 Pharmacokinetics Sub -Study Assessment  ................................................................................................. 88 
12.4.1  PK Sampling  Schedule ................................................................................................................ 88 
12.4.2  Adverse Events During PK Sampling ......................................................................................... 89 
12.5 Sample Collection and Handling Procedures  ............................................................................................. 89 
12.6 PK Analysis ............................................................................................................................................... 89 
12.7 Pharmacokinetics Sub -Study Ethical Considerations  ................................................................................ 90 
 
Page 6 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
Table of Tables  
 
Table--1 Screening and Treatment Period  ................................................................................................................... 16 
Table--2 Follow-up Periods  ......................................................................................................................................... 17 
Table--3 Response Rates in Protocol PIX301 Patients, N (%)  .................................................................................... 24 
Table--4 Chemoimmunotherapy Studies with Gemcitabine and/or Rituximab  ........................................................... 28 
Table--5 Protocol PIX306 Treatment Regimens  ......................................................................................................... 42 
Table--6 Pixantrone Dose Modifications for Reduced ANC and Infection  ................................................................. 47 
Table--7 Pixantrone Dose Modifications for Platelet Counts  ...................................................................................... 47 
Table--8 Gemcitabine Dose Modifications for ANC and Platelet Counts  ................................................................... 48 
Table--9 Pixantrone and Gemcitabine Dose Levels  .................................................................................................... 49 
Table--10 Disease Assessment Definitions  ................................................................................................................. 59 
Table--11 Modified IWG 2007 Revised Response Criteria for Malignant Lymphoma  .............................................. 61 
Table--12 Event and Censoring Rules for Progression -Free Survival Analysis  .......................................................... 73 
Table--13 Stopping Parameters Based on the Potential Number of Events  ................................................................. 75 
Table--14 Sample Collection Times for Pharmacokinetic Evaluation ......................................................................... 88 
 
Table of Figures  
 
Figure--1 Pixantrone Dimaleate Chemical Structure and Molecular Weight  .............................................................. 23 
Figure--2 PIX301 Progression -Free Survival (End of Study) ...................................................................................... 25 
Figure--3 Study Flow Chart  ......................................................................................................................................... 32 
 
Page 7 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
Synopsis 
 
Study Title  A Randomized, Multicenter Study Comparing Pixantrone + Rituximab with 
Gemcitabine + Rituximab in Patients with Aggressive B -cell Non-Hodgkin 
Lymphoma Who Have Relapsed after Therapy with CHOP -R or an 
Equivalent Regimen and are Ineligible for Stem Cell Transplant  
Study No.  PIX306 
Name of Sponsor  CTI BioPharma Corp. 
Phase of Development  3 
Investigational Drug Pixantrone  
Study Objectives  Primary Objective  
The primary objective of this study is to evaluate the efficacy (as measured by progression -free survival [PFS]) of pixantrone + rituximab 
(pixantrone + R) compared with gemcitabine + rituxim ab (gemcitabine + R) 
in patients with a diagnosis of de novo diffuse large B- cell lymphoma 
(DLBCL), DLBCL transformed from indolent lymphoma, or follicular grade 
3 lymphoma who have relapsed after at least 1 prior chemotherapy regimen  
and who are currently ineligible for high -dose (myeloablative) chemotherapy 
and stem cell transplant (SCT).  
 
Secondary Objectives  
To compare the two treatment arms with regard to the following secondary 
endpoints: 
 
• Overall survival (OS)  
• Overall response rate (ORR)  
• Complete res ponse (CR) rate  
• Safety 
 
Exploratory Objectives 
 
• Assess the duration of overall response between treatments  
• Assess the duration of complete response (CR) between treatments  
• Determine the proportion of randomized patients who receive an SCT 
after study trea tment 
 
Pharmacokinetics Sub -Study Objective  
(participating sites refer to Section 12 Addendum: Pharmacokinetics Sub-
Study)  
 
• To characterize the PK profile of pixantrone when co- administered with 
rituximab 
 
Study Design This is a randomized, active-controlled, multicenter, phase 3 study evaluating 
the objectives described above.  
 
Page 8 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
Eligible patients will be randomized to receive up to six 28 -day cycles of 
treatment with pixantrone + R, or gemcitabine + R. Details of the treatment 
period are presented in Table--1.  
 Patients who complete study treatment or discontinue study treatment for any 
other reason will participate in the follow-up periods described below. At the 
time patients experience progressive disease per Modified IWG criteria 
during Study Treatment, or Early or Intermediate Follow-up, or withdraw 
consent for study procedures, they enter the Survival Follow-up Period. 
Patients who begin a subsequent systemic anticancer therapy, except for 
rituximab given as maintenance therapy, will enter the Survival Follow -up 
Period. Details of assessments in the follow -up periods are found in Table--2. 
 Early Follow- up: After treatment completion or discontinuation, patients will 
enter a 24 -week follow- up period.  
 
Intermediate Follow -up: After completing the 24 -week Early Follow -up 
period, patients will enter an additional 72- week follow -up period. 
 Survival Follow -up: All patients will b e monitored for survival.  
 
The sample size for this trial is based on the number of PFS events (per IRC).  
Approximately 320 patients are planned to be randomized in a 1:1 ratio to one of the two treatment arms to reach the required number of PFS events. 
The randomization will be stratified by number of prior therapies for DLBCL 
or follicular grade 3 lymphoma (0 -2 vs ≥ 3), International Prognostic Index 
(IPI) score (0 -2, ≥ 3), and length of time from initiation of first- line therapy 
for DLBCL or follicular grade  3 lymphoma until first relapse (<  1 year vs 
≥ 1 
year). 
Enrollment Period  Approximately 80 months from study initiation  
Study Population  Eligible patients are patients with a current d iagnosis of DLBCL (de novo 
DLBCL or DLBCL transformed from indolent lymphoma) or follicular grade 3 lymphoma on the basis of a tissue biopsy, who are not currently 
eligible for high -dose (myeloablative) chemotherapy and SCT and who have 
relapsed after at least 1 prior chemotherapy regimen.  
 
• Patients with de novo DLBCL must have received 1 -3 prior regimens for 
DLBCL  
• Patients with follicular grade 3 lymphoma must have received 1 -3 prior 
regimens for follicular lymphoma (any grade)   
• Patients with DLBCL transformed from indolent lymphoma must have 
received 1 -4 prior regimens for NHL (any type)  
 
Patients must have received at least one rituximab -containing multi- agent 
regimen and must have had no progression for at least 12 weeks after last dose of a treatment regimen (see Section  3.4
 for details). Patients must have 
at least one bidimensionally measurable site of disease that has not been 
previously irradiated : nodal disease ≥ 1.5 cm in short axis or extranodal 
disease > 1.0 cm in short axis. Lesion must be PET positive if PET scan is 
Page 9 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
obtained.  
 
Additional requirements include  left ventricular ejection fraction (LVEF) 
≥ 45% by echocardiogram. 
Planned No. of Patients  Approximately 320 patients are planned to be randomized in a 1:1 ratio to 
one of the two treatment arms. Enrollment will continue until 195 PFS events 
(per IRC response assessments)  occur. 
Test Product, Dose, 
and Mode of 
Administration Pixantrone + R: rituximab 375 mg/m2 IV on Day 1 and pixantrone 50 mg/m2 
IV on Days 1, 8, and 15. 
Reference Therapy, 
Dose, and Mode of 
Administration  Gemcitabine + R: rituximab 375 mg/m2 IV on Day 1, and gemcitabine 
1000 mg/m2 IV on Days 1, 8, and 15. 
Treatment Regimen  Pixantrone + R : rituximab 375 mg/m2 IV on Day 1 and pixantrone 50 mg/m2 
IV on Days 1, 8, and 15. The drug is supplied in vials, each containing 29 mg pixantrone.  Regimen is given in 28- day cycles. Up to 6 cycles may be 
administered. 
 
Gemcitabine + R : rituximab 375 mg/m2 IV on Day 1 and gemcitabine 
1000 mg/m2 IV on Days 1, 8, and 15. Regimen is given in 28- day cycles. Up 
to 6 cycles may be administered.  
 
Patients who must discontinue pixantrone or gemcitabine due to toxicity may 
remain on rituximab every 28 days to complete up to 6 total cycles of study 
treatment. Patients who must discontinue rituximab due to toxicity may remain on gemcitabine or pixantrone to complete up to 6 total cycles of study treatment.  
 
Inclusion Criteria  The study’s inclusion criteria include the following:  
 1. Signed Institutional Review Board or Institutional Ethics Committee -
approved Informed Consent Form  
2. Age ≥ 18 years old  
3. Diagnosis of DLBCL (de novo DLBCL, or DLBCL transformed from indolent lymphoma) or follicular grade 3 lymphoma on the basis of a tissue biopsy  
4. Pathology and immunohistochemistry reports documenting the current histological diagnosis acco rding to World Health Organization (WHO) 
classification must be reviewed by the sponsor or designee prior to randomization 
5. Number of prior therapies allowed:  
a. Patients with de novo DLBCL must have received 1 -3 prior 
regimens for DLBCL  
b. Patients with follicul ar grade 3 lymphoma must have received 1 -
3 prior regimens for follicular lymphoma (any grade)  
c. Patients with DLBCL transformed from indolent lymphoma must have received 1 -4 prior regimens for NHL (any type) 
The salvage combination therapy used to achieve a  response in 
Page 10 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
preparation for possible SCT (eg, R -ICE, R -ESHAP, or R -DHAP), along 
with the subsequent high-dose myeloablative therapy (eg, BEAM) and 
SCT, is counted as a single regimen. 
 Maintenance therapy with rituximab or similar agents, single-agent 
corticosteroids, and local radiation therapy are not counted  as treatment 
regimens.  
 6. Received a rituximab -containing multi-agent regimen (eg, rituximab, 
cyclophosphamide, doxorubicin, vincristine, prednisone [R- CHOP]; 
rituximab, cyclophosphamide, vincristine, prednisone [R- CVP]; or  
bendamustine- R)  
7. Patients with DLBCL transformed from indolent lymphoma must have had a complete or partial response to a therapy for NHL lasting at least 
12 weeks 
8. Not eligible for high -dose (myeloablative) chemotherapy and SCT. 
Patients not eligible for SCT include those who:  
a. Relapsed after previous SCT  
b. Did not respond to a standard salvage regimen 
c. Did not mobilize an adequate number of stem cells for SCT  
d. Are unsuitable for SCT due to other medical conditions or age 
e. Do not wish to undergo SCT  
f. Have financial issues precluding SCT  
g. Are considered by the investigator as unsuitable for SCT for 
any other reason  
9. At least 28 days from completion of last NHL therapy to randomization 
10. At least one bidimensionally measurable site of disease that has not been 
previously irradiated: nodal disease ≥ 1.5 cm in short axis or extranodal 
disease > 1.0 cm in short axis. Lesion must be PET positive if PET scan is obtained.  
11. Slides confirming diagnosis of follicular grade 3 lymphoma or DLBCL available for independent histology review  
12. Eastern Cooperative O ncology Group (ECOG) performance status (PS) 
≤ 2 (Section 8.2)  
13. Life expectancy ≥ 12 weeks in investigator’s judgment  
14. Left ventricular ejection fraction (LVEF) ≥ 45% by echocardiogram and normal serum troponin T 
15. Hemoglobin ≥ 8 g/dL (can be post-transfusion)  
16. Platelet count ≥ 100 × 10
9/L; platelet count ≥ 75 × 109/L permitted if 
documented bone marrow involvement  
17. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L; ANC ≥ 1.0 × 109/L 
permitted if documented bone marrow involvement  
18. Serum bilirubin ≤ 1.5 × upper limit of normal (ULN); patients with proven Gilbert’s syndrome and bilirubin ≤ 5 × ULN may be enrolled. 
19. Aspartate aminotransferase (AST; also called serum glutamic -oxaloacetic 
Page 11 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
transaminase [SGOT]) and alanine amino transferase (ALT; also called 
serum glutamic- pyruvic transaminase [SGPT]) ≤  2 × ULN, or ≤ 5 × ULN 
if elevation is due to hepatic involvement by lymphoma 
20. Serum creatinine ≤  2 × ULN  
21. All acute toxicities related to prior treatment recovered to grade ≤ 1, 
except alopecia  
22. Willingness and ability to comply with the visit schedule and assessments required by the study protocol 
23. Due to the long retention time of rituximab in B cell- depleted patients, 
both males and females must agree to use effective birth control. Women 
of childbearing potential (WOCBP) must use highly effective methods 
(defined as those resulting in a failure rate of <  1% per year when used 
consistently and correctly) for the duration of study treatment and for 
12 months after last dose of study dr ug.  The contraceptive methods that 
are considered highly effective are intrauterine devices and hormonal contraceptives (contraceptive pills, implants, transdermal patches, 
hormonal vaginal devices, or injections with prolonged release). 
 
Exclusion Crite ria The study’s exclusion criteria include the following:  
 
1. Any of the following as the only site(s) of disease: palpable lymph nodes 
not visible on imaging studies, skin lesions, or bone marrow involvement 
only 
2. Primary refractory de novo DLBCL or primary refractory follicular grade 3 lymphoma, defined as documented progression within 12 weeks 
of the last cycle of the first -line multi- agent regimen  
3. Prior treatment with a cumulative dose of doxorubicin or equivalent exceeding 450 mg/m² (see Section 8.5 for formula)  
4. LVEF < 45% by echocardiogram 
5. Active National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 3/4 infection 
6. Major surgery ≤  28 days prior to randomization  
7. Known acute or chronic hepatitis B or hepatitis C virus infection  
8. Known seropositivity for human immunodeficiency virus (HIV) 
9. Current CNS involvement by lymphoma 
a. Any history or evidence of current leptomeninge al involvement by 
lymphoma is prohibited. 
b. Patients with prior localized CNS involvement who have been 
without recurrence for ≥ 12 months and currently have a negative 
head MRI may be eligible; please discuss with the Medical Monitor.  
10. Any experimental therapy ≤ 28 days prior to randomization 
11. Myocardial infarction within the past 6 months 
12. New York Heart Association class III or IV heart disease (Section  8.4) 
13. Other malignancy within the last 5 years. Exceptions are:   
a. Curatively treated basal cell/squamous cell skin cancer  
Page 12 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
b. Carcinoma in situ of the cervix  
c. Superficial transitional cell bladder carcinoma 
d. In situ ductal carcinoma of the breast after complete resection  
e. Localized, resected and/or low- risk prostate cancer may be eligible; 
please discuss with the Medical Monitor  
14. Any contraindication, known allergy, or hypersensitivity to any study 
drugs 
15. Pregnant or lactating  
16. Concomitant therapy with any anticancer agents, immunosuppressive agents, other investigational anticancer therapies. Low -dose 
corticosteroids for the treatment of non -cancer-related illnesses are 
permitted  
17. Any psychological, familial, sociological, or geographical condition 
potentially hampering compliance with the study procedures or follow-up 
schedules 
18. Severe and/or uncontrolled medical disease that could compromise participation in the study, or any medical or psychiatric condition that, in 
the opinion of the investigator, would make study drug administration hazardous or obscure the interpretation of  data. 
 
Schedule of Treatment 
and Assessments  • All treatment cycles are 28 days.  
• Three (3) days is the maximum visit delay allowable for nonmedical 
reasons (eg, scheduling problems, holidays) during a 28- day treatment 
cycle. Visit delays >  3 days for nonme dical reasons may be permitted 
with prior Medical Monitor approval. See Section 3.6 for details of dose 
adjustments and treatment delays.  
• Disease response is assessed by imaging every 8 weeks ± 1 week during the Treatment and Early Follow-up periods, and every 12 weeks ±  2 
weeks during Intermediate Follow- up. All time points for disease 
assessment are calculated from Day 1 of Cycle 1. If an assessment is 
done off schedule, the next assessment should be calibrated  as closely as 
possible back to the original schedule starting at Day 1 Cycle 1.  
• The EOT visit occurs at 4 to 7 weeks (inclusive) after the last dose of 
study drug, or before subsequent systemic anticancer therapy is given, 
whichever occurs first. Rituximab given as maintenance therapy is not 
allowed prior to the EOT visit per protocol window.  
• A patient who develops progressive disease per Modified IWG criteria during the Treatment, Early Follow-Up or Intermediate Follow-up 
periods, or begins subsequent sys temic anticancer therapy, except for 
rituximab given as maintenance therapy, enters the Survival Follow -up 
Period.  
• A patient who discontinues study treatment without meeting Modified IWG criteria for progression will enter the Early Follow -up period and 
will continue to have imaging assessments per protocol, until developing 
progressive disease per Modified IWG criteria or beginning subsequent 
systemic anticancer therapy, except for rituximab given as maintenance 
therapy, at which point the patient will en ter the Survival Follow -up 
Page 13 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
period. 
• A patient who is randomized, but not treated, will immediately enter the 
Early Follow -Up period.  
• A patient who withdraws consent for study procedures will enter the Survival Follow-up period. 
• End-of-Study (EOS) is defined as the date when the required OS events 
have occurred or the study is terminated.  
• See Table--1 for screening and treatment details, and  Table--2 for 
information on the fo llow-up periods. 
 
Criteria for Evaluation  Efficacy Evaluation  
 
Disease Response Assessment  
The Modified IWG 2007 Revised Response Criteria used in this study are 
detailed in Table--11. Baseline disease assessment of the neck, chest, 
abdomen, and pelvis is required. Computed tomography (CT) with 
intravenous (IV) contrast is the preferred imaging modality, but patients 
intolerant of CT IV contrast may have MRI of the neck, abdomen, and pelvis 
with noncontrast chest C T (see Section 3.9.1). The imaging method used at 
baseline must be used throughout the study. All scans obtained during the course of the study will be reviewed by an Independent Radiology Committee (IRC), whose members will be blinded to treatment assignment. Baseline 
positron emission tomography (PET) is not required, but PET images 
obtained at baseline or during the study are to be submitted. PET/CT images 
should not typically be used for lesion measurements, unless the CT images 
are obtained using optimal CT imaging protocols in a fashion consistent with 
other study CT imaging time points (ie, similar imaging energies and use of 
IV contrast). If a PET scan is obtained at baseline, all sites of disease selected  
as target lesions must be PET positive. An end -of-treatment (EOT) PET scan 
is required, unless it is geographically unavailable, the patient has progressive 
disease per Modified IWG criteria, or the patient has started subsequent systemic anticancer therapy, except for rituximab given as maintenance 
therapy. 
 
Regardless of whether serum samples, radiologic material, and other patient 
data are sent to a central lab or an independent review panel for study purposes, treatment and eligibility decisions must be made by the investigator 
based on his or her clinical assessment of the patient and interpretation of local labs, radiology assessments, and other tests.  
 
Survival  
Survival status will be recorded at each scheduled visit during treatment and 
follow-up periods until the end of the study. 
 
Safety Evaluation  
Safety will be assessed in all randomized patients by monitoring and 
recording all adverse events (AEs), serious adverse events (SAEs), cardiac, 
Page 14 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
hematologic and blood chemistry parameters, vital signs , performance status 
(PS), and any abnormal findings observed during the performance of physical 
examinations. 
 
• Safety measurements 
• Adverse events  
• Clinical labs  
• Physical examinations  
• Cardiac assessments (serial LVEF evaluations by echocardiogram and 
serum troponin T)  
Statistical Methods and 
Analyses The primary efficacy endpoint of the study is PFS, defined as the time from 
the date of randomization to the date of disease progression or death due to 
any cause (whichever occurs first). The primary analysis of PFS will use 
disease progression, assessed by the IRC. The stratified log -rank test will be 
used for the primary analysis comparing PFS between the two treatment arms 
based on the intent- to-treat population. The secondary efficacy endpoints are 
OS, ORR , and CR rate. 
 
One hundred ninety- five (195) PFS events are required to detect at least a 
35% improvement (ie, HR = 0.65) in PFS with 85% power. Based on updated study projections, i t is estimated  that approximately 320 patients are needed 
to reach the 19 5 PFS events .  
 
Page 15 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
Table--1 
Screening and Treatment Period  
 Screening/  
Baseline Cycle 1 Cycles 2-6 
EOT14 Day -28 to 
Randomi -
zation Day 1 Day 8 Day 
15 Day 1 Day 8 Day 15 
Wk 1 Wk 2 Wk 3  
Informed consent  X        
Path samp le to central lab; report to sponsor 0 X        
Medical history and eligibility review  X        
NHL treatment and history, IPI, staging  X        
Randomization ≤ 14 days prior to first dose1 X        
Safety Assessment  
CBC with differential2,3 X X X X X X X X 
Chemistry panel (including LDH)2,4 X X   X   X 
Urinalysis  X        
Vital signs (before drug administration)  X X X X X X X X 
Weight and EC OG PS 3 X X   X   X 
Physical examination5 X X X X X X X X 
Pregnancy test 6(WOCBP only)  X X   X    
Adverse events 13 X X X X X X X X 
Concomitant medications 7 X X X X X X X X 
Cardiac Assessment  
LVEF by echo 8 X    X8 X 
ECG  X  X 
Serum troponin T8 X    X8 X 
Pharmacokinetics Assessments (participating sites see Section  12.4.1) 
Treatment Administration  Pix + R Rituximab 375 mg/m2 IV  X   X    
Pixantrone 50 mg/m2 IV9  X X X X X X  Gem + R  
Rituximab 375 m g/m2 IV  X   X    
Gemcitabine 1000 mg/m2 IV  X X X X X X  
Disease Assessment  
 Screening/  
Baseline 
Day -28 to Randomi -
zation Wk 8 
(± 1 Wk)  Wk 16 
(± 1 Wk)  Wk 24 
(± 1 Wk)  EOT14 
CT scan 10 X X X X  
PET scan 11     X 
Bone marrow biopsy with core12     X 
Page 16 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
Table--2 
Follow-up Periods  
 Early Follow -up15 
(± 1 Week)  Intermediate Follow -up 
(± 2 Weeks)  Survival Follow -up 
(± 2 Weeks)  
 
FU 
Wk 
8 FU 
Wk 
16 FU 
Wk 
24 FU 
Wk 
36 FU 
Wk 
48 FU 
Wk 
60 FU 
Wk 
72 FU 
Wk 
84 FU 
Wk 
96 Every 12 
Wks Until 
Death or 
Study 
Termination  EOS 
Adverse events13 X 
LVEF by echo8   X         
Troponin T8   X         
CT scan10 X X X X X X X X X   
LDH X X X X X X X X X   
Documentation 
of all subsequent systemic anti -
cancer therapy  X X X X X X X X X   
Survival X X X X X X X X X X X 
Abbreviations:  
AEs = adverse events  CBC = complete blood count  CR = complete response 
CT = computed tomography  DLBCL = diffuse large B -cell lymphoma  ECG = electrocardiogram 
ECOG = Eastern Cooperative Oncology Group EOS = end of study  
EOT = en d of treatment, at 4 to 7 weeks after last study drug dose, inclusive  FU = follow -up 
IPI = International Prognostic Index  IV = intravenous(ly)  LDH = lactate dehydrogenase  
LVEF = left ventricular ejection fraction  mg/m2 = milligrams per square meter  MRI = magnetic resonance 
imagingNHL = non-Hodgkin lymphoma  PD = progressive disease  PET = positron emission tomography  
PS = performance status  wk(s) = week(s)  R = rituximab  
WOCBP = women of childbearing potential.  
 
Footnotes for  Table--1 and Table--2 
0 Pathology and immunohistochemistry reports documenting a current diagnosis of DLBCL (de novo DLBCL or DLBCL transformed from indolent lymphoma) or follicular grade 3 lymphoma must be  reviewed by sponsor or designee prior to 
randomization. Tissue slides should be requested during the screening period for central review, but completion of central review is not required prior to randomization and treatment.  
1 All screening procedures to  determine eligibility must be completed prior to randomization.  
2 Chemistry and hematology labs are evaluated locally to direct patient treatment and determine eligibility; samples are also 
sent to central laboratory for study analysis. Dose delays may re quire that both local and central labs are redrawn.  
3 ≤ 1 day before study drug administration; no time parameter at EOT visit (at 4 to 7 weeks after last study drug dose, 
inclusive); see Section 8.2 for ECOG PS grades  and definitions).  
4 ≤ 7 days before study drug administration; no time parameter at EOT visit (at 4 to 7 weeks after last study drug dose, 
inclusive).  
5 Physical examination required ≤ 3 days prior to Day 1 study drug administration for Cycles 2-6 and at EOT (at 4 to 7 weeks 
after last study drug dose, inclusive). Symptom -directed examination as needed ≤ 1 day before study drug administration on 
Day 1 Cycle 1 and Days 8 and 15 of all cycles.  
6 Pregnancy test (WOCBP only) ≤ 1 day before study drug administ ration; serum test at screening; urine test permitted at all 
other time points.  
7 If used, colony -stimulating factors must be discontinued ≥ 2 days prior to next scheduled drug administration. If Neulasta 
(pegfilgrastim) is used, it should be given only af ter the Day 15 dose.  
8 LVEF ≥ 45% by echocardiogram and normal troponin T test results are required for eligibility. LVEF is then done ≤ 7 days 
before expected Day 1 of Cycles 3 and 5 and at Follow -up Week 24; troponin T samples are obtained before Cycles  3 and 5 
and at Follow -up Week 24. Echocardiogram and troponin T need not be repeated, if a dose is delayed for reasons other than 
abnormal LVEF (see Section  3.10.4).  
9 The drug is supplied in vials each contai ning 29 mg pixantrone.  
10 CT with IV contrast of the neck, chest, abdomen, and pelvis. Patients intolerant of IV contrast will have MRI and noncontrast  
CT (see Section  3.9.1) and the reason for not using contras t specified in source documents. The imaging method used at 
Page 17 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
Table--2 
Follow-up Periods  
 Early Follow -up15 
(± 1 Week)  Intermediate Follow -up 
(± 2 Weeks)  Survival Follow -up 
(± 2 Weeks)  
 
FU 
Wk 
8 FU 
Wk 
16 FU 
Wk 
24 FU 
Wk 
36 FU 
Wk 
48 FU 
Wk 
60 FU 
Wk 
72 FU 
Wk 
84 FU 
Wk 
96 Every 12 
Wks Until 
Death or 
Study 
Termination  EOS 
baseline must be used throughout the study. All time points for CT/MRI are calculated from Day 1 Cycle 1. If an assessment 
is done off schedule, the next assessment should be calibrated as closely  as possible back to the original schedule starting at 
Day 1 Cycle 1.  
11 PET scan may be obtained alone or in combination with CT scan. PET scan is not required at baseline, but any PET images 
obtained at baseline or during the study are to be submitted for central review. PET scan is required at EOT visit, unless geographically unavailable, patient has PD per Modified IWG criteria, or patient has started subsequent systemic anticancer therapy, except for rituximab given as maintenance therapy.  
12 A bone marrow biopsy (with core) is required at EOT (at 4 to 7 weeks after last study drug dose, inclusive) to confirm a CR, 
unless a bone marrow biopsy was obtained at baseline and was negative. All bone marrow biopsies obtained during the study 
should be submitte d for local review.  
13 For randomized patients, study -drug related AEs and cardiac AEs ≥ grade 3, including LVEF declines, are collected and 
followed until resolution or no further improvement is expected or EOS, and AEs not related to study drug and cardi ac AEs 
≤ grade 2 are collected and followed for 30 days after the last dose of study drug, or until no further improvement is 
expected, or until the patient begins a subsequent systemic anticancer therapy,  except for rituximab given as maintenance 
therapy, whichever occurs first.  
14 The EOT visit occurs at 4 to 7 weeks, inclusive, after the last dose of study drug is administered (or was scheduled to be administered), or before subsequent systemic anticancer therapy is given, whichever occurs first. Rituxim ab given as 
maintenance therapy is not allowed prior to the EOT visit per protocol window. However, even if rituximab is given as maintenance therapy prior to EOT, all EOT procedures, including PET, will be performed. In the unanticipated event that a patient is randomized, but receives no study treatment, no EOT procedures are required and the patient would continue per 
protocol Section 3.8.1.4. 
15 The Early FU Week 8 visit occurs 8 weeks after the last protocol  calendar scheduled CT/MRI imaging disease assessment to 
ensure an 8 -week interval between protocol calendar scheduled scans. In the case of CT/MRI imaging done outside the 
calendar schedule (unscheduled), consult with Medical Monitor for appropriate sched uling of the next CT/MRI.  
 
Page 18 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
List of Abbreviations and Acronyms 
AE adverse event  
ALT alanine aminotransferase  
AML acute myeloid leukemia 
ANC absolute neutrophil count 
aSCT autologous stem cell transplant  
AST aspartate aminotransferase  
BSA body surf ace area 
CBC complete blood count  
CDC clinical document control  
CFR Code of Federal Regulations  
CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone 
CHOP-R cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab 
CHF congestive heart failure  
CR complete response  
CRA clinical research associate  
CRF case report form  
CRO contract research organization  
CRu complete response unconfirmed  
CT computed tomography 
CTCAE Common Terminology Criteria for Adverse Events 
CTI CTI BioPharma Corp. 
dFdCDP gemcitabine diphosphate 
dFdCTP gemcitabine triphosphate  
DLBCL diffuse large B -cell lymphoma  
DLT dose-limiting toxicity  
DNA deoxyribonucleic acid 
EC Ethics Committee  
ECG electrocardiogram  
ECOG Eastern Cooperative Oncology Group  
eCRF electronic case report form  
EDC electronic data capture 
EF ejection fraction  
EOS end of study  
EOT end of treatment  
Page 19 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
List of Abbreviations and Acronyms 
EPOCH etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone 
ESR expedited safety report  
EU European Union 
FDA Food and Drug Administration 
FDG 2-deoxy-2- [18F]fluoro -D-glucose 
FU follow-up 
GCP Good Clinical Practice  
GVHD graft-versus-host disease  
HDC high-dose chemotherapy 
HIV human immunodeficiency virus 
HR hazard ratio  
IB investigator brochure 
IC50 50% inhibitory concentration 
IDMC Independent Data Monitoring Committee 
IEC Independent Ethics Committee 
IND Investigational New Drug  
INR international normalized ratio 
IPI International Prognostic Index 
IRB Institutional Review Board  
IRC Independent Radiology  Committee  
ITT intent-to-treat 
IV intravenous(ly) 
IWG International Working Group  
LDi longest diameter of a measurable lesion  
LVEF left ventricular ejection fraction  
MDS myelodysplastic syndrome  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI magnetic resonance imaging  
NCCN National Comprehensive Cancer Network  
NHL non-Hodgkin lymphoma  
NYHA New York Heart Association  
ORR overall response rate  
OS overall survival  
PD progressive disease  
Page 20 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
List of Abbreviations and Acronyms 
PET positron emission tomography 
PFS progression- free survival  
PK pharmacokinetic(s)  
PML progressive multifocal leukoencephalopathy 
PP per protocol 
PPD product of the perpendicular diameters 
PR partial response  
PS performance status  
QA quality assurance 
R rituximab 
R-CVP rituximab, cyclophosphamide, vincristine, prednisone 
R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone 
RR response rate  
r/r relapsed/refractory  
SAE serious adverse event  
SAP statistical analysis plan  
SCID severe combined immunodefic iency disease  
SCT stem cell transplant  
SD stable disease   
SDi short diameter; the longest diameter perpendicular to the LDi  
SGOT serum glutamic- oxaloacetic transaminase (obsolete, see AST)  
SGPT serum glutamic- pyruvic transaminase (obsolete, see ALT)  
SOC system organ class  
SPD sum of the products of the perpendicular diameters  
SSC Study Steering Committee  
SUSAR  suspected unexpected serious adverse reaction  
TLS tumor lysis syndrome 
TTP time to tumor progression 
ULN upper limits of normal 
WHO World Health Organization 
wk(s) week(s) 
WOCBP women of childbearing potential 
 
Page 21 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
1 Background and Rationale  
 
1.1 Overview of Relapsed/Refractory Aggressive NHL 
 
Non-Hodgkin lymphomas (NHLs) are the 7th-most-common type of cancer, with an estimated annual 
incidence of 70,800 new patients in the United States in 2014 (1). Aggressive NHL comprises 60% of all 
NHL, and diffuse large B -cell lymphoma (DLBCL) is the most common subtype, accounting for 75% of 
all aggressive v arieties. Regardless of histology, survival for patients with aggressive NHL is brief 
without intensive chemotherapy or chemoimmunotherapy(2). 
 
Anthracycline -based regimens have long been the standard of care fr ont-line therapy in patients with 
aggressive NHL, with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) possessing 
the best combination of efficacy and tolerability(3). CHOP was the prevailing i nternational regimen until 
2006 in the USA and 2007 in Western Europe, when the addition of rituximab made CHOP- R the 
standard front- line chemotherapy for DLBCL(4). 
 While a substantial number of patients with a ggressive NHL obtain a durable response with 
anthracycline-containing first-line regimens, 30% to 50% relapse or prove to be refractory to initial 
therapy. Following relapse to initial therapy, a high- dose myeloablative regimen followed by stem cell 
transplant (SCT) is a potential curative option for patients who can tolerate the procedure.  
 
However, the 3- year disease- free survival for SCT -eligible patients in first relapse after standard front-
line therapy with CHOP -R is only approximately 20%, and the m edian progression -free survival (PFS) is 
6.5 months
(5). A substantial number of relapsed patients do not receive SCT because of comorbidities, 
advanced age, patient choice, or failure to have a major response to  second-line therapy(5, 6). Eighty-
percent of patients who receive second -line therapy experience disease progression. Among patients who 
are not candidates for SCT o r who relapse following second- line regimens, response rates are low, 
complete remissions are rare, and expected survival is less than 6 months.  
 There is no standard or consensus treatment for patients with relapsed/refractory aggressive NHL beyond 
second-line treatment regimens. Retreatment with anthracyclines is generally precluded, due to the risk of 
cardiac toxicity that increases with the cumulative dose
(7). By the time of first relapse, most patients have 
received 300 to 400 mg/m2 doxorubicin -equivalent cumulative dose, and thus are already near the 
recommended lifetime limit of 450  mg/m2 (400 mg/m2 doxorubicin-equivalent if cyclophosphamide or 
thoracic radiation was previously given)(8). 
 
In the second- line setting for patients who are not transplant eligible, NCCN guidelines recommend 
single-agent rituximab, lenalidomide, clinical trial participation, or intensive multi- agent regimens (ie, 
EPOCH, CEPP) if the pa tient can tolerate the high incidence of grades 3 to 4 toxicities associated with 
such regimens. For patients who relapse after, or are refractory to, second-line therapy, there is no 
approved therapy in the US or EU, and NCCN guidelines recommend palliati ve care or participation in a 
clinical trial.  
 
The lack of consensus regarding treatment of patients with relapsed/refractory NHL and the paucity of 
robust data supporting current clinical practices clearly demonstrate a need for controlled trials in this setting to define an effective therapy for the unmet medical need in this patient population. Pixantrone 
may offer a more effective alternative to the diverse therapies currently in use.  
 
Page 22 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
1.2 Pixantrone  
 
Pixantrone is a novel aza-anthracenedione compound rel ated to anthracyclines and anthracenediones, 
such as doxorubicin and mitoxantrone, classes of drugs whose antineoplastic activity is due to deoxyribonucleic acid (DNA) intercalation and inhibition of topoisomerase II. Figure--1
 illustrates the 
chemical structure of pixantrone dimaleate.  
 Pixantrone was designed to improve the efficacy and reduce the toxicity associated with anthracyclines 
and anthracenediones by increasing the stability of DNA adduct formation, while reducing the potential to 
form oxygen- free radicals and toxic drug -metal complexes. Pixantrone lacks the 5, 8 -dihydroxy-
substitution of mitoxantrone, and instead contains a nitrogen heteroatom. The quinone-hydroquinone site 
responsible for oxygen- free radical generation and iron binding in mitoxantrone and doxorubicin is not 
present in pixantrone.  
 
Because of this design, pixantrone exhibits physiochemical and DNA-binding properties that are distinct 
from these agents
(9). Unlike other anthracycline- like agents, pixantrone forms stable DNA adducts 
through alkylation with specificity for DNA hypermethylated sites(10). 
 Furthermore, pixantrone cannot bind iron, and consequently does not generate oxygen- free radicals, the 
putative mechanism linked to the acute cardiac toxicity of other anthracycline-like agents. In addition, pixantrone does not form alcohol metabolites (eg, doxorubinol), which are implicated as important 
contributors to late -onset cardiac toxicity. 
 
Figure--1 
Pixantrone Dimaleate Chemical Structure and Molecular Weight  
 
2 x
C25H27N5O10      Mol. Wt 557.52OHO
OOHNO
ON
NH N
H NaHH
HHb c
 
 
Multiple nonclinical hematological tumor models demonstrated enhanced antitumor efficacy of 
pixantrone compared with doxorubicin and mitoxantrone. 
 Treatment with multiple cycles of pixantrone alone did not cause major myocardial changes, whereas 
doxorubicin and mitoxantrone induced the expected myocardial toxicity
(11). In animals pretreated with 
doxorubicin, pixantrone caused significantly less additional myocardial damage than did mitoxantrone or additional doxorubicin.  
 
Page 23 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
1.2.1 Pixantrone Clinical Studies  
 
Pixantrone has been evaluated in a total of 407 patients with hematologic and solid- tumor malignancies in 
single-agent and combination regimens. 
 
Previously, the expression of the pixantrone dose used in clinical and nonclinical studies was based on the drug’s salt form (pixantrone dimaleate), which could be confusing when pixantrone is prescribed and 
dispensed. In previous studies and publications, the dose was expressed as 85 mg/m
2, based on the salt 
form. This dose is equivalent to 50 mg/m2 pixantrone (active substance).  
 
In response to a recommendation from the European Medicines Agency, the dose is now expressed as 
50 mg/m2 and refers to the active substance (pixantrone). The expression of the dose as the salt form in 
historical documents and previous studies will not be corrected.   
1.2.1.1  Pixantrone Efficacy: Study PIX301 
 
Protocol PIX301 was the first randomized, controlled study in patients with aggressive NHL who had 
previously received two or more lines of systemic therapy, such as chemotherapy or chemoimmuno-therapy, which could include SCT following high-dose myeloablat ive therapy. Patients (N = 140) age 18 
years or older with stage III to IV aggressive NHL who had adequate organ function, including left ventricular ejection fraction (LVEF) of 50% or greater, were eligible.  
 Patients were randomized to pixantrone dimale ate 85 mg/m
2 by 1 hour infusion on Days 1, 8, and 15 of 
each 28-day cycle for up to 6 cycles, or to physician’s choice of a single-agent comparator drug most 
appropriate for that patient using the standard dose and schedule for that drug. Response and dise ase 
progression assessments were standardized to every 8 weeks (± 1 week) through the end of the treatment 
period and during the 18 month follow-up period. 
 The primary endpoint of ProtocolPIX301 was the CR/CRu rate at the end of treatment. Twenty percent of 
pixantrone patients and 6% of comparator patients achieved a CR/CRu (p = 0.021), which met the 
primary study endpoint. Without additional therapy during follow-up, 3 additional patients receiving 
pixantrone and 1 control patient achieved a CR/Cru, for final CR/CRu rates of 24% and 7% (p = 0.009). 
 As shown in Table--3, ORRs were similarly in favor of pixantrone, with 40% of pixantrone patients and 
14% of comparator patients (p = 0.001) achieving a response by the end of the study.  
 
Table--3 
Response Rates in Protocol PIX301 Patients, N (%)  
 End of Treatment  End of Study  
(18-month Follow -up) 
Pixantrone  
N = 70 Comparator  
N = 70 P-value Pixantrone  
N = 70 Comparator  
N = 70 P-value 
CR 8 (11%) 0  11 (16%)  0  
CRu 6 (9%) 4 (6%)  6 (9%) 5 (7%)  
CR/CRu 14 (20%)  4 (6%) 0.021 17 (24%)  5 (7%) 0.009 
ORR 26 (37%)  10 (14%)  0.003 28 (40%)  10 (14%)  0.001 
Source: CSR PIX301 EOS Tables 11.1 -1 and 11.1 -2 (derived from statistical tables 14.2.1.1, 14.2.1 .2, 14.2.5.1, and 14.2.5.2).  
Abbreviations:  
CR = complete response CRu = complete response unconfirmed  EOS = end of study  
N = number of patients  ORR = overall response rate.  
Page 24 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
As shown in Figure --2, pixantrone was also associated with a statistically significant increase in PFS (5.3 
vs 2.6 months; HR: 0.60, p = 0.005). Overall survival also favored pixantrone, with a median of 10.2 vs 7.6 months (hazard ratio [HR] = 0.79, p = 0.25). 
 
Figure--2 
PIX301 Progression -Free Survival (End of Study)  
 
 
Source: CSR PIX301 EOS Figure 11.1- 1 (based on statistical table 14.2.4.1).  
Abbreviations:  
HR = hazard ratio  N = number of patients  PD = progressive disease  
PFS = progression -free survival.  
 
1.2.1.2  Pixantron e Safety in Clinical Studies  
 
The safety of pixantrone in NHL has been well characterized in 407 patients. Thirteen studies have been 
conducted in cancer patients: 8 studies were Phase 1, 3 were Phase 2, and 2 were Phase 3. Multiple dose 
levels, dose sched ules, and both single-agent and treatment combinations were studied. 
 
The safety of pixantrone as a single agent has been well characterized in 197 patients. The most common 
adverse events (AEs) reported for pixantrone- treated patients in single -agent stud ies were neutropenia 
(43%), leukopenia (35%), anemia (32%), lymphopenia (32%), nausea (27%), asthenia (24%), pyrexia (22%), vomiting (21%), skin discoloration (20%), diarrhea (18%), and alopecia (17%).  
In the safety database, cardiac failure events grade ≥ 3 occurred in 6 of 197 patients ( 3%) receiving 
pixantrone as single-agent therapy and in 4 of 210 patients (2%) receiving pixantrone in combination 
regimens. In Protocol PIX301, the controlled single-agent study, decreased LVEF (defined as a > 10% 
decrease)  was reported in 13 (19.1%) patients in the pixantrone group. Of these, 11 (16.2%) were grade 1 
or 2 and 2 (2.9%) were grade 3. In the comparator group, decreased LVEF was reported in 7 patients 
(10.4%), and all were grade 1 or 2. Independent cardiology review demonstrated that no patient treated with pixantrone developed CHF that was considered typical for anthracyclines, and no grade 4 declines in 
LVEF were observed.  
 
Page 25 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
Assessment of cardiac safety is confounded, since many of the patients in these studi es have been heavily 
pretreated  with anthracyclines or anthracenediones, which may manifest latent cardiotoxic effects. It is 
possible that events identified during pixantrone administration represent late effects attributable to 
anthracyclines or anthracenediones. Many cardiac events observed in these studies were not typical of 
anthracycline-associated left ventricular dysfunction and did not exhibit a dose- response relationship with 
pixantrone. 
 
The occurrence of secondary AML or MDS is a well -described complication of chemotherapy regimens 
containing anthracyclines and other DNA- damaging agents. Relatively few patients treated with 
pixantrone are long -term survivors, and the relative frequency of secondary AML or MDS cannot be 
estimated. To date, of the 50 clinical study patients with at least 1 reported treatment-emergent AE in the 
SOC category of neoplasms, 38 patients had progressive neoplastic disease, 8 had simple complications of the neoplasm (infection or pain), 5 had non- melanoma skin neoplasms or  benign tumor (oncocytoma), 
and 2 (one Grade 3) had tumor lysis syndrome. In addition, 2 safety reports of secondary AML or MDS have been reported, 1 each from ongoing study PIX306 and from an ongoing investigator-sponsored trial. 
In both cases, the patien ts had previously received multiple lines of chemotherapies, including agents 
known to cause secondary MDS or AML.  
1.2.2 Pixantrone Nonclinical Photosensitivity Study  
 
Photosensitivity is a potential risk, based on in vitro and in vivo nonclinical data; however, no confirmed 
cases have been reported in the clinical study program. A study (RTC Study No. 90740) was performed to 
investigate the acute phototoxicity of pixantrone (BBR2778) in nude rats after IV administration of a single 50 mg/kg dose and subsequent ultraviolet (UV) irradiation. Negative -control (similarly drug 
treated, but not irradiated) and positive-control rats (treated with lomefloxacin) were included in the test system. In vivo and post mortem examinations of the animals revealed that an inflamm atory reaction had 
occurred in the skins of animals treated with pixantrone compared with nonirradiated controls. The reaction was of lower intensity than that seen in the positive- control lomefloxacin -treated animals. 
Animals treated with 25  mg/kg pixantr one and UV irradiation had reactions that were limited in severity 
and/or incidence, and the reactions were restricted to males; these reactions were considered not toxicologically relevant. Thus, under these test conditions, pixantrone may result in an ac ute phototoxic 
reaction after a single 50  mg/kg IV dose, but a dose of 25 mg/kg is not expected to elicit a phototoxic 
reaction.  
Given these nonclinical data, as a precaution, patients should be advised to follow sun protection 
strategies, including weari ng sun-protective clothing and using sunblocking agents; these strategies are 
recommended for patients who are treated with pixantrone. Since most medicinal product-induced photosensitivity reactions are caused by wavelengths in the UVA range, the use of sunscreen that strongly absorbs UVA irradiation is recommended.  
 
1.3 Rituximab  
 
Rituximab is a genetically engineered chimeric mouse/human monoclonal antibody that binds to the 
transmembrane antigen CD20, which is located on pre-B and mature B lymphocytes. The CD20 antigen 
is expressed on >  95% of all B cell NHLs and on normal B cells, but not on hematopoietic stem cells or 
plasma cells
(12). 
 Treatment with rituximab is generally well tolerated, particularly in terms of adverse hematological 
effects and serious or opportunistic infections relative to standard chemotherapy. Infusion- related 
reactions, usually mild -to-moderate influenza -like symptoms, are common with rituximab treatment, but 
usually decrease in frequency  with subsequent infusions. However, approximately 10% of patients 
Page 26 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
develop severe infusion -related reactions (eg, bronchospasm, hypotension) that are usually reversible with 
appropriate interventions and supportive care, but there have been fatalities. 
 
Rituximab has been evaluated for treatment of patients with relapsing or refractory aggressive lymphoma. 
In a study by Coiffier et al(13), patients received 8 weekly infusions of rituximab at 375 mg/m2 or a single 
infusion of 375 mg/m2 followed by 7 weekly infusions of 500 mg/m2. Five complete responses (CRs) and 
12 partial responses (PRs) were observed among the 54  enrolled patients, and no difference was observed 
between the two doses. The CR rate was 9% and the PR rate was 22%, for an overall response rate (ORR) of 31%. The median time to progression exceeded 246 days. The most frequently reported AEs were mild 
and related to an infusion syndrome. Nineteen patients had grade 3 related AEs, and only 1 patient had a 
grade 4 related AE. Two patients (3.7%) withdrew from treatment because of severe adverse events.  
 
Tobinai et al
(14) studied 68 Japanese patients with relapsed or refractory aggressive B -cell lymphoma who 
were treated with rituximab (375 mg/m2) in 8 consecutive weekly infusions. The ORR for 57 eligible 
patients was 37%. The median PFS of 53  evaluable patients was 52  days, whereas time to progression of 
21 eligible responders was 245 days. Mild- to-moderate infusion- related toxicities were observed 
frequently at the first infusion, but all of them were reversible.  
 
1.4 Gemcitabine  
 
Gemcitabine exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S -phase) 
and also blocking the progression of cells through the G1/S -phase boundary. Gemcitabine is metabolized 
intracellularly by nucleoside kinases to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic effect of gemcitabine is attributed to a combination of two a ctions of the 
diphosphate and the triphosphate nucleosides, which leads to inhibition of DNA synthesis.  
The activities of gemcitabine ± R were evaluated in vitro and in severe combined immunodeficiency 
disease (SCID)/human NHL xenograft models using two t(14;18)+, CD20+ follicular B- cell NHL cell 
lines; DoHH2, a transformed NHL line; and WSU- FSCCL cells, isolated from the pleural fluid of a 
patient with indolent NHL
(15). 
 
Gemcitabine was cytotoxic to DoHH2 and WSU -FSCCL cells in vitro, and the 50% inhibitory 
concentration (IC 50) was 2- to 3-fold lower in the presence of rituximab. Apoptosis was also enhanced in 
the presence of rituximab. Clearance of NHL cells from ascites in SCID mice was prolonged by gemcitabin e + R when compared with either agent alone. Most importantly, survival of SCID mice 
bearing human NHL cells was significantly prolonged by the combination of gemcitabine + R. Activity was also demonstrated in a second model, using a transformed human B- cell lymphoma.
 
 
Gemcitabine has been evaluated in multiple trials in the relapsed/refractory lymphoma population(16). It is 
well tolerated and has demonstrated antitumor activity in patients who have failed conventional regimens. No cross- resistance with other nucleoside analogues has been reported.  
 A summary of patient populations and their responses in several published studies of gemcitabine + R is 
provided in Table--4. 
 
Page 27 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
 
Table--4 
Chemoimmunotherapy Studies with Gemcitabine and/or Rituximab  
Reference  Regimen  Patient Population  Response  AEs 
Bernell(17) Gemcitabine 
monotherapy  N = 3 r/r high grade 
NHL  1 CR, 1 PR and 1 SD  Two AEs of grade 4 
thrombocytopenia  
Savage(18) Gemcitabine 
monotherapy N = 15 r/r patients  
14 NHL, 6 DLBCL, 1 
Hodgkin disease  1 CR (7.6%) in Hodgkin 
disease patient, 3 PR and 3SD  33% Grade 3/4 
leukopenia; 60% thrombocytopenia; 6.7% 
anemia  
Fosså(19) Gemcitabine 
monotherapy N = 31 (65% DLBCL)  19% ORR (all PR patients)  11% anemia, 9% 
neutropenia, 22% 
thrombocytopenia  
Wegner(20) Rituximab 
and 
gemcitabine  N = 7 (5 DLBCL)  
Elderly patients not 
eligible for transplant  2 CR (1 in DLBCL). 20% CR 
in DLBCL and 3 PR (all 
DLBCL); ORR= 71%  Grade 3/4 leukocytopenia 
in 4 patients; 1 febrile 
neutropenia  
Coffier(13) Rituximab  N = 54; 30 DLBCL; 
17%  untreated  CR 9%, PR 22%  
ORR 31%  Infusion toxicity  
Rothe(21) Rituximab 
monotherapy  21 r/r NHL  
 (16/21 resistant to 
conventional therapy  
and ineligible for aSCT)  CR 4.8%, PR 33.3%  
SD 19%, ORR 38.1%  
refractory pts ORR 43%  Infusion reactions  
Palacios(22) Rituximab -
chemo or rituximab 
monotherapy  N = 36 (25 r/r/ DLBCL, 
all with prior R -chemo) 53% ORR 38% CR  
15% PR  
Abbreviations:  
aSCT = autologous stem cell transplant  chemo = chemotherapy  CR = complete response 
DLBCL = diffuse large B -cell lymphoma  NHL = non -Hodgkin lymphoma  ORR = overall response rate, or CR + PR  
PR = partial resp onse pts = patients  R-chemo = rituximab chemotherapy  
RR = response rate  r/r = relapsed/refractory.  
 
1.5 Combination Chemoimmunotherapy  
 
Currently there is no established standard of care for the treatment of patients with relapsed/refractory 
DLBCL who are not candidates for SCT. Patients may be ineligible for transplant due to failure to 
respond to a standard salvage regimen, advanced age, toxicity from prior therapies, and serious 
comorbidities. For these patients, current  National Comprehensive Cancer Network NCCN Clinical 
Practice Guidelines in Oncology (NCCN Guidelines®)(23) recommend  a clinical study or single -agent, 
doublet, or multi- agent regimens, some containing gemcitabine and/or rituximab.  
 As single agents, gemcitabine with an approximately 20% ORR, and rituximab with approximately a 30% ORR, have demonstrable activity against DLBCL. As these two drugs do not share overlappin g toxicities, 
they have been used in combination.  
1.5.1 Rationale for Pixantrone + R Combination  
 
The combination of pixantrone + R was compared with rituximab alone in a small randomized trial in 
patients with relapsed follicular NHL who were rituximab naïve ( AZA302). The combination was well 
tolerated and was associated with a significantly higher response rate and progression- free survival than 
rituximab alone. Although single- agent rituximab has only modest activity in patients with aggressive 
NHL who have h ad prior rituximab therapy, even when administered as radioimmuno-therapy
(24), it is 
Page 28 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
likely to have additive or synergistic activity with an active agent such as pixantrone or gemcitabine in a 
combination setting. Since there is minimal overlapping toxicity between cytotoxic agents such as 
pixantrone or gemcitabine, the potential benefit of added efficacy for this combination outweighs the risks 
of combining these agents in a setting for which there is no standard therapy.  
 Pixantrone is highly effective, with tolerable toxicity, in patients with relapsed and refractory aggressive B cell lymphoma when administered on Days 1, 8, and 15 of a 28- day cycle.  Weekly dosing of 
chemotherapeutic agents such as paclitaxel,  docetaxel, and doxorubicin decreases toxicity compared with 
every-3-week dosing without compromising efficacy.  Therefore, this schedule was chosen for 
development of pixantrone as monotherapy in patients with advanced disease following Phase 1 studies using weekly (Days 1, 8, and 15 of a 28- day cycle) or every -3-week schedules.  Pixantrone on a weekly 
schedule had substantial activity in late -stage lymphoma patients, with an acceptable toxicity profile.  At 
the maximum tolerated dose (MTD) of pixantrone, 50 mg/m
2 (equivalent to 85 mg/m2 pixantrone 
dimaleate), this schedule resulted in a dose intensity of 37.5 mg/m2/week.  Although it is possible to 
achieve similar dose intensity on an every -3-week schedule at 104 mg/m2 with pixantrone, as this dosing 
regimen was not studied in the relevant patient population as monotherapy, there is limited evidence for 
safety or efficacy.  
 Rituximab does not affect metabolism or clearance of small -molecule chemotherapeutic agents and 
enhances the activity of other anti-B-cell NHL therapeutics. Pixantrone has been used with rituximab on an every-3-week schedule in less heavily pretreated patients with indolent lymphoma, in combination 
studies on an every -3-week schedule with cyclophosphamide, vincristine, and prednisone, and on an 
every-4-week schedule with fludarabine and dexamethasone.  In each case, efficacy was demonstrated.  
Because dose intensity is comparable on the weekly and every -3-week schedules, the sponsor believes it 
is appropriate to use the current schedule, i n which both safety and efficacy have been demonstrated in a 
similar patient population.  
 
1.5.1.1  Potential for Drug -Drug Pharmacokinetics Interactions 
 
Pixantrone is excreted predominantly unchanged by the liver, whereas rituximab is a humanized 
monoclonal antibody with no known effects on hepatic excretory function. The likelihood of a 
pharmacokinetic (PK) interaction is extremely low. No unexpected toxicity was observed with the 
combination of pixantrone + R in a combination study (AZA302).  
1.5.2 Rationale for Gemcit abine + R Combination  
 
There are a small number of potentially active drugs not previously employed for patients as third- line 
therapy for DLBCL. Most patients have been exposed to CHOP- R, and in second line they likely received 
treatment with a platinate,  etoposide, and/or cytarabine, as well as additional alkylating agent therapy. 
There is no standard of care regimen beyond second- line therapy; potentially active drugs available 
include gemcitabine, lenalidomide, and bendamustine. Gemcitabine has activity  as a single agent
(19), and 
in preclinical studies in lymphoma models demonstrated synergy with rituximab, as described in Section 
1.4. 
 
Gemcitabine + R has been suggested as a reasonable therapeutic option in patients with relapsed NHL ineligible for SCT. A study by Wenger et al
(20) showed a 72% response rate for the combination of 
gemcitabine + R in a very limited number o f patients. In relapsed/refractory DLBCL patients, the CR rate 
was 20%. This response rate aligns with rates of 20% to 50% reported with other regimens. Significant 
variability in the result of these studies can be attributed to small patient numbers, vary ing exposure to 
prior rituximab, varying lines of therapy, and some variations in disease subtypes (eg, grade 3 follicular 
lymphoma, DLBCL, and mantle cell lymphoma).  
Page 29 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
Although the numbers are limited, in a study by Palacios(22), patients who received an aggressive regimen 
(R-ESAHP, R -ICE, and R-TT) had a CR rate of 22% and those treated with less- aggressive regimens (R -
GEM-Ox, R-mono) had a CR rate of 45%, suggesting that more aggressive regimens do not necessa rily 
lead to better responses. This appears to support the argument that using the least toxic regimen may be most appropriate, and suggests that early treatment with rituximab does not preclude reuse in the salvage setting as patients continued to respond . 
 Gemcitabine + R combination therapy was evaluated in a small study of elderly patients with high -grade 
B-cell lymphoma who had relapsed after CHOP therapy, or were medically unfit to tolerate CHOP as first-line therapy
(20). Seven patients were treated with gemcitabine 1000  mg/m2/week × 3 q 28 days and 
rituximab 325 mg/m2 weekly × 4 in the first cycle and on Day 1 of all subsequent cycles. A median of 4 
cycles was delivered. Major toxicities were hematologic; t he estimated median time to tumor progression 
was 12 months. R- gemcitabine has been suggested as a reasonable therapeutic option in patients with 
relapsed NHL who are ineligible for SCT(16).  
 
1.5.2.1  Potential for Drug -Drug Pharmacokinetics Interactions 
 
Gemcitabine is excreted almost entirely in the urine as an inactive metabolite. Rituximab is a humanized 
monoclonal antibody with a long half-life that has an important impact on the metabolism of other drugs. 
There is broad clinical experience with co -administration of gemcitabine and rituximab in combination 
with oxaliplatin (R -GEMOX) as treatment for DLBCL(25). The likelihood of a clinically important PK 
interaction is extr emely low.  
 
2 Study Objectives  
 2.1 Primary Objective  
 
The primary objective of this study is to evaluate the efficacy (as measured by progression -free survival 
[PFS]) of pixantrone + R compared with gemcitabine + R in patients with a diagnosis of de novo diffus e 
large B-cell lymphoma (DLBCL), DLBCL transformed from indolent lymphoma, or follicular grade 3 
lymphoma who have relapsed after at least 1 prior chemotherapy regimen and who are currently ineligible for high-dose (myeloablative) chemotherapy and stem cel l transplant (SCT) .  
 
• Patients with de novo DLBCL must have received 1 -3 prior regimens for DLBCL 
• Patients with follicular grade 3 lymphoma must have received 1 -3 prior regimens for follicular 
lymphoma (any grade)  
• Patients with DLBCL transformed from indo lent lymphoma must have received 1 -4 prior regimens 
for NHL (any type)  
 
Patients must have received at least one rituximab -containing multi-agent regimen and must have had no 
progression for at least 12 weeks after the last dose of a treatment regimen (see Section  3.4 for details).  
 
Page 30 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
 
Patients ineligible for SCT include those who: 
 
• Relapsed after previous SCT  
• Did not respond to a standard salvage regimen 
• Did not mobilize an adequate number of stem cells for SC T  
• Are unsuitable for SCT due to other medical conditions or age 
• Do not wish to undergo SCT  
• Have financial issues precluding SCT  
• Are considered by the investigator as unsuitable for SCT for any other reason  
 
2.2 Secondary Objectives  
 
To compare the two treatm ent arms with regard to the following secondary endpoints: 
 
• Overall survival (OS)  
• Overall response rate (ORR)  
• Complete response (CR) rate  
• Safety  
 
2.3 Exploratory Objectives  
 
• Assess the duration of overall response between treatments  
• Assess the duration of complete response (CR) between treatments  
• Determine the proportion of randomized patients who receive an SCT after study treatment 
 
Pharmacokinetics Sub -Study Objective  
(participating sites refer to Section 12  Addendum: Pharmacokinetics Sub-Study) 
 
• To characterize the PK profile of pixantrone when co- administered with rituximab.  
 
Page 31 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
3 Investigational Plan  
 3.1 Overall Study Design  
 
This is a randomized, active-controlled, multicenter, phase 3 study evaluating the efficacy of pixantrone + R versus gemcitabine + R in patients with a d iagnosis of DLBCL (de novo DLBCL or DLBCL 
transformed from indolent lymphoma), or follicular grade 3 lymphoma on the basis of a tissue biopsy who are currently ineligible for high -dose (myeloab lative) chemotherapy and SCT and who relapsed after 
at least 1 chemotherapy regimen.  
 
• Patients with de novo DLBCL must have received 1 -3 prior regimens for DLBCL  
• Patients with follicular grade 3 lymphoma must have received 1 -3 prior regimens for follicular 
lymphoma (any grade)  
• Patients with DLBCL transformed from indolent lymphoma must have received 1-4 prior regimens 
for NHL (any type) 
 The study will be conducted in North America and Europe.  
 Treatment assignment will be known to investigators, site pe rsonnel, and patients, but the sponsor (except 
as defined in the PIX306 treatment blinding plan) will remain blinded during the study.   
This study includes screening, treatment, and follow- up periods (Figure--3). Patients will be randomized 
to the investigational treatment (pixantrone + R) or the control treatment (gemcitabine + R). Treatment will be administered in 28- day cycles.  
 
Figure--3 
Study Flow Chart  
 
 
Abbreviations:  
CT = computed tomography  Q 8 = every 8  R = rituximab.  
PD = progressive disease per Modified IWG criteria or initiation of subsequent systemic anticancer therapy, 
except for rituximab given as maintenance therapy  
 
Patients who must discontinue pixantrone or gemcitabine due to toxicity may remain on rituximab every 
28 days for up to a total of 6 cycles of study treatment. Patients who must discontinue rituximab due to 
toxicity may remain on gemcitabine or pixantrone for up to a total of 6 cycles of study treatment.  
Page 32 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
Disease response will be assessed (Table--1 and Table --2) by CT or MRI at baseline, every 8 weeks ± 1 
week during the treatment period and during the Early Follow- up period, t hen every 12 weeks ± 2 weeks 
during the Intermediate Follow- up period. If an assessment is done off schedule, the next assessment 
should be calibrated as closely as possible back to the original schedule starting at Day 1 Cycle 1. Patients with a response (CR or PR) or stable disease (SD) and who the investigator believes are deriving clinical 
benefit at the time of each assessment will be allowed to continue treatment up to a maximum of 6 cycles. 
Therapy will be discontinued for progressive disease per Modified IWG criteria, patient refusal to 
continue, or pregnancy.  Therapy may be discontinued for toxicity precluding further treatment, 
intercurrent illness, or Progressive Disease Due to Symptomatic Deterioration (patients unable to continue 
study treatmen t due to progressing lymphoma that does not meet the Modified IWG 2007 Revised 
Response Criteria for Malignant Lymphoma). 
 
3.1.1 Participation in Treatment and Follow -up Periods  
 
Patients may withdraw consent from participation in any phase of the study. Patient s may withdraw 
consent for treatment or withdraw consent for treatment and study procedures.  However, unless they have signed a separate written withdrawal of consent, all randomized patients will be followed for survival and safety, as described below.  
 
Randomized patients who complete or discontinue study treatment for any reason, other than progressive 
disease per Modified IWG criteria, will participate in the follow -up periods, as described below. 
 
At the time patients experience progressive disease p er Modified IWG criteria during treatment or during 
Early or Intermediate Follow -up, begin subsequent systemic anticancer therapy, except for rituximab 
given as maintenance therapy, or withdraw consent for study procedures, they will enter the Survival 
Follow-up Period. 
 
For randomized patients, study-drug related AEs and cardiac AEs ≥ grade 3, including LVEF declines, 
are collected and followed until resolution, until no further improvement is expected, or until EOS, 
whichever occurs first. AEs not related  to study drug and cardiac AEs ≤ grade 2 are collected and 
followed for 30 days after the last dose of study drug, until no further improvement is expected, or until the patient begins a subsequent systemic anticancer therapy, except for rituximab given as maintenance therapy, whichever occurs first.  
 All time points for CT/MRI disease assessment are calculated from Day 1 of Cycle 1 (Table--1 and 
Table--2). In the case of CT /MRI imaging done outside the calendar schedule (unscheduled), consult with 
Medical Monitor for appropriate scheduling of the next CT/MRI.  
 
• End of Treatment (EOT)  is defined as the date of the end -of-treatment visit. The EOT visit occurs at 
4 to 7 weeks af ter last study drug dose, inclusive, or before subsequent systemic anticancer therapy, 
whichever occurs first. Note that rituximab given as maintenance therapy is not allowed prior to the 
EOT visit per protocol window, but even if rituximab is given, EOT procedures will be obtained per 
this window. In the unanticipated event that a randomized patient receives no study drug, no EOT 
procedures are required, and the patient would continue per protocol Section 3.8.1.4. 
• Early Follow- up: After treatment discontinuation or completion, patients will enter the 24- week 
Early Follow -up Period. CT/MRI disease response, survival status, details of subsequent systemic 
anticancer therapy, including rituximab given as maintenance therapy, and safety will be evaluated 
every 8 weeks ± 1 week.  
Page 33 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
• Intermediate Follow -up: After completing the 24 -week Early Follow -up Period, patients will enter 
an additional 72-week Follow- up Period, in which CT/MRI disease response (every 12 weeks ± 2 
weeks), survival status, details of subsequent systemic anticancer therapy, including rituximab given 
as maintenance therapy, and safety will be evaluated.  
• Survival Follow -up: All patients will be monitored for survival status every 12 weeks ± 2 weeks until 
the end of the study. For any patient who is lost to follow -up, the study site will attempt to ascertain 
survival information via public database search. Informed consent to obtain these data will be 
obtained from patients at the time of enrollment.  
• End of Study (EOS):  is defined as the date when the required OS events have occurred or the study is 
terminated.  
 At the time that 195 PFS events per IRC are reached, patients will be at various stages of the study, 
including those who have been consented, have been randomized, have started treatment, or are in follow-up.  All patients who have consented for enrollment prior to this time will continue on the study per protocol, until EOT, whereupon they will enter Survival Follow-up.  All patients in Early or Int ermediate 
Follow-up at this time will subsequently only be followed according to the Survival Follow -up schedule. 
 
The sample size for this trial is based on the number of PFS events  per the IRC.   Approximately 320 
patients are planned to be randomized in a 1:1 ratio  to reach the required number of PFS events . The 
randomization will be stratified by International Prognostic Index (IPI) score (0-2 vs ≥ 3), prior lines of therapy for DLBCL or follicular grade 3 lymphoma (0- 2 vs ≥ 3), and length of time from initiation of 
first-line therapy for DLBCL or follicular grade 3 lymphom a until first relapse (< 1 year vs ≥ 1 year).  
 
Enrollment will take place in North America and Europe. The expected duration of enrollment is 
approximately 80 months.  
 
3.1.2 Study Conduct  
 
Regardless of whether serum samples, radiologic material, and other pat ient data are sent to a central 
laboratory or independent review panel for study purposes, treatment and eligibility decisions must be made by the investigator, based on his or her clinical assessment of the patient and interpretation of local labs, radiol ogy assessments, and other tests.  
 Local laboratory tests are required, as needed, for time -limited evaluation windows, per protocol, and to 
support urgent clinical decisions.  
 
3.1.2.1  Independent Data Monitoring Committee  
 
The Independent Data Monitoring Committe e (IDMC) will meet throughout the study, approximately 
every 6 months or after 30 additional patients are randomized, whichever occurs first. The first meeting will take place after 25 patients are randomized.  
 The IDMC’s responsibilities include:  
 
• Minimize the exposure of patients to an unsafe therapy or dose.  
• Evaluate the toxicity and appropriateness of doses in both arms in order to make recommendations for 
changes in study if appropriate. 
• Advise on the need for dose adjustments because of safety issues.  
Page 34 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
• Make any other safety associated assessments, including endorsing continuation of the study per 
protocol. 
• Be in charge of the interim OS analyses and release the unblinded OS results to the sponsor after all 
patients have completed study treatment.  
 
Details on the membership, responsibilities, and working procedures of the IDMC are described in the 
IDMC Charter, which is provided as a separate document in the study file.  
 
3.1.2.2  Study Steering Committee  
 
The Study Steering Committee (SSC) will be composed of ex ternal medical experts, CTI representatives, 
and selected investigators participating in this study. These investigators will represent all the study investigators.  
 
The SSC will provide advice on modifications as circumstances require, in particular:  
 
• Changes in study design  
• Changes in any aspects of study conduct 
• One or more SSC representatives may attend the open sessions of the IDMC meetings and be 
available to clarify issues. The Open Session Minutes of the IDMC meetings, without any treatment 
arm comparisons, will be shared with the SSC, as requested.  
 
Details on the membership and responsibilities of the SSC are described in the charter, which is part of 
the study file.  
 
3.1.2.3  Independent Radiology Committee  
 
An Independent Radiology Committee (IRC) will determine the disease responses for all randomized 
patients according to the modified IWG 2007 Revised Response Criteria detailed in Table --11. The IRC 
will be blinded to site identifiers, patient treatment arm, an d investigator’s designation of target lesions. 
 Investigative sites will be provided with a Site Procedure Manual describing how the imaging portion of 
the study is to be conducted. The manual will include requirements for the diagnostic evaluations, pati ent 
assessment objectives, patient preparation for examination, image media requirements and imaging 
procedures. The manual will also provide instructions for transferring imaging data for the IRC review.  
 
Images will be read by two radiologists. Any disa greements in the radiological response assessment will 
be adjudicated by a third radiologist as described in the Image Charter. 
 
The final disease response assessment determined at each imaging evaluation will be determined by an 
independent oncologist and one of the radiologists who evaluate each patient’s clinical, pathologic, and 
radiologic data.  
 
Details of the IRC operation are described in the Image Charter, which is part of the study file. 
 
Page 35 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
3.1.2.4  Central Pathology Review  
 
A central pathology review comm ittee will evaluate biopsy specimens from all randomized patients to 
confirm the histologic diagnosis of DLBCL (de novo DLBCL, DLBCL transformed from indolent lymphoma) or follicular grade 3 lymphoma per World Health Organization (WHO) classification.  
A Site Procedure Manual describing how the pathology portion of the study is to be conducted, including 
procedures and requirements for obtaining, preparing, processing, and sending biopsy material to the central pathology review committee, will be provided t o all investigative sites.  
 
Pathology tissues/images will be read by two pathologists. Disagreements in the disease confirmation will 
be adjudicated by a third pathologist, as described in the Pathology Charter. 
 
The “histologically confirmed” population w ill include all patients with DLBCL (de novo DLBCL or 
DLBCL transformed from indolent lymphoma) and follicular grade 3 lymphoma per WHO classification confirmed by the central pathology review committee.  
 The detailed operation and procedures of the centr al pathology review committee will be described in the 
Pathology Charter, which is part of the study file.  
Bone marrow biopsies (with cores) obtained during the study will undergo local pathology review to 
confirm a CR.   
3.2 Discussion of Study Design 
 
The underlying research hypothesis for this study is that the combination of pixantrone + R is a more 
effective therapy than treatment with gemcitabine + R in patients with a current diagnosis of DLBCL (de 
novo DLBCL or DLBCL transformed from indolent lymphoma) or follicular grade 3 lymphoma, on the 
basis of a tissue biopsy, who are not currently eligible for high -dose (myeloablative) chemotherapy and 
SCT and who have relapsed after at least 1 prior chemotherapy regimen.  
Page 36 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
All patients must have received at least  one multi-agent regimen containing rituximab.  
 
In patients with DLBCL who have failed or are not eligible for curative therapy, no therapy has 
demonstrated improved survival, and thus, there is no standard of care. PIX301, the first randomized 
study performed in this setting and the predecessor to the current study, compared single-agent pixantrone 
to the physician’s choice of other single-agent therapies in a total of 140 patients (70 per arm). This study 
demonstrated improvement in the CR/CRu rate, overall response rate, and PFS, for pixantrone compared 
with control. 
 
3.2.1 Choice of Endpoints  
 
Progression-free survival (PFS) is the primary endpoint, as it reflects the effect of therapy on tumor 
growth and can be assessed as a surrogate for OS. Unlike the surv ival endpoint, PFS is not confounded by 
subsequent systemic anticancer therapy and has been used as a measure of the clinical efficacy of therapy in similar settings.  Overall survival (OS) is a secondary endpoint, as a standard endpoint used to measure 
clinical benefit.  
 
3.2.2 Interim Analysis and OS Analysis  
 
No interim analysis of the PFS primary endpoint is planned for this study. See Section 5 for a description 
of the OS analysis.  
 
3.2.3 Choice of Dose and Schedule of P ixantrone 
 
The drug is supplied in vials; each vial contains 29 mg pixantrone. (The dose of pixantrone is 50 mg/m
2.) 
 The choice of pixantrone dose (50 mg/m
2 on Days 1, 8, and 15 in 28- day cycles) is based on preclinical 
testing and clinical evaluation in phase 1 to 3 studies. The phase 1/2 studies (in which pixantrone doses 
were expressed in terms of the salt, pixantrone dimaleate) administered dose-dense monotherapy to 
heavily pretreated patients with lymphoid neoplasia or solid tumors. These studies defi ned a pixantrone 
dimaleate dose range of ≥ 56 mg/m2 (with which no grade 3 toxicity was observed) and ≤ 112.5 mg/m2 
(with which 50% of patients had grade 3/4 neutropenia). Although some responses were noted at lower 
dose levels, in patients with relapsed o r refractory lymphoma, 84 mg/m2 pixantrone dimaleate (dose 
intensity 60.5 mg/m2/week) was the lowest dose at which durable CRs were seen. This dose choice 
(which is equivalent to the present dose of 50 mg/m2 of pixantrone) was confirmed in the phase 2 study, 
AZA II-01, in patients with relapsed aggressive NHL, and in the phase 3 study, PIX301. Overall, 
109 patients have been treated on this dose and schedule.  
3.3 Study Population  
 
The target population is patients with a current diagnosis of DLBCL (de novo DLB CL or DLBCL 
transformed from indolent lymphoma) or follicular grade 3 lymphoma on the basis of a tissue biopsy, who are not currently eligible for high -dose (myeloablative) chemotherapy and stem cell transplant and 
who have relapsed after at least 1 prior chemotherapy regimen. All patients must have received a multi -
agent regimen containing rituximab.  
• Patients with de novo DLBCL must have received 1 -3 prior regimens for DLBCL  
• Patients with follicular grade 3 lymphoma must have received 1 -3 prior regimens for follicular 
lymphoma (any grade)   
Page 37 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
• Patients with DLBCL transformed from indolent lymphoma must have received 1-4 prior regimens 
for NHL (any type) 
 Patients not eligible for SCT include those who: 
 
• Relapsed after previous SCT  
• Did not respond to a standa rd salvage regimen  
• Did not mobilize an adequate number of stem cells for SCT  
• Are unsuitable for SCT due to other medical conditions or age 
• Do not wish to undergo SCT  
• Have financial issues precluding SCT  
• Are considered by the investigator as unsuitable fo r SCT for any other reason 
 
The Investigator must ensure that only those patients who meet all of the inclusion (Section  3.3.1) and 
none of the exclusion (Section 3.3.2 ) criteria are allowed to enroll in the study. The Investigator should 
apply no additional criteria to determine patient eligibility.  
 
3.3.1 Inclusion Criteria  
 
The study’s inclusion criteria include the following: 
 
1. Signed Institutional Review Board or Institutional Ethics Committee -approved Informed Consent 
Form  
2. Age ≥18 years old 
3. Diagnosis of DLBCL (de novo DLBCL, or DLBCL transformed from indolent lymphoma) or 
follicular grade 3 lymphoma on the basis of a tissue biopsy 
4. Pathology and immunohistochemistry reports documenting the current histological diagnosis according to World Health Organization (WHO) classification must be reviewed by the sponsor or 
designee prior to randomization  
5. Number of prior therapies allowed:  
a. Patients with de novo DLBCL must have received 1 -3 prior regimens for DLBCL 
b. Patients with follicular grade 3 lymphoma must have received 1 -3 prior regimens for follicular 
lymphoma (any grade)  
c. Patients with DLBCL transformed from indolent lymphoma must have received 1-4 prior regimens for NHL (any type) 
The salvage combination therapy used to achieve a response in preparation for possible SCT (eg, R-ICE, R -ESHAP or R-DHAP), along with the subsequent high-dose myeloablative therapy (eg, BEAM) 
and SCT, is counted as a single regimen.  
Maintenance ther apy with rituximab or similar agents, single-agent corticosteroids, and local 
radiation therapy are not counted  as treatment regimens.  
 6. Received a rituximab -containing multi-agent regimen (eg, rituximab, cyclophosphamide, 
doxorubicin, vincristine, prednisone [R -CHOP]; rituximab, cyclophosphamide, vincristine, 
prednisone [R- CVP]; or bendamustine -R)  
Page 38 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
7. Patients with DLBCL transformed from indolent lymphoma must have had a complete or partial 
response to a therapy for NHL lasting at least 12 weeks 
8. Not eligible f or high-dose (myeloablative) chemotherapy and SCT. Patients not eligible for SCT 
include those who:  
a. Relapsed after previous SCT  
b. Did not respond to a standard salvage regimen 
c. Did not mobilize an adequate number of stem cells for SCT  
d. Are unsuitable for SCT due to other medical conditions or age 
e. Do not wish to undergo SCT  
f. Have financial issues precluding SCT  
g. Are considered by the investigator as unsuitable for SCT for any other reason  
9. At least 28 days from completion of last NHL therapy to randomization 
10. At least one bidimensionally measurable site of disease that has not been previously irradiated: nodal 
disease ≥ 1.5 cm in short axis or extranodal disease > 1.0 cm in short axis. Lesion must be PET 
positive if PET scan is obtained.  
11. Slides confirming diagnosis of follicular grade 3 lymphoma or DLBCL available for independent 
histology review  
12. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 (Section 8.2 ) 
13. Life expectancy ≥ 12 weeks in investigator’s judgment 
14. Left ventricular ejection fraction (LVEF) ≥ 45% by echocardiogram and normal serum troponin T 
15. Hemoglobin ≥ 8 g/dL (can be post-transfusion)  
16. Platelet count ≥ 100 × 109/L; platelet count ≥ 75 × 109/L permitted if documented bone marrow 
involvement  
17. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L; ANC ≥ 1.0 × 109/L permitted if documented bone 
marrow involvement  
18. Serum bilirubin ≤ 1.5 × upper limit of normal (ULN); patients with proven Gilbert’s syndrome and bilirubin ≤ 5 × ULN may be enrolled. 
19. Aspartate aminotransferase (AST; also called serum glutamic- oxaloacetic transaminase [SGOT]) and 
alanine aminotransferase (ALT; also called serum glutamic- pyruvic transaminase [SGPT]) ≤2 × 
ULN, or ≤ 5 × ULN if elevation is due to hepatic involvement by lymphoma 
20. Serum creatinine ≤ 2 × ULN 
21. All acute toxicities related to prior treatment recovered to grade ≤ 1, except alopecia 
22. Willingness and ability to comply with the visit schedule and assessments required by the study protocol 
23. Due to the long retention time of rituximab in B cell-depleted patients, both males and f emales must 
agree to use effective birth control. Women of childbearing potential (WOCBP) must use highly effective methods (defined as those resulting in a failure rate of < 1% per year when used consistently 
and correctly) for the duration of study treatment and for 12 months after last dose of study drug.  The 
contraceptive methods that are considered highly effective are intrauterine devices and hormonal 
contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices, or injections with prolonged release). 
 
Page 39 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
3.3.2 Exclusion Criteria  
 
The study’s exclusion criteria include the following: 
 
1. Any of the following as the only site(s) of disease: palpable lymph nodes not visible on imaging 
studies, skin lesions, or bone marrow involvement only 
2. Primary refractory de novo DLBCL or primary refractory follicular grade 3 lymphoma, defined as 
documented progression within 12 weeks of the last cycle of the first- line multi- agent regimen  
3. Prior treatment with a cumulative dose of doxorubicin or equ ivalent exceeding 450  mg/m² (see 
Section 8.5  for formula)  
4. LVEF < 45% by echocardiogram 
5. Active National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 3/4 infection  
6. Major surg ery ≤ 28 days prior to randomization 
7. Known acute or chronic hepatitis B or hepatitis C virus infection  
8. Known seropositivity for human immunodeficiency virus (HIV) 
9. Current CNS involvement by lymphoma 
a. Any history or evidence of current leptomeningeal involvement by lymphoma is prohibited. 
b. Patients with prior localized CNS involvement who have been without recurrence for 
≥ 12 months and currently have a negative head MRI may be eligible; please discuss with the 
Medical Monitor.  
10. Any experimental therapy ≤ 28 days prior to randomization 
11. Myocardial infarction within the past 6 months 
12. New York Heart Association class III or IV heart disease (Section  0) 
13. Other malignancy within the last 5 years. Exceptions are:   
a. Curatively treated basal cell/squamous cell skin cancer  
b. Carcinoma in situ of the cervix 
c. Superficial transitional cell bladder carcinoma 
d. In situ ductal carcinoma of the breast after complete resection  
e. Localized, resected and/or low- risk prostate cancer may be eligi ble; please discuss with the 
Medical Monitor  
14. Any contraindication, known allergy, or hypersensitivity to any study drugs 
15. Pregnant or lactating  
16. Concomitant therapy with any anticancer agents, immunosuppressive agents, other investigational 
anticancer therapies. Low- dose corticosteroids for the treatment of non -cancer-related illnesses are 
permitted  
17. Any psychological, familial, sociological, or geographical condition potentially hampering 
compliance with the study procedures or follow-up schedules 
18. Severe and /or uncontrolled medical disease that could compromise participation in the study, or any 
medical or psychiatric condition that, in the opinion of the investigator, would make study drug administration hazardous or obscure the interpretation of data.  
 
Page 40 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
3.3.3 Completion and Discontinuation of Treatment  
 
Patients who receive 6 cycles of pix antrone + R or gemcitabine + R are considered to have completed 
study treatment.  
 
Patients who must discontinue pixantrone or gemcitabine due to toxicity may remain on rituximab for up to a total of 6 cycles of study treatment.  
 Patients who must discontinue rituximab due to toxicity may remain on gemcitabine or pixantrone for up 
to a total of 6 cycles of study treatment.  
 
Study treatment may be discontinued before completion due to: 
 
• Progressive disease per Modified IWG criteria  
• Any clinical adverse event, laboratory abnormality, abnormal test result or intercurrent illness which, 
in the opinion of the investigator, indicates that continued treatment with study therapy is not t he best 
interest of the patient  
• Progressive Disease Due to Symptomatic Deterioration (patients unable to continue study treatment due to progressing lymphoma that does not meet the Modified IWG 2007 Revised Response Criteria 
for Malignant Lymphoma). 
• Treatment refusal, including withdrawal of consent 
• Protocol violation that would jeopardize patient safety  
• Patient lost to follow -up  
• Pregnancy  
 Patients who have progressive disease per Modified IWG criteria, begin subsequent systemic anticancer 
therapy, except for rituximab given as maintenance therapy, or withdraw consent for study procedures 
will enter the Survival Follow -up Period. Patients who complete study treatment, or discontinue study 
treatment for any other reason (including Progressive Disease Due to Symptomatic Deterioration), will 
participate in the Early and Intermediate Follow -up periods, as described in Section 3.8.1.4.  
 
Patients may withdraw consent from participation in any phase of the study. Patients may withdraw 
consent for any of the following: treatment; treatment and study procedures; or treatment, study 
procedures, and survival follow-up. All randomized patients will be followed for survival and safety, as 
described in Section 3.8.1.4 , unless patients have rendered a separate written withdrawal of consent for 
survival information.  
 For any patient who is lost to follow- up, the study site will attempt to ascertain survival information via 
public data base search. Informed consent to obtain these data will be obtained from patients at the time of 
enrollment.  
 
At the time of the primary endpoint analysis when study recruitment is halted , patients will be at various 
stages of the study, including those who have been consented, have been randomized, have started treatment, or are in Follow-up.  All patients who have consented for enrollment prior to this time will 
continue on the study per protocol, until EOT, whereupon they will enter Survival Follow-up.  All patients in Early or Intermediate Follow -up at the time of primary endpoint analysis will subsequently 
only be followed according to the Survival Follow- up schedule.  
 
Page 41 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
3.4 Study Treatment  
Th
e investigational treatment in this trial is pixantrone in combina tion with rituximab (pixantrone + R). 
The control treatment is gemcitabine in combination with rituximab (gemcitabine +  R). 
It
 is recommended that rituximab be administered prior to the cytotoxic agent. 
The
 dose (in mg) of pixantrone, gemcitabine, and/or rituximab to be administered will be determined by 
the patient’s body surface area (BSA). The BSA should be determined using the institutional standard for 
BSA calculation.  
The
 investigational drug is supplied in vials that each contain 29 mg pixantrone.  (The dose of pixantrone 
is 50 mg/m2.) 
The
 pixantrone + R regimen (investigational therapy) is given in up to six 28-day cycles, consisting of 
rituximab 375 mg/m2 IV on Day 1 and pixantrone 50 mg/m2 IV on Days 1, 8, and 15 ( Table--5). 
Th
e gemcitabine +  R regimen (control therapy) is given in up to six 28-day cycles, consisting of 
rituximab 375 mg/m2 IV on Day 1 and gemcitabine 1000 mg/m2 IV on Days 1, 8, and 15 (Table--5). 
Table--5 
Protocol PIX306 Treatment Regimens  
Treatment Regimen  Dosing Schedule  
Investigational Therapy Pixantrone + R  
Rituximab 375 mg/m2 IV on Day 1  
Pixantrone 50 mg/m2 IV on Days 1, 8, and 15  Up to six 
28-day cycles  
Control Therapy  Gemcitabine + R  
Rituximab 375 mg/m2 IV on Day 1  
Gemcitabine 1000 mg/m2 IV on Days 1, 8, and 15  Up to six 
28-day cycles  
Abbreviations:  
IV = intravenous(ly)  mg/m2 = milligrams per square meter  R = rituximab.  
3.4.1 Trea
tment Assignment  
At
 the screen ing visit, patients will be assigned a unique screening ID number by the electronic data 
capture system. Upon the Medical Monitor’s confirmation of eligibility, patients will be randomized (1:1) 
to receive either investigational or control therapy. The ran domization will be stratified by number of 
prior therapies for DLBCL or follicular grade 3 lymphoma (0 -2 vs. ≥ 3), IPI score (0-2, ≥ 3; see Section 
8.1), and length of time from initiation of first-line therapy for DLBCL or follicular grade  3 lymphoma 
until first relapse (< 1 year vs. ≥ 1 year). 
3.4.2 Tr
eatment Blinding  
Treatment assignment will be known to investigators, site personnel and patients , but the sponsor (except 
as defined in the PIX306 treatment blinding plan) will remain blinded during the study until the core 
database lock.  After the core database lock, the sponsor will remain blinded to OS datasets (although  
death contributing to the PFS events in the core locked database will be unblinded) until afte r the final 
OS analysis. Sponsor will have access to the unblinded OS interim results via IDMC once last patient 
completes the study treatment.  
Page 42 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
3.4.3 Treatment Compliance  
 
The investigator or designee should administer study drugs exactly as described. The study medication 
used, dosages administered, dates, and start and stop times of administration must be recorded as 
described in the study manual. All treatment visits should comply with the schedule described in Section 
3.8, Table--1, and Table --2 of this protocol.  
 
3.4.4 Rituximab Preparation, Storage, and Handling  
 
The current rituximab package insert should be consulted for specific precautions and warnings(26).  
Rituximab should be administered at the Investigator's discretion and according to current institutional 
standards.  
 Rituximab is a sterile, clear, colorless, preservative- free, liquid concentrate for IV administration. 
Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. Rituximab vials (100 mg [NDC 50242-051-21] and 500 mg [NDC 50242-53- 06]) are 
stable at 2 °C to 8°C (36°F to 46°F). Vials should not be used beyond the expiration date stamped on the 
carton. Rituximab vials should be protected from direct sunlight and should not be frozen or shaken. 
Rituximab solutions for infusion may be stored at 2 °C to 8°C (36°F to 46°F) for 24 hours. Rituximab 
solutions for infusion have been shown to be stable for an additional 24 hours at room temperature. 
However, since diluted rituximab solutions contain no preservative, diluted solutions should be 
refrigerated at 2 °C to 8°C (36°F to 46°F). No incompatibilities have been observed between rituximab 
and polyvinylchloride or polyethylene bags.  
 
The rituximab solution for infusion should be prepared using appropriate aseptic technique. Parenteral 
drug products should be visually inspected for particulate matter and discoloration prior to administration, 
and the vial should not be used if particulates or discoloration are observed. The necessary amount of 
rituximab is withdrawn and diluted to a final concentration of 1 to 4 mg/mL in an infusion bag containing 
either 0.9% Sodium Chloride, USP or local pharmacopeial equivalent, or 5% Dextrose in water, USP or 
local pharmacopeial equivalent, and then the bag is gently inverted to mix the solution. The solution 
should not be mixed or diluted with other drugs. Any unused portion of solution left in the vial is to be discarded.  
 
3.4.5 Pixantrone Handling, Preparation, Administration, and Storage 
 3.4.5.1  Handling of Pixantrone  
 
Pixantrone is a cytotoxic agent. All work practices must be designed to reduce human exposure to 
pixantrone.  Avoid inhalation, ingestion, contact with the eyes, and contact with skin. Avoid prolonged or 
repeated exposure. Pixantrone should be handled only by qualified individuals trained in laboratory 
procedures and familiar with the potential hazards of handling chemicals.  
 
Equipment and supplies used for pixantrone preparation and administration, such as used vials, needles, 
syringes, and IV bags, should be handled and disposed of as hazardous waste, according to all applicable 
laws and regulations. 
 
3.4.5.2  Pixantrone Preparation and Administration 
 
The investigational drug is supplied in a vial containing 50 mg pixantrone dimaleate, which is equivalent 
to 29 mg pixantrone.  
Page 43 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
Infusion solutions should be prepared and transferred using aseptic technique (see Section  3.4.5.1 on 
pixantrone handling precautions). Reconstitution to a solution containing pixantrone 5.8 mg/mL is done 
by adding 5 mL sterile 0.9% Sodium Chloride for Injection, USP/Ph. Eur. or equ ivalent, aseptically 
withdrawn from a 250 mL infusion bag. The solution should be agitated for a minimum of 60 seconds to ensure complete dissolution. The color of the reconstituted solution will be dark blue.  The reconstituted 
vial must be used within 24 hours after reconstitution.  
 The required volume corresponding to the prescribed dose per square meter of BSA is to be aseptically 
withdrawn and injected back into the 250 mL infusion bag containing normal saline for IV injection 
(0.9% NaCl, USP, or local  pharmacopeial equivalent). The final pixantrone concentration will be 
< 1 mg/mL (0.4 mg/mL pixantrone for a patient with a BSA of 2.0 m
2).  
 The diluted solution must be administered as a slow IV infusion over a period of 1 hour (± 10  minutes). 
To ensure exact drug administration, a chronoinfusor should be used. Pixantrone is compatible with the 
diluent contained in polyethylene infusion bags. Polyethersulfone 0.2-micron pore- size inline filters 
should be used.  
3.4.5.3  Storage of Pixantrone 
 
Unopened, non-reconstituted vials of pixantrone are to be stored cold at 2°C to 8° C (36°F to 46°F) and 
protected from light. Diluted or reconstituted pixantrone vials should be protected from freezing.  
 All temperature excursions beyond 2°C to 8°C (36° F to 46°F) should be documented. The following 
temperature excursions must be reported to CTI before the vial is used:  
 
• Any excursions above 8° C (46°F) for more than 24 hours  
• Any excursions above 25° C (77°F) for any amount of time 
• Any excursions below 0 °C (32°F) for any amount of time  
 
Contact CTI BioPharma Corp. for information on additional allowable temperature excursions.  
 
Lot/batch numbers within a single patient’s dose should not be mixed. Mixing of lot/batch numbers is 
allowed within a patient’s treatment cycle.  
 
Pixantrone contains no preservatives, and each vial is intended for single use. Once prepared, the diluted 
solution should be used as soon as possible, and in any case, it should be used within 24 hours of reconstitution (including the 1 -hour infusion time). 
 The diluted solution is stable for up to 24 hours at room temperature (< 25°C/77°F) and under normal light exposure while in polyethylene (PE) standard infusion bags. Stability of reconstituted pixantrone 
solution stored above room temperature has not been ev aluated . 
 
3.4.6 Gemcitabine Preparation, Storage, Handling, and Administration 
 
The current gemcitabine package insert must be consulted for specific precautions and warnings
(27). 
 Gemcitabine for injection, USP or lo cal pharmacopeial equivalent, is a white to off -white lyophilized 
powder available in sterile single-use vials containing 200 mg or 1 g gemcitabine.  
 
Page 44 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
The half-life of gemcitabine is influenced by the length of the infusion, and toxicity appears to be 
increased if gemcitabine is administered more frequently than once weekly, or with infusions longer than 
60 minutes. 
 
The recommended diluent for reconstitution of gemcitabine is 0.9% Sodium Chloride Injection without 
preservatives. Due to solubility considerations, the maximum concentration for gemcitabine upon reconstitution is 40 mg/mL. Reconstitution at concentrations greater than 40 mg/mL may result in 
incomplete dissolution and should be avoided.  
 
To reconstitute, add 5 mL 0.9% Sodium Chloride Injection to a 200 mg vial of gemcitabine or 25 mL 
0.9% Sodium Chloride Injection to a1 g vial. Shake to dissolve. These dilutions each yield a gemcitabine concentration of 38 mg/mL, which accounts for the displacement volume of the lyophilized powder 
(0.26 mL for the 200 mg vial, or 1.3 mL for the 1 g vial). The total volume upon reconstitution will be 
5.26 mL or 26.3 mL, respectively. Complete withdrawal of the vial contents will provide 200 mg or 1 g of 
gemcitabine, respectively. The appropriate amount of gemcitab ine may be administered as prepared, or it 
may be further diluted with 0.9% Sodium Chloride Injection to concentrations as low as 0.1 mg/mL.   
Reconstituted gemcitabine is a clear, colorless to light- straw-colored solution. After reconstitution with 
0.9% Sodium Chloride Injection, the resulting solution is in the range of pH 2.7 to 3.3. The solution 
should be visually inspected for particulate matter and discoloration prior to administration, whenever 
solution or container permits. If particulate matter or discoloration is found, do not administer the drug.  
 When prepared as directed, gemcitabine solutions are stable for 24 hours at controlled room temperature, 20°C to 25°C (68°F to 77°F). Solutions of reconstituted gemcitabine should not be refrigerated, a s 
crystallization may occur. Unopened vials of gemcitabine are stable until the expiration date indicated on the package when stored at controlled room temperature, 20°C to 25°C (68°F to 77°F), which allows for 
excursions between 15°C and 30°C (59°F to 86° F). 
 
No incompatibilities have been observed with infusion bottles or polyvinylchloride bags and 
administration sets.  
 Caution should be exercised in handling and preparing gemcitabine solutions. The use of gloves is 
recommended. If gemcitabine solution contacts the skin or mucosa, immediately wash the skin thoroughly with soap and water, or rinse the mucosa with copious amounts of water. Although acute 
dermal irritation has not been observed in animal studies, 2 of 3 rabbits exhibited drug- related systemic 
toxicities (death, hypoactivity, nasal discharge, shallow breathing) due to dermal absorption.  
3.5 Pixantrone Drug Accountability and Disposal 
 
Drug accountability records will be accurately maintained at the study site. The pharmacist or designee 
must recor d patient and drug information, as described in the study manual. 
 The study drug accountability log must be available for inspection by CTI or its designee and is subject to 
regulatory inspection at any time. The investigator must agree not to destroy or distribute any used or 
unused drug supplies, unless otherwise directed by CTI or its designee.  
 
At the completion of the study, all unused drugs will be destroyed at the site or returned according to 
procedures in the study manual. 
 
Investigational product s should be stored in a secure area according to local regulations. It is the 
Investigator’s responsibility to ensure that investigational products are dispensed only to study patients. 
Page 45 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
Investigational products must be dispensed only from official study sites by authorized personnel 
according to local regulations.  
 
3.6 Study Drug Precautions, Dose Adjustments, and Delays 
 
Unless otherwise specified, dose modification and delay rules in this section apply to both study arms. 
 Dose delays may require that both local and central labs are redrawn. Treatment decisions are based on 
local results. Local labs are required, as needed, for time-limited evaluation windows, per protocol, and to 
support urgent clinical decisions.  
 1. There must be at least 7 days between doses of any study medication.  
2. There must be at least 10 days between Day 15 of one cycle and Day 1 of the subsequent cycle.  
3. Three (3) days is the maximum visit delay allowable for nonmedical reasons (eg, scheduling problems, holidays) during a 28- day treatment cycle. Visit delays > 3 days for nonmedical reasons 
may be permitted with prior Medical Monitor approval.  
4. If Day 1 study drugs of any cycle are delayed ≥ 14 days due to gemcitabine or pixantrone- related 
toxicity, that drug must be discontinued. 
5. If ≥ 28 days have elapsed since the last gemcitabine or pixantrone dose, regardless of the reason, that drug must be discontinued.  
6. Only 1 pixantrone dose reduction is permitted for each patient.  
7. Once a patient has required a pixantrone dose reduction, the dose r emains reduced for all subsequent 
doses. No re -escalation of pixantrone is permitted.  
8. Patients who must discontinue pixantrone or gemcitabine due to toxicity may remain on rituximab every 28 days for up to a total of 6 cycles of study treatment. 
9. Patients who must discontinue rituximab due to toxicity may remain on pixantrone or gemcitabine for 
up to a total of 6 cycles of study treatment.  
10. LVEF should be assessed ≤ 7 days before the expected Day 1 of Cycles 3 and 5. Serum troponin T is 
to be drawn before C ycles 3 and 5 and sent to the central laboratory for batched processing. 
Echocardiogram and troponin T assessments need not be repeated if a dose is delayed for reasons 
other than abnormal LVEF. 
 
Photosensitivity is a potential clinical risk, based on in vitro and in vivo nonclinical data (Section 1.2.2 ). 
No confirmed cases have been reported in the clinical trial program.  
 As a precaution, patients should be advised to follow sun- protection strategies, including  wearing sun -
protective clothing and using sunscreen.  Since most medicinal product-induced photosensitivity reactions are caused by wavelengths within the UV -A range, use of a sunscreen that strongly absorbs UV- A is 
recommended. 
 
 
Page 46 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
3.6.1 Pixantrone Dose Modifi cations for Hematologic Toxicity 
 
Pixantrone treatment modifications for decreased ANC, neutropenic infection, and decreased platelet 
counts are shown in Table--6 and Table--7. 
 
Table--6 
Pixantrone Dose Modifications for Reduced ANC and Infection  
ANC ≥ 1.0 × 109/L No dose change or modification.  
ANC ≥ 0.5 to < 1.0 × 109/L  On Day 1, delay both drugs up to 14 days until recovery to ≥1.0 × 109/L.  
 On Day 8 or 15, skip dose.  
ANC < 0.5 × 109/L  On Day 1, delay both drugs up to 14 days until recovery to ≥1.0 × 109/L. 
 On Day 8 or 15, skip dose.  
 When ANC ≥ 1.0 × 109/L, resume rituximab and restart pixantrone at 
41 mg/m2. No dose reduction is required for patients with bone marrow 
involvement.  
Febrile neutropenia or grade 3/4 
neutropenic infection docu mented 
after the last administered dose.  Pixantrone dose must be reduced to 41 mg/m2 for all subsequent doses.  
 
 
Table--7 
Pixantrone Dose Modifications for Platelet Counts  
Platelet count ≥ 50 × 109/L No dose change or modificat ion. 
Platelet count ≥ 25 to < 50 ×109/L with 
no bleeding   On Day 1, delay both drugs up to 14 days until recovery to 
≥ 50 × 109/L.  
 On Day 8 or 15, skip dose.  
Platelet count < 25 × 109/L  
or 
Bleeding, regardless of platelet levels, if 
platelet transfusio ns are readily available   On Day 1, delay both drugs up to 14 days.  
 On Day 8 or 15, skip dose.  
 When recovery to ≥ 50 × 109/L, resume rituximab and restart 
pixantrone at 41 mg/m2. No dose reduction is required if there is bone 
marrow involvement.  
 
3.6.2 Gemcitabine Dose Modifications for Hematologic Toxicity 
 
All patients should receive the full gemcitabine + R dose for Cycle 1 Day 1. Thereafter, gemcitabine dose 
modifications for hematologic toxicity should follow the guidelines in Table--8. 
 At the investigator’s discretion, a gemcitabine dose can be skipped or decreased. At the investigator’s 
discretion, gemcitabine may be re- escalated after a dose reduction when blood counts have sufficiently 
recovered.  
Page 47 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
 
Table--8 
Gemcitabine Dose Modifications for ANC and Platelet Counts  
Day 8 or 15 of Cycle 1 and  
Day 1, 8, or 15 of Cycles 2 -6 Dose/Schedule  
ANC ≥ 1.0 × 109/L  
AND platelet count ≥100 × 109/L  
If bone marrow involvement, platelet 
count must  be ≥ 75 × 109/L 100% of full dose  
ANC 0. 5 to 0.99 × 109/L  
OR  
platelet count 50 to 99 × 109/L Reduce gemcitabine dose by 25% (to 750 mg/m2) until ANC recovery to 
≥ 1.0 × 109/L  
 
AND platelet count ≥  100 × 109/L  
(If bone marrow involvement, platelet count must recover to 75 × 109/L; 
then dose may be re- escalated to full dose, at the investigator’s discretion.)  
 
A second dose reduction (to 500 mg/m2) is allowed, at the investigator’s 
discretion, if ANC does not recover to ≥  1.0 × 109/L and platelet coun t 
≥ 100 × 109/L. If ANC and platelet count do recover, the dose may be re-
escalated, at the investigator’s discretion.  
ANC < 0.50 ×109/L  
OR 
platelet count <  50 ×109/L Delay gemcitabine treatment, until recovery to ANC ≥  1.0 × 109/L 
and platelet count ≥  100 × 109/L  
(If bone marrow involvement, platelet count must recover to ≥  75 × 109/L.) 
 
If no recovery within 14 days, patient must be discontinued from 
gemcitabine and entered into Follow -up or continued on rituximab alone.  
 
3.6.3 Gemcitabine and Pixantrone Do se Modifications for Nonhematologic Toxicity  
 
1. Unless otherwise specified, dose modification and delay rules in this section apply to both study arms. 
2. Grade 1 study drug- related nonhematologic toxicities require no change in treatment.  
3. For grade 2 or 1- grade increases from baseline study drug -related nonhaematologic toxicities, 
treatment with that study drug must be delayed until recovery to grade 1 or baseline at the discretion of the investigator, with retreatment at the same dose level.  
4. Any grade 3 or higher nonhaematologic AE related to a study drug requires, at the discretion of the 
investigator, either discontinuation of treatment or delay of treatment with a 1-level dose reduction 
(Table--9), until recovery to grade 1 or less, or to baseline. Recurrence of grade 3/4 toxicity at the 
reduced dose requires that the patient be discontinued from that agent.  
 
Page 48 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
The dose levels for pixantrone and gemcitabine are as shown in  Table--9. 
 
Table--9 
Pixantrone and Gemcitabine Dose Levels  
Drug Dose Level  Dose (mg/m2) 
Pixantrone  1 50 
2 41 
Gemcitabine  1 1,000 
2 750 
3 500 
 
Exceptions include a 1 -grade increase from baseline, alopecia, grade 3 nausea and  vomiting if 
controlled by supportive measures, central line-related thrombosis, and LVEF declines for pixantrone patients (see below). Gemcitabine, but not pixantrone, can be re- escalated, at the discretion of the 
investigator, after the AE recovers to grade 1 or less.  
 
5. Patients on pixantrone who have an absolute decrease in LVEF from baseline values of ≥ 16% or an 
absolute LVEF decrease of ≥ 10% to below institutional limits of normal should have treatment held 
and the LVEF confirmed with a repeat echocardiogram in 1 to 2 weeks. If the repeat LVEF is within the institutional limits of normal and the absolute decline is ≤ 15% from baseline, resume study drugs. 
If LVEF is still abnormal, the patient must be discontinued from pixantrone treatment, but may, at the 
investigator’s discretion, continue rituximab treatment for up to a total of 6 cycles.  
6. Pixantrone patients who develop congestive heart failure (CHF) during study treatment must be discontinued from pixantrone. The patient may, at the investigator’s discretion, continue rituximab treatment for up to a total of 6 cycles.  
3.6.4 Rituximab Precautions and Discontinuation  
 
The current rituximab package insert must be consulted for full prescribing information.  
 The most common adverse reactions from rituximab (incidence ≥25%) observed in clinical trials were 
infusion reactions, fever, neutropenia, lymphopenia, chills, infection, and asthenia. The incidence of 
infusion reactions was highest during the first infusion (77%) and decreased with each subsequent 
infusion. These infusion reactions typically resolved with slowing or interruption of the infusion and with 
supportive care. The most frequent grade 3 or 4 adverse reaction observed in NHL was cytopenia, 
including lymphopenia. 
 
Any grade 3/4 adverse reactions to  rituximab may require (at the discretion of the investigator and the 
institutional standard) discontinuation of rituximab, but the patient may, at the investigator’s discretion, remain on study and continue to receive the other study drug (pixantrone or g emcitabine) for up to a total 
of 6 cycles.  
 
3.6.4.1  Cytokine Release Syndrome 
 
Patients should be monitored for cytokine release syndrome for at least 2 hours following the first 
infusion of rituximab. Patients who develop evidence of severe reactions, especially severe dyspnea, 
bronchospasm or hypoxia should have the infusion interrupted immediately. Patients should then be evaluated for evidence of tumor lysis syndrome (TLS), including appropriate laboratory tests and, for 
Page 49 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
pulmonary infiltration, with a chest x-ray. In all patients, the infusion should not be restarted until 
complete resolution of all symptoms and normalization of laboratory values and chest x-ray findings. At 
that time, the infusion can be initially resumed at not more than one- half the previous rate. If the same 
severe adverse reactions occur a second time, the decision to stop the treatment should be seriously considered on a case-by- case basis.  
 
Patients with a high tumor burden, or with a high number (25 × 10
9/L) of circulating malignant cells, may 
be at higher risk of especially severe cytokine release syndrome, and should be treated with extreme caution. These patients should be very closely monitored throughout the first infusion.  
 
Severe cytokine release syndrome is characterised by severe dyspnoea, often accompanied by bronchospasm and hypoxia, in addition to fever, chills, rigors, urticaria, and angioedema. The syndrome 
frequently manifests itself within 1 or 2  hours of initiating the first infusion. Cytokine release syndrome 
may be associated with some features of TLS, such as hyperuricemia, hyperkalemia, hypocalcaemia, hyperphosphatemia, acute renal failure, and elevated lactate dehydrogenase (LDH), and may be 
associated with acute respiratory failure and death. Acute respiratory failure may be accompanied by 
events such as pulmonary interstitial infiltration or edema, visible on a chest x- ray.  
 
Patients with a history of pulmonary insufficiency, or those with pulmonary tumor infiltration, may be at 
greater risk of poor outcome and shoul d be treated with increased caution. Patients who develop severe 
cytokine release syndrome should have their infusion interrupted immediately and should receive aggressive symptomatic treatment. Since initial improvement of clinical symptoms may be followed by 
deterioration, these patients should be closely monitored until TLS and pulmonary infiltration have been resolved or ruled out. Further treatment of patients after complete resolution of signs and symptoms has 
rarely resulted in repeated severe cytoki ne release syndrome.  
 
3.6.4.2  Hypersensitivity Reactions and Anaphylaxis  
 
In contrast to cytokine release syndrome, true hypersensitivity reactions typically occur within minutes 
after starting an infusion with rituximab. Infusion- related adverse reactions are usually reversible, with 
interruption of rituximab infusion and administration of an antipyretic, an antihistaminic, and, occasionally, oxygen, IV saline or bronchodilators, and glucocorticoids. Medicinal products for the 
treatment of hypersensitivity reactio ns, such as epinephrine (adrenaline), antihistamines, and 
glucocorticoids should be available for immediate use during administration of rituximab in the event of 
an allergic reaction.  
 Clinical manifestations of anaphylaxis may appear similar to clinical manifestations of the cytokine 
release syndrome.  
 
3.6.4.3  Progressive Multifocal Leukoencephalopathy  
 
Use of rituximab may be associated with an increased risk of progressive multifocal leukoencephalopathy 
(PML). Patients must be monitored at regular intervals for any new or worsening neurological symptoms 
or signs that suggest PML. If PML is suspected, further dosing must be suspended until PML has been 
excluded. The physician should be particularly alert to symptoms suggestive of PML that the patient may not notice (eg, cognitive, neurological, or psychiatric symptoms). Patients should also be advised to 
inform their partner or caregivers about their treatment, since their partners or caregivers may notice 
symptoms that the patient is unaware of. 
 
If a patient dev elops PML, the dosing of rituximab must be permanently discontinued. 
 
Page 50 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
3.7 Concomitant Medications 
 
Patients may receive all concomitant therapy deemed necessary to provide adequate support, but only 
study-prescribed investigational agents can be used during the study. Patients may not receive subsequent 
systemic anticancer therapy or radiotherapy to target lesions while receiving treatment in this study. Low -
dose corticosteroids may be used for the treatment of non- cancer-related illness at the discretion of the 
investigator.  
 
Colony-stimulating factors may be used at the investigator’s discretion and according to the institutional 
guidelines, but must be discontinued at least 2 days prior to the next scheduled study drug administration. If Neulasta (pegfilgrast im) is to be used, it should be given only after the Day 15 dose of each cycle.  
 
Routine prophylaxis with antiemetics is recommended per institutional guidelines. In addition, routine 
premedication and additional treatments to help prevent or treat hypersensitivity and anaphylaxis to 
rituximab are recommended (see rituximab package insert), or per institutional guidelines. Routine 
prophylaxis to prevent TLS by administration with either allopurinol or rasburicase will also be allowed, 
per the investigator’ s clinical judgment. 
 
Patients who receive pixantrone and are concomitantly taking medications that are CYP1A2 substrates, 
such as tricyclic antidepressants or theophylline, should be closely monitored, as pixantrone has the 
potential to impair metabolism of these agents.  
 Patients receiving pixantrone must be encouraged to avoid excessive exposure to sunlight and use effective sunblocker agents. Topical sunblocking agents should not be reported as concomitant 
medications.  
 All concomitant medications, including routine prophylaxis and premedications, are to be recorded on the 
electronic case report forms for the study.  
 
In vitro studies with the most common human cytochrome P450 isoforms (including CYP1A2, 2B6, 2C8, 
2C9, 2C19, 2D6 and 3A4) have shown a possible mixed-type inhibition of CYP1A2and CYP2C8 that 
may be of clinical relevance. No other significant clinically relevant interactions with CYPP450 isozymes were observed.  
 
Theophylline is primarily metabolised by CYP1A2. When co- administering the narrow -therapeutic index 
medicinal product theophylline with pixantrone, there is a theoretical concern that this substrate may increase in concentration, resulting in theophylline toxicity. Theophylline levels should be carefully 
monitored in the weeks immediat ely following initiation of pixantrone concurrent therapy. 
 
Warfarin is partially metabolised by CYP1A2, and a theoretical concern exists with regard to co -
administration of this medicinal product and the effect inhibition of its metabolism might have on i ts 
intended action. Coagulation parameters, specifically international normalised ratio (INR), should be 
monitored in the days immediately following the initiation of pixantrone concurrent therapy. 
 
Amitriptyline, haloperidol, clozapine, ondansetron and propranolol are metabolised by CYP1A2, and therefore a theoretical concern exists that co -administration of pixantrone may increase blood levels of 
this medicinal product.  
 
Based on in vitro studies, pixantrone was found to be a substrate for the membrane tr ansport proteins P -
gp/BRCP and OCT1.  Agents that inhibit these transporters have the potential to decrease hepatic uptake 
and excretion efficiency of pixantrone.  Blood counts should be closely monitored when co- administered 
Page 51 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
with agents that inhibit such transporters, such as cyclosporine A or tacrolimus, commonly used to control 
chronic graft- versus-host disease (GVHD), and the anti -HIV agents, ritonavir, saquinavir, or nelfinavir. 
 
In addition, caution should be taken when pixantrone is continuously co-a dministered with efflux 
transport inducers, such as rifampicin, carbamazepine, and glucocorticoids, as pixantrone excretion maybe increased with a consequent decrease of systemic exposure.  
 
3.8 Visit Schedule and Assessments  
 3.8.1 Visit Schedule  
 
At randomization, the planned visit schedule according to the Study Schedule  (Table--1, Table--2) will be 
discussed with the patient. All efforts should be made to adhere to this visit schedule. Deviation from the planned visit dates must be avoided in order to ensure that assessments are performed at the predefined 
time points.  
 
3.8.1.1  Screening Period  
 
Patient consent will be obtained prior to performance of any study related procedures; standard of care 
procedures applicable to screening obtained within 28 days of randomization can be used for 
qualification, unless otherwise specified.  
 
Following confirmation of eligibility criteria, patients will be randomized to treatment (Section 3.4.1). 
 
The assessments performed at the screening visit are listed below. Unless otherwise specified, screening 
assessments can be performed up to 28 days before randomization. All laboratory test values collected as 
part of the study will be evaluated by the central laboratory as well as by local laboratories. Local 
laboratory evaluations are used for real -time decisions regarding study eligibility. Local labs are required, 
as needed, for time -limited evaluation windows, per protocol, and to support urgent clinical decisions. 
 
• Pathology and immunohistochemistry reports documenting a current histological diagnosis of 
DLBCL (de novo DLBCL or DLBCL tr ansformed from indolent lymphoma), or follicular grade 3 
lymphoma according to WHO classification are required and must be reviewed by the sponsor or 
designee prior to randomization.  
• Tissue biopsy slides confirming follicular grade 3 lymphoma or DLBCL should be requested during 
the screening period and sent as soon as possible for retrospective central pathology review, but completion of central review is not required prior to randomization and treatment. In addition, if a 
bone marrow biopsy (with core) was performed within 8 weeks of randomization to evaluate bone 
marrow involvement of disease this should be submitted to the local pathology laboratory for review. 
•  Medical/cardiac history  
• Demographics and baseline disease characteristics  
• Physical examinatio n, vital signs, and weight  
• Detailed history of primary NHL diagnosis and all prior treatments for NHL  
• Adverse events are collected for randomized patients from the time of signing the Informed Consent Form  
• Serum HCG (WOCBP only)  
• IPI score (Section  8.1), calculated using the screening LDH value and current disease stage  
• CBC with differential  
Page 52 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
• Chemistry panel for central laboratory (includes total bilirubin, alkaline phosphatase, ALT, AST, total 
protein, albumin, sodium, potassium, calcium, magnesium, phosphorus, glucose, creatinine, LDH, 
and uric acid).  Local chemistry panel is used for eligibility  
• Urinalysis  
• Cardiac assessment: LVEF by echocardiogram, ECG, and serum troponin T (see Section  3.10.4) 
• Concomitant medications 
• Baseline disease assessment of the neck, chest, abdomen and pelvis. CT with intravenous contrast is 
the preferred imaging modality, but patients intolerant of CT IV contrast may have MRI of the neck, 
abdomen, and pelvis with noncontrast chest CT (see Section 3.9.1 ). The imaging method used at 
baseline must be used throughout the study 
• Baseline PET is not required; however, if PET scan was obtained within 28 days prior to 
randomization, images are to be submitted for IRC review  
• ECOG performance status (Section  8.2) 
• Ann Arbor stage (Section 8.3 ) 
 
3.8.1.2  Treatment Period  
 
Treatment  must be initiated as soon as possible and no more than 14 days after randomization. The 
treatment period continues until the end-of- treatment visit. Patients will be evaluated through this period 
for toxicities and adverse events. Assessments to be perfor med during the treatment period are listed 
below and are detailed in Table--1. 
 
• CBC with differential ≤ 1 day prior to every study drug administration   
• Chemistry panel for central laboratory (includes total biliru bin, alkaline phosphatase, ALT, AST, total 
protein, albumin, sodium, potassium, calcium, magnesium, phosphorous, glucose, creatinine, LDH, 
and uric acid) ≤ 7 days prior to study drug administration on Day 1 of each cycle.  Local chemistry panel may be used  to guide dosing.   
• Vital signs prior to study drug administration 
• Weight on Day 1 of all cycles for BSA used for dosing should be calculated at least at the beginning 
of each cycle or by institutional standards.  
• Physical examination required ≤ 3 days prior to Day 1 study drug administration for Cycles 2-6. 
Symptom-directed examination as needed ≤ 1 day before study drug administration on Day 1 Cycle 1 
and Days 8 and 15 of all cycles. 
• Urine pregnancy test for WOCBP ≤ 1 day prior to study drug administration on Day 1 of all cycles  
• Adverse events at each visit day  
• Concomitant medications at each visit day  
• LVEF by echocardiogram ≤ 7 days before Day 1 of Cycles 3 and 5. Troponin T is obtained before Cycles 3 and 5 (see Section  3.10.4). Echocardiogram and troponin T need not be repeated if a dose is 
delayed for reasons other than abnormal LVEF.  
• ECOG performance status ≤ 1 day prior to study drug administration on Day 1 of each cycle 
• Disease assessment by CT/MRI imaging is to be obtained every 8 weeks ± 1 week and must be performed as close as possible to the scheduled dates. Disease assessment time points during the 
study are to be calculated from Day 1 of Cycle 1. In the case of CT/MRI imaging done outside the 
calendar schedule (unscheduled), consult with Medical Monitor for appropriate scheduling of the next 
CT/MRI. 
Page 53 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
• Pharmacokinetics Assessments (participating sites refer to Section  12 Addendum: Pharmacokinetics 
Sub-Study) 
 
Routine local laboratory panels and LVEF measurement reports must be reviewed by a qualified health 
professional participating in the study prior to the next administration of study drug. Dose modifications 
will be done according to the rules in Section 3.6 . 
 
PET scans are not required during treatment, but disease response must be evaluated (per criteria in 
Section 3.9.6)  and reported by the site for all PET images ob tained at any time during the study prior to 
progressive disease per Modified IWG criteria or subsequent systemic anticancer therapy, except for rituximab given as maintenance therapy. All such PET images will be submitted for IRC review.  
 
Regardless of whether serum samples, radiologic material and other patient data are sent to a central lab 
or independent review panel for study purposes, treatment, and eligibility decisions must be made by the 
investigator based on his or her clinical assessment of the p atient and interpretation of local labs, 
radiology assessments, and other tests.  
 
Dose delays may require that both local and central labs are redrawn to comply with these time periods.  
 
3.8.1.3  End of Treatment Visit 
 
The EOT visit is defined as being at 4 to 7 w eeks, inclusive, after the last dose of study drug is 
administered (or was scheduled to be administered), or before subsequent systemic anticancer therapy is given, whichever occurs first. Note that rituximab given as maintenance therapy is not allowed pri or to 
the EOT visit per protocol window. However, even if rituximab is given as maintenance therapy prior to 
EOT, all EOT procedures, including PET, will be performed. In the unanticipated event that a patient 
receives no study drug, no EOT procedures are required and the patient would continue per protocol 
Section 3.8.1.4.  
 
Additional information on AE reporting can be found in Section 3.10 . 
 
End of Treatment Procedures  
 
The following assessments should be performed at the EOT visit (at 4 to 7 weeks after last study drug dose, inclusive):  
 
• CBC with differential  
• Chemistry panel for central laboratory (includes total bilirubin, alkaline phosphatase, ALT, AST, total 
protein, albumin, sodium, potassium, calcium, magnesium, phosphorous, glucose, creatinine, LDH, and uric acid)  
• Physical examination, vital signs, and weight  
• Concomitant medications 
• Adverse events  
• ECOG performance status  
• Measurement of LVEF by echocardiogram  
• ECG 
• Serum troponin T  
• PET scan  
Page 54 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
• Bone marrow biopsy with core to confirm a CR, unless a bone marrow biopsy was obtained at 
baseline and was negative 
 A bone marrow biopsy (with core) is required at EOT (at 4 to 7 weeks after last study drug dose, 
inclusive) to confirm a CR, unless a bone marrow biopsy was obtained at baseline and was negative. 
Bone marrow biopsies are submitted for local review.  
 A PET scan is required at the EOT visit (at 4 to 7 weeks after last study drug dose, inclusive), unless 
geographical ly unavailable or the patient has PD per Modified IWG criteria, or the patient has received 
subsequent systemic anticancer therapy, except for rituximab given as maintenance therapy. If the PET scan cannot be done at EOT, it may be scheduled to coincide wi th the first early follow -up disease 
assessment.  
 Note that rituximab given as maintenance therapy is not allowed prior to the EOT visit. However, even if 
rituximab is given as maintenance therapy prior to EOT, all EOT procedures, including PET, will be 
performed.   
 
Out-of-Window PET Scan and Bone Marrow Biopsy 
 
If it is not possible to obtain the EOT PET scan within the protocol-specified window (at 4 to 7 weeks 
after last study drug dose, inclusive), ongoing attempts should be made to obtain a PET scan f or every 
patient who has not progressed or started subsequent systemic anticancer therapy, except for rituximab 
given as maintenance therapy (ie, chemotherapy, radiation therapy, or oncologic surgical therapy). 
 If it is not possible to obtain the EOT bone marrow biopsy (with core) within the protocol -specified 
window, ongoing attempts should be made to obtain this biopsy from every patient who achieves and remains in CR, and has not started subsequent systemic anticancer therapy, except for rituximab given  as 
maintenance therapy (ie, chemotherapy, radiation therapy, or oncologic surgical therapy).  
 
3.8.1.4  Follow- up Periods  
 
Please see Table--2 for details of the Follow -up Schedule. 
 Patients who complete or discontinue study treatment will enter the Early Follow -up Period.  This 
includes patients assessed as Progressive Disease Due to Symptomatic Deterioration.  
 However, a patient enters the Survival Follow-up Period if, during the treatment, Early Follow-up or 
Intermediate Follow -up periods, he or she: 
 
• Develops progressive disease per Modified IWG criteria  
• Receives subsequent systemic anticancer therapy, except for rituximab given as maintenance therapy  
• Withdraws consent for study procedures 
 
All randomized patients who withdraw consent will be followed for survival and safety as described 
below, unless they have rendered a separate written withdrawal of consent.  
 Study-drug related adverse events and cardiac adverse events ≥ grade 3, including LVEF declines, are collected and followed until resolution or no further improvement is expected or until the end of the 
study.  
Page 55 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
Adverse events not related to study drug and cardiac AEs ≤ grade 2 are collected and followed for 30 
days after the last dose of the study drug, until no further improvement is expected, or until the patient 
begins a subsequent systemic anticancer therapy, except for rituximab given as maintenance therapy, 
whichever occurs first.  
 Early Follow- up 
 
The Early FU Week 8 visit occurs 8 weeks after the last protocol calendar scheduled CT/MRI imaging 
disease assessment to ensure an 8 -week interval between protocol calendar scheduled scans. In the case of 
CT/MRI imaging done outside the calendar schedule (unscheduled), consult with Medical Monitor for appropriate sch eduling of the next CT/MRI. 
 
The Early Follow- up period lasts 24 weeks. Safety evaluation includes measuring LVEF by 
echocardiogram and obtaining a troponin T sample at Week 24 ± 1 week.   
All other assessments, including CT/MRI disease response, LDH, surv ival status, and details of any 
subsequent systemic anticancer therapy, including rituximab given as maintenance therapy, are evaluated and recorded every 8 weeks ± 1 week.  
 
Intermediate Follow -up 
 
Patients who complete the 24- week Early Follow -up period then enter the 72- week Intermediate Follow -
up period. During Intermediate Follow- up, CT/MRI disease response, LDH, survival status, and details of 
any subsequent systemic anticancer therapy, including rituximab given as maintenance therapy, are 
evaluated and recorded every 12 weeks ± 2 weeks.  
 
Survival Follow -up 
 
Patients enter the Survival Follow -up period when one of the following occurs: 
 
• Completes Intermediate Follow -up 
• Develops progressive disease per Modified IWG criteria  
• Receives a subsequent systemi c anticancer therapy, except for rituximab given as maintenance 
therapy 
• Withdraws consent for study procedures 
• Completes study treatment and EOT evaluations after 195 PFS events have occurred 
• Is in Early or Intermediate Follow-up at the time that 195 PFS e vents have occurred  
 
The first Survival Follow -up visit should be scheduled 12 weeks (± 2 weeks) from the last study visit. 
During the Survival Follow -up period, each patient is followed for survival status every 12 weeks ±  2 
weeks until death, the end of the study, or the patient withdraws informed consent. 
 
Page 56 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
3.9 Efficacy Assessment  
 
An Independent Radiological Committee (IRC) will assess radiographic images obtained during this 
study based on a prespecified Image Charter.  
 A Site Procedures Manual will be p rovided to all clinical sites to facilitate the consistent and quality 
acquisition of imaging data. All clinical sites and imaging centers will be certified by the independent imaging CRO according to their ability to obtain quality images. 
 
Investigators will assess radiographic images obtained during this study per protocol based on the modified IWG criteria; decisions regarding treatment and eligibility must be made by the investigator 
based on his or her assessments.  
 
3.9.1 Disease Assessment by Imaging  
 
All patients are required to have scans of the neck, chest, abdomen, and pelvis at the evaluation time 
points specified in  Table--1. At each evaluation time point, every target and non -target lesion must be 
evaluated. Detailed procedures for assessment and measurement of disease are found in Section  8.6. The 
method used to assess measurable disease at baseline must be used at all subsequent evaluations. Once a 
patient is assessed by the investigator as having PD as defined by the Modified IWG criteria, no further 
CT or PET scans or disease response assessments are required by the study.  
 
CT with IV contrast is the preferred anatomic imaging modality. Patients who have an allergy to 
iodinated contrast media will have magnetic resonance imaging (MRI) of the neck, abdomen and pelvis 
and noncontrast CT of the chest. Excluded from MRI examination are patients with contraindicated 
implants, allergy to gadolinium, and acute or chroni c severe renal insufficiency (glomerular filtration rate 
< 60 ml/min). If a patient cannot have a contrast CT or MRI, noncontrast CT scan of the neck, chest, 
abdomen, and pelvis must be obtained. 
 
PET/CT images should not typically be used for lesion measurements, unless the CT images are obtained 
using optimal CT imaging protocols in a fashion consistent with other study CT imaging time points (ie, 
similar imaging energies and use of IV contrast). Lesions should be measured with CT/MRI imaging per the above paragraph. Chest X-ray, other radionuclide scans, and ultrasonography may not be used to 
evaluate measurable disease.  
 
3.9.2 PET Scans  
 
PET scans obtained alone or in combination with CT scan (PET/CT) should be acquired from the skull 
base to the upper thighs following standard imaging protocols. 
 A baseline PET scan is not required, but if obtained within 28 days prior to randomization, images are to 
be sent to the IRC for review and all sites of disease chosen as target lesions must be PET -positive.  If a 
baseline PET scan is not done, all lesions are assumed to be PET -positive.  
 Any unscheduled PET scans obtained during treatment or follow-up periods must be evaluated for disease 
response (per criteria in Section 3.9.6), reported by the site, and be sent to the IRC for review.  
 A PET scan is required at EOT, unless not geographically available and/or the patient has progressive 
disease per Modified IWG criteria, or has received subsequent systemic anticancer therapy. Rituximab given as maintenance therapy is not allowed prior to the EOT visit per protocol window. However, even 
Page 57 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
if rituximab is given as maintenance therapy prior to EOT, all EOT procedures, including PET, will be 
performed.   
 
If it is not possible to  obtain the EOT PET scan within the protocol-specified window (at 4 to 7 weeks 
after last study drug dose, inclusive), ongoing attempts should be made to obtain a PET scan for every patient who has not progressed or started subsequent systemic anticancer therapy, except for rituximab given as maintenance therapy (ie, chemotherapy, radiation therapy, or oncologic surgical therapy). As per 
the Modified IWG criteria, a PET scan (and bone marrow) at EOT is required for determination of CR at 
EOT (and subsequent time points). If no PET scan (and bone marrow) is available at EOT, PR is the best 
possible response assessment at and after EOT until such time as the PET scan and bone marrow are 
obtained. Disease response assessments at time points after EOT are based solely on CT/MRI findings, 
within these limitations.  
 
3.9.3 Disease Assessment Definitions  
 3.9.3.1  Measurable Disease  
 
Measurable sites of disease are defined as clearly bidimensionally measurable lymph nodes, nodal masses 
and extranodal sites of lymphoma. Measurable l ymph nodes and nodal masses must be ≥ 1.5 cm, and 
extranodal sites of disease must be >1.0 cm in short axes. Measurable lesions must always be assessed by 
imaging. 
 
3.9.3.2  Nonmeasurable Disease  
 
Nonmeasurable disease includes other lesions or sites of disease that are not bidimensionally measurable, 
such as positive bone marrow, peripheral blood, bone lesions, mucosal lesions in the GI tract, effusions, 
and peritoneal/bowel wall thickening. 
Page 58 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
Table--10 
Disease Assessment Definitions  
Node/Nodal disease A lymph node lesion 
Extranodal disease  A non-nodal lesion in a solid organ such as the liver, spleen, kidneys, lung, etc  
LDi Longest diameter of a measurable lesion (nodal or extranodal)  
SDi Short diameter is the longest perpendicular diameter to the LDi  
PPD Product of the perpendicular diameters (applies to a single lesion). SDi × LDi = PPD  
SPD Sum of the products of the perpendicular diameters (applies to a group of lesions). The 
SPD is the sum of all target lesions’ PPDs  
CR Complete response 
PR Partial response  
SD Stable disease  
PD Progressive or relapsed disease  
Nadir The lowest value, whether at baseline or any other study time point.  
 
3.9.4 Selection of Nodal and Extranodal Target Lesions 
 
One to six bidimensionally measurable noda l or extranodal sites of disease (Section 3.9.3.1 and Section 
8.6.1) should be selected at baseline as target lesions. Measurable lesions representative of all affect ed 
organs should be included, and sites of disease should be chosen from as disparate regions of the body as possible. If measurable nodal disease is present in the mediastinum or retroperitoneum, at least one lesion 
from that region should be included as a target lesion.  
 Measureable lesions in a previously radiated site cannot be considered target lesions.  
 
If a baseline PET scan was done, nodal and extranodal lesions selected as target lesions must be PET 
positive. 
 
All measurements of target lesions are based on SDi and LDi ( Table--10). 
 
3.9.5 Selection of Non -Target Lesions  
 
Up to six sites of disease may be selected at baseline as non -target lesions. If more than six sites of nodal 
and extranodal disease are measurab le, additional sites may be followed as non- target lesions. Lesions 
present at baseline and clearly abnormal by CT/MRI but negative by PET scan should be followed as 
non-target lesions. Other nonmeasurable disease may be followed as non -target lesions.  
 
At each disease assessment, non -target lesions are individually visually assessed as absent, stable, 
increased, or decreased (see Section 8.6.3). 
 
3.9.6 Criteria for Response  
 
The modified IWG 2007 Revised Response Cri teria used in this study are detailed in  Table--11. See 
Table--10 for definitions of terms and abbreviations.  Disease response assessments at time points prior to 
EOT are based on all criteria, with the exception of bone marrow and PET scan results.  Bone marrow 
Page 59 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
and PET assessments are only scheduled per protocol at EOT and are required to assess CR status at and 
after EOT. If not obtained at EOT, bone marrow (Section 3.9.7 ) and PET assessments (Section 3.9.2) may 
be subsequently obtained and used to assess CR status at that time. CR assessments at and after EOT require the bone marrow and PET results obtained at EOT. 
 
Regardless of the size on CT/MRI, a nodal lesion that is PET negative may be compatible with a CR. Extranodal lesions, however, must be absent for a CR. 
 
Progressive disease includes any new FDG -avid lesion compatible with lymphoma or recurrent FDG-
avidity in a preexisting lesion that is ≥ 1.5 cm for nodal disease and > 1.0 cm in any axes for extranodal disease and has unequivocally progressed. Increased FDG -avidity in a previously unaffected site can only 
be considered progressive disease after confirmation by CT or MRI scans obtained within 2  weeks of the 
PET scans.  Lesion size confirmation must be obtained using optimal CT or MRI imaging in a fashion consistent with other study CT or MRI imaging time points (ie, similar imaging energies and use of IV 
contrast). If progression per PET scan is later confirmed by CT scan, the date of PD is considered the date the increased avidity was noted on PET scan. Once a patient is assessed as having PD by imaging criteria, 
no further CT or PET scans or disease response assessments are required by the study.   
 
All scans must be complete per protocol to determine the disease response. In the case of a patient with 
incomplete baseline imaging, subsequent response assessments are limited to either “Unknown” or 
“Progressive Disease”.  In a patient with complete baseline imaging, but incomplete or inadequate imaging at one or more subsequent time points, response assessments at time points with missing data are 
limited to either “Unknown” or “Progressive Disease”.   
 
Some patients may be unable to continue study treatment due to progressing lymphoma that does not 
meet the Modified IWG 2007 Revised Response Criteria for Malignant Lymphoma. In patients who are 
determined to have “Progressive Disease due to Symptomatic Deterioration”, or otherwise are withdrawn 
from treatment, study- specified imaging will continue to be obtained and disease response assessed, 
unless the patient withdraws consent for this imaging. Date of progressive disease per Modified IWG 
criteria must be reported if assessed prior to initiation of subsequent systemic anticancer therapy, except 
for rituximab given as maintenance therapy.  
 After a patient is assessed as having PD per Modified IWG criteria or starts subsequent systemic anticancer therapy, except for rituximab given as maintenance therapy, no further CT or PET scans or 
disease response assessments are required by the study.   
 See Sections 8.6.2 and 8.6.3 for detailed instructions regarding the lesion assessments necessary to 
evaluate responses according to these criteria.  
 
Page 60 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
Table--11 
Modified IWG 2007 Revised Response Criteria  for Malignant Lymphoma  
Assessment of response is compared with baseline; assessment of PD is compared with nadir.  
See text section  3.9.6  for further details regarding response assessments in the case of incomplete imaging at  
protocol -scheduled time points.  
Responsea Evaluation  Criteria 
CR 
 
All criteria are 
required.b Target Nodal Lesions  Nodal sites <  1.5 cm in LDi and SDi. A nodal lesion  of any 
size is permitted if PET negative . 
Target Extranodal Lesions  Absent (0 × 0 cm)  
Non-Target Lesions  Regression to normal . A nodal lesion  of any size is permitted if 
PET negative . 
Spleen/Liver  Prior enlargement has regressed to normal  
New Lesions  None  
PET b No evidence of residual disease.  
Bone Marrow b If bone marrow was involved by lymphoma before treatment, 
the infiltrate must have cleared on repeat biopsy; if 
indeterminate is immunohistochemistry negative  
LDH  Normal  
PR 
 
All criteria are 
required 
and 
criteria for PD or 
CR are NOT met  Target Lesions  At least a 50% decrease in  SPD of all target lesions combined  
Non-Target Lesions  Absent, normal, regressed or stable (no increase)   
Spleen/Liver  Any enlargement has decreased, regressed to normal, or is 
stable (stable enlargement)   
New Lesions  None  
PET N/A 
Bone Marrow  N/A  
LDH  N/A  
SD Criteria for PD, PR or CR are NOT met.  
PD 
 
At least one criteria is met 
(cannot be LDH alone) Target Lesions  
(at least one of these criteria is 
met) At least a 50% increase in SPD (sum of all target lesions)   
Individual target les ion(s) must be abnormal in size in any axes 
(≥ 1.5 cm for nodal disease, > 1.0 cm for extranodal disease)  
AND the LDi or SDi has increased by ≥  50%  
OR the PPD has increased by ≥  50% 
Non-Target Lesions  Unequivocal progression  
Spleen/liver  Unequivoca l increase  
New Lesions  A new node ≥ 1.5 cm in any axis  
A new extranodal site > 1.0 cm in any axis 
Assessable disease of any size unequivocally attributable to 
lymphoma  
PET A new FDG -avid lesion compatible with lymphoma  
Recurrence of FDG -avidity in a preexisting lesion(s) that is 
≥ 1.5 cm for nodal disease and > 1.0 cm for extranodal disease 
in any axes and has unequivocally progressed  
Bone Marrow  New or recurrent involvement  
LDH Elevated 
Page 61 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
Table--11 
Modified IWG 2007 Revised Response Criteria  for Malignant Lymphoma  
Assessment of response is compared with baseline; assessment of PD is compared with nadir.  
See text section  3.9.6  for further details regarding response assessments in the case of incomplete imaging at  
protocol -scheduled time points.  
Responsea Evaluation  Criteria 
aCheson B, Pfistner B, Juweid M et al.(28). 
b PET and bone marrow are required evaluations at EOT only and are required to assess CR status.  If not obtained at EOT, bone 
marrow (Section 3.9.7) and PET (Section 3.9.2) may be subsequently obtained to assess CR status at that time.  CR assessments 
during FU (after EOT) require the bone marrow and PET results obtained at or after EOT in order to assess CR status.  
 
3.9.7 Bone Marrow Biopsy  
 
A bone marrow biopsy (with core) is required at EOT to confirm a CR, unless it was obtained within 8 weeks prior to randomization and was negative. All bone marrow biopsies obtained during the study 
should be locally assessed and recorded on the CRF. 
 
 If it is not possible to obtain the EOT bone marrow biopsy within the protocol-specified window (at 4 to 
7 weeks after last study drug dose, inclusive), ongoing attempts should be made to obtain this biopsy from every patient who achieves and remains in CR, and has not started subsequent systemic anticancer 
therapy, except for rituximab given as maintenance therapy (ie, chemotherapy, radiation therapy, or oncologic surgical therapy). 
 
3.9.8 Efficacy Endpoints  
 
Disease response will be assessed according to the Modified IWG 2007 Revised Response Criteria in Table--11. Efficacy analyses will use the response assessments of the IRC. All obtained CT, MRI, and 
PET scans, and LDH and bone marrow evaluations will be locally assessed by the investigator during the conduct of the study for the purpose of eligibility and disease response assessment.  
 
3.9.8.1  Primary Endpoint 
 
Progression -free survival (PFS)  is defined as the time from the date of randomization to the date of PD 
or death due to any cause (whichever occurs first) in the intent -to-treat (ITT) population. Patients with no 
documented progression or death before data cutoff will be censored at the date of the last adequate 
radiological assessment (defined as the last radiological assessment or set of radiological assessments sufficient to allow IRC disease response assessment per PIX306 Modified IWG 2007 Revised Response 
Criteria). 
 Patients who receive high -dose therapy and SCT or other subsequent systemic anticancer therapy, except 
for rituximab given as maintenance therapy, without evidence for relapse will be censored for the PFS 
analysis at the last radiologic adequate assessment date prior to the start of a new therapy.  
 
Page 62 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
3.9.8.2  Secondary Endpoints 
 
Overall survival (OS) is defined as the time from randomization until death due to any cause. If the 
patient is alive or the survival status is unknown, the date of death will be censored on the date the patient was last known to be alive.   
Overall Response Rate (ORR)  is defined as the prop ortion of patients who achieve a CR or PR without 
additional therapy.  
 
Complete Response (CR)  rate is defined as the proportion of patients who achieve a CR without 
additional therapy.  
 
3.9.8.3  Exploratory Endpoints 
 
Duration of Overall Response (CR, PR)  will be calculated from the date of initial documentation of 
response to the date of first documented evidence of PD (or relapse for patients who experience a CR on this study) or death. Responders without disease progression or relapse will be censored at the date of their last disease assessment.  
 Duration of Complete Response (CR) will be calculated from the date of initial documentation of a CR 
to the date of first documented evidence of relapse or death. Responders who do not relapse will be censored at the dat e of their last disease assessment.  
 
Proportion of patients who receive a stem cell transplant  is defined as the percentage of all randomized 
patients who receive a stem cell transplant after study treatment.  
 
3.10 Safety Assessments  
 
Safety will be assessed by  monitoring and recording adverse events, serious adverse events (SAEs), 
cardiac, hematologic and blood chemistry parameters, vital signs, performance status (PS), and any abnormal findings observed on physical examinations. Refer to Table--1 and Table --2 for the timing of 
assessments.  
 Regardless of whether serum samples, radiologic material and other patient data are sent to a central 
laboratory or independent review panel  for study purposes, treatment and eligibility decisions must be 
made by the Investigator based on his or her clinical assessment of the patient and his or her interpretation of local labs, radiology assessments, and other tests.  
 
3.10.1  Adverse Events  
 3.10.1.1  Definitio n of an Adverse Event  
 
An adverse event (AE) is defined as any untoward medical occurrence, or worsening of a preexisting 
medical condition, in a patient who has signed the Informed Consent Form.  For randomized patients, AEs are collected and reported fro m the time of signing the Informed Consent Form.  
 An AE does not necessarily have a causal relationship with the study drug. An AE can be any unfavorable 
and unintended sign, including an abnormal laboratory finding, or a symptom or concomitant disease 
temporally associated with the use of the study drug, whether considered related to study drug or not.  
 
Page 63 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
Progression of the disease under study is not an AE. However, signs and symptoms of progressive disease 
are captured as AEs on this study. 
 
Progressive/relapsed disease is not an AE, unless it is the primary cause of death. Signs and symptoms 
associated with disease progression may be recorded as secondary AE terms.  
 
Adverse events can be spontaneously reported or elicited during open-ended questioning, examination or 
evaluation of the patient. The investigator will evaluate changes in physical signs, laboratory values, or 
results of other diagnostic procedures to determine if an AE has occurred. (To prevent bias, patients 
should not be questioned regarding the specific occurrence of one or more AEs.)  
 
The NCI-CTCAE, version 4.0, will be used to assess the severity of any AEs and other symptoms. A 
copy of these criteria is provided in the study manual.  
Abnormalities observed during the study, including a ca rdiac evaluation, that meet any of the criteria 
below should be reported as AEs or SAEs, as appropriate:  
• Any laboratory or other test result, including cardiac, that is clinically significant or requires active 
intervention, retesting, or ongoing medical monitoring 
• Meets the definition of an SAE 
• Requires discontinuation or delay of study drug administration 
• Requires that the patient receives specific corrective therapy  
• Additionally, clinically significant changes noted during physical examinations, electro cardiograms, 
x-rays and any other safety assessments, whether or not these procedures were required by the 
protocol, should be recorded on the appropriate eCRFs. 
 
3.10.1.2  Reporting Adverse Events  
 
All AEs are collected and recorded in eCRFs from the time of Inform ed Consent for randomized patients. 
 
Study-drug related AEs and cardiac AEs grade ≥ 3, including LVEF declines, are collected and 
followed until resolution or no further improvement is expected, or until the end of the study. 
 Adverse events not related to study treatment and cardiac AEs ≤grade 2  are collected and followed 
for 30 days after the last dose of the study drug, until no further improvement is expected, or until the patient begins a subsequent systemic anticancer therapy, except for rituximab given as maintenance 
therapy, whichever occurs first.  
 
All identified AEs must be recorded and described on the appropriate eCRFs. SAEs for randomized 
patients must have a corresponding AE recorded with a logical match to the event term or description.  
The following information should be captured for all AEs: date of onset and resolution, CTCAE grade of 
the event, whether considered serious, the investigator’s assessment of causal relationship to study drug 
(see Section  3.10.1.3 for criteria), and outcome of the event. If concomitant treatment i s given for the AE, 
this information should be captured on the appropriate eCRF. If the AE is an abnormal local laboratory 
value or test result, this information should also be captured on the appropriate eCRF.  
 When recording AEs, the diagnosis of the underlying illness or disorder should be used as the event term 
or description on the eCRF. Symptoms of the illness or disorder should not be reported as separate AEs, 
unless related to progressive relapsed disease. Progressive relapsed disease is not an AE o r SAE event 
Page 64 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
term, unless it is the primary cause of death.  All AEs ongoing at the time of death that are not the primary 
cause of death will remain “unresolved” on the eCRFs.   
 
It is expected that wherever possible the clinical, rather than the laborator y, term for the AE will be used 
by the reporting investigator (eg, anemia versus low hemoglobin value ). 
 If an AE results in early termination of the patient’s study treatment period, AE  should be selected as the 
reason for discontinuation on the End-of- Treatment eCRF. However, if the AE that resulted in early 
termination was a sign or symptom of progressive disease, progressive/relapsed disease should be 
selected as the reason for discontinuation on the End -of-Treatment eCRF.  
 
The investigator shall suppl y the sponsor and Ethics Committee with any additional information 
requested, notably for reported deaths of subjects.  
 
For screened patients who are not randomized, only SAEs occurring between the time of informed 
consent and determination of screen failure are reported (see Section 3.10.2 for SAE guidelines); AEs 
occurring in this time period that do not meet the definition of an SAE do not need to be reported.  
 
3.10.1.3  Criteria for Assessing Causality of Adverse Events  
 
The following definitions should be used to assess the causal relationship between study drug 
administration and an AE.  
 
Definite  
 
There is a reasonable causal relationship between the study drug and the event, and the event occurred 
within a plausible time relationship to drug administration, and the event cannot be explained by the 
condition under study, concurrent disease, other drugs or chemicals, or other circumstances. The event responds to withdrawal of study drug (dechallenge) and recurs with r echallenge (if clinically feasible to 
rechallenge and if rechallenge is allowable per Section  3.6 Dose Adjustments and Delays).  
 
Probable 
 
There is reasonable causal relationship between the event and the study drug, the event occurred within a 
plausible time relationship to drug administration, the event is unlikely to be attributed to the condition under study, concurrent disease, other drugs or chemicals, or other circumstances. The event follows a 
clinically reasonable response on withdrawal of study drug.  
 
Possible 
 
There is a reasonable causal relationship between the event and study drug, the event occurred within a 
plausible time relationship to study drug administration, but the event could also possibly be explained by 
the condition under study, concurrent disease, other drugs or chemicals, or other circumstances. 
Dechallenge information is lacking or unclear.  
 
Unlikely  
 
There is a temporal relationship of the event to study drug but not a reasonable cau sal relationship, or 
there is no temporal relationship to study drug administration or the condition under study, concurrent disease, other drugs or chemicals, or other circumstances provide a plausible explanation for the event.  
 
Page 65 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
Unrelated  
 
There is no temporal relationship between the event and study drug administration (too early or late or 
study drug not administered). There is no reasonable causal relationship between the event and the study 
drug. The condition under study, concurrent disease, other dr ugs or chemicals, or other circumstances 
provides a plausible explanation for the event. 
 
3.10.2  Serious Adverse Events  
 3.10.2.1  Definition of a Serious Adverse Event  
 
A serious adverse event is an adverse event that meets any of the criteria below.  
 1. Results in death.  
2. Is life-threatening: in the view of the investigator, the event placed the patient at immediate risk of 
death. This does not include an AE that, had it occurred in a more severe form, might have caused 
death. 
3. Requires inpatient hospitalization or prolongation of an existing hospitalization (see  Exceptions  
below). 
4. Results in persistent or significant disability or incapacity or substantial disruption of the ability to 
conduct normal life functions. 
5. Is a congenital anomaly/bi rth defect.  
6. Is an important medical event that is not fatal, life threatening, or requiring hospitalization, but may be considered serious if, based on appropriate medical judgment, the event jeopardized the patient 
and required medical or surgical intervention to prevent one of the outcomes listed above (1-5). 
7. Cancer/overdose: All cases of new cancers and drug overdose (defined as accidental or intentional ingestion of any dose of a product that is considered both excessive and medically important) must be 
reported immediately using the SAE form. Determination of seriousness will be reached in consultation with the Safety Physician, CTI Global Pharmacovigilance US Headquarters or designee.  
 If either the investigator or sponsor believes an AE is serious, the event must be considered serious and 
will be evaluated by the sponsor, using the current Investigator’s Brochure, for expedited reporting 
(21 CFR 312.32(a)).  
Exceptions 
 
Hospitalizations not reported as SAEs include admissions for:  
 
• Planned, nonlife thr eatening medical/surgical procedures  
• Routine health assessments requiring admission for health status documentation (eg, routine 
gastroscopy, colonoscopy) 
• Other life circumstances that have no bearing on health status and requiring no medical/surgical intervention (eg, lack of housing, family circumstances)  
• Administration of study medication 
 
3.10.2.2  Reporting Serious Adverse Events  
 
SAEs are collected and recorded from the time of signing the Informed Consent Form. 
Page 66 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
For screened patients who are not randomized, only SAEs occurring between the time of signing the 
Informed Consent Form and determination of screen failure are reported (see Section 3.10.2 for SAE 
guidelines).  
 
For randomized patients, all SAEs that occur through 30 days after the last treatment  should be reported 
immediately to the sponsor or designee. All study-drug related SAEs occurring through the end of the 
study must be reported immediately to the Sponsor. 
 
All SAEs for randomized patients must have a corresponding AE recorded on the eCRF with an exact 
match to the event term or description.  
 
An SAE form should be completed for any event for which doubt exists regarding its seriousness. 
 
Within 24 hours of the time that the study personnel learn of an SAE, a paper SAE Report Form, with a 
corresponding AE recorded in the source documents and AE eCRF, must be completed and the SAE form 
sent to the Pharmacovigilance (PVG) Department. An SAE report should be completed and faxed or 
emailed to the PVG Department at:  
 Fax (US Only): 1 -508-416-2654 
Fax (outside the US): +44 870 7107157 
Email: safety@aptivsolutions.com  
 
A narrative outlining the details of the SAE, treatment, and outcome are to be included on the SAE form. 
The narrative must state whether there is a reasonable possibility that study drug caused the event (see 
Section 3.10.1.3). Follow- up information, such as laboratory reports, discharge summaries, autopsy 
reports, and information concerning outcome of the event, should be submitted by revising the SAE 
Report Form as soon as the information becomes available.  
 In addition, investigators must follow the policies of their IRB/EC regarding IRB/EC notification of 
SAEs. 
 
Source documents should be submitted only in English. If source documents are not in English, the 
investigator must summarize the source documents, providing a complete English narrative that includes 
a description of the event as it evolved the results of all diagnostic procedures perf ormed, treatments 
administered, and outcome of the event.  
Pregnancy  
 
Pregnancy is not considered an SAE. However, if a patient becomes pregnant or causes a pregnancy, this 
must be reported to the sponsor or designee immediately on the pregnancy reporting form. The 
investigator must obtain written authorization (medical records release) from a female partner of a male subject prior to obtaining follow -up. 
 The investigator must follow the pregnancy either to term or termination and will collect data on both 
maternal and fetal outcome. All pregnancy outcomes will be recorded on the Pregnancy Report Form. 
Normal outcomes will be communicated to the Sponsor within 30 calendar days of birth/delivery. Abnormal pregnancy outcomes and/or any AE for the child or fet us (including miscarriage) will also be 
recorded in the AE eCRF and on the SAE Report Form. The associated SAE Report Form should be sent to the Sponsor per the procedure and timelines described in Section 3.10.2.2, Reporting Serious Adverse 
Events. 
Page 67 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
Deaths  
 
Every death that occurs from the time of signing the Informed Consent Form until 30 days after 
completing protocol treatment must be reported as an SAE. Death alone is not an AE; it is an outcome of 
an AE and should be accompanied by a corresponding AE term for the event that led to the outcome of death. Special considerations include the following:   
 
• Progressive/relapsed disease is not an AE, except when it is a cause of death.   
• Sudden death, or death due to unexplainable cause(s), should be reported as an SAE, while follow-up 
is pursued to determine the cause.  
• Deaths that occur after 30 days following administration of the last dose of the study drug and are unlikely or unrelated to the study drug do not need to be reported as SAEs, but are captured only on 
the Death Information eCRF. 
 
3.10.3  Expedited Safety Reports  
 
In accordance with local regulations, CTI will notify investigators of all SAEs that are unexpected and 
definitely, possibly, or probably related to study drug in the form of an expedited safety report (ESR). An unexpected AE is an AE not described in the current Investigator Brochure (IB), or an AE that occurs 
with a specificity or severity inconsistent with the current IB.  
 Upon receiving such notic e, the investigator must review and retain the notice with the Investigator’s 
Brochure and submit the ESR as required by the site’s local IRB. Where required by local regulations or where there is a central IRB/IEC for the study, the sponsor or designee wi ll submit the ESR to the 
appropriate IRB/IEC. The sponsor, investigator, and IRB/IEC will determine if the Informed Consent 
Form requires revision. In addition, suspected serious adverse reactions (whether expected or unexpected) 
shall be reported by CTI or its designee to the relevant competent health authorities in all concerned 
countries according to the local regulations (either as expedited and/or in aggregate reports). 
 
Other important findings that may be reported by the sponsor or designee as an ESR include increased frequency of a clinically significant expected SAE, an SAE considered associated with a study procedure 
that could modify the conduct of the study, lack of efficacy that poses significant hazard to study subjects, 
clinically significant safety findings from a nonclinical (eg, animal) study, important safety 
recommendations from a study data monitoring committee, or the sponsor’s decision to end or temporarily halt the clinical study for safety reasons.  
 
The IB will be updated periodically to include new and relevant safety information. Until an AE is 
identified in the IB, it is considered unexpected, regardless of whether the AE has been the subject of a 
previous ESR. 
 
3.10.4  Laboratory Evaluation 
 
All laboratory test values collected as part of the study will be evaluated by a central laboratory, with the 
exception of urine pregnancy tests after the screening period.   
 The investigator will use local laboratory evaluations to facilitate real -time decisions about study 
treatment administration, el igibility, dose modifications, and for evaluation of signs and symptoms. If any 
clinical intervention results from local laboratory tests, the test result and local laboratory normal ranges 
for that test will be reported on the appropriate eCRF. 
Page 68 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
The centr al laboratory troponin T result should be used to determine eligibility. A local laboratory result 
may be used if the central laboratory turnaround time (approximately 5 days) would delay randomization. After baseline, serum troponin T samples are stored at the central laboratory for batch processing. The 
central laboratory will complete troponin T testing within 1 year of the end of study, at which time results 
will be provided to the investigator and any remaining specimens will be destroyed.    
Dose dela ys may require that both local and central labs are redrawn. Treatment decisions are based on 
local results. Complete blood count (CBC) with differential is required within 1 day of every administration of study drug (Days 1, 8 and 15 of all cycles); chemistry panel is required within 7 days of 
Day 1 of all cycles; and a pregnancy test for WOCBP is required within 1 day of Day 1 of all cycles.  
 
Regardless of whether serum samples, radiologic material and other patient data are sent to a central 
laboratory or independent review panel for study purposes, treatment decisions must be made by the 
investigator based on his or her clinical assessment of the patient and his or her interpretation of local laboratory results, radiology assessments, and other tests.  
 
3.10.4.1  Cardiac Assessment  
 
Cardiac assessments during the treatment period are described in  Table--1
, and Table --2 shows 
assessments during Follow -up. Routine ECG is performed, collected, and analyzed at baseline and at 
EOT.  
 
The LVEF of all patients will be evaluated by echocardiogram during the screening period; ≤ 7 days 
before the expected Day 1 of Cycles 3 and 5, at EOT, and at Follow- up Week 24. Echocardiograms will 
be review ed at the investigational site.  
 Serum troponin T is evaluated at baseline, before cycles 3 and 5, at EOT, and at Follow- up Week 24 
(Section 3.10.4). 
 The echocardiogram and troponin T test before Cycles 3 and 5 need not be repeated if a dose is delayed 
for reasons other than abnormal LVEF. Cardiac -related SAEs ≥ CTCAE grade 3 that occur through the 
end of the study should be immediately reported to the sponsor or designee. Cardiac adverse events ≥ CTCAE grade 3 , including LVEF declines, are collected and followed until resolution or no further 
improvement is expected, or until the end of the study. 
 
3.10.5  Vital Signs and Physical Examination  
 
Vital signs will be obtained prior to every study drug administration. Physi cal examinations are 
performed during screening and ≤ 3 days before study drug administration on Day 1 of Cycles 2-6. A 
symptom-directed examination may be done as needed ≤ 1 day prior of study drug administration on 
Day 1 of Cycle 1 and on Days 8 and 15 o f all cycles. Vital signs and physical examination are also 
performed at the EOT visit.  
 
3.10.6  ECOG Performance Status 
 
ECOG performance status (Section  8.2) will be assessed ≤ 1 day before Day 1 of all cycles and at EOT 
(at 4 to 7 weeks after last study drug dose, inclusive).  
  
Page 69 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
3.11 Pharmacokinetics Assessments (for participating sites)  
 
PK samples will be collected from approximately 20 patients (see Section  12 Addendum: 
Pharmacokinetics Sub -Study). 
 
4 Data Management 
 
The CTI Clinical Data Management Department or its designee will prepare guidelines for data entry and 
data handling, which will include procedures for data verification and electronic edit checks. The 
complete data management process will be described in the Data Management Plan.  
 
 
4.1 Data Collection 
 
An electronic data capture (EDC) system will be used for this study. Designated site personnel will enter 
subject data required by the protocol directly into electronic case report forms (eCRFs). Personnel will not 
receive access to the EDC system until they have completed all training requirements. The EDC system will provide an automatic audit trail of all changes made to the clinical database.  
 
4.2 Data Entry and Quality C ontrol 
 
Data items will be entered directly from source documents by designated site personnel using single data 
entry. Concomitant medications entered into the database will be encoded using the WHO Drug Reference List. Adverse events, coexisting disease,  and other data items will be encoded using the 
Medical Dictionary for Regulatory Activities (MedDRA) terminology. 
 
CTI staff or designees will review the data on a periodic basis to ensure validity, accuracy, and 
completeness. Data suspected to be discrep ant or incomplete will be questioned using data queries. Data 
queries resulting from these reviews will be sent to the study sites via the EDC system. The staff at the 
study sites will respond to the queries; these responses will be reviewed by CTI staff or designee.  
 This study will be conducted using in- house blinding procedures. The official clinical database will not be 
unblinded for the primary endpoint analysis until data review has been completed, protocol violations 
have been identified, the data ha ve been declared clean, and a detailed Statistical Analysis Plan has been 
written and approved.  
 
5 Statistical Analysis  
 
The statistical analyses of the data from this study will be the responsibility of Biostatistics at CTI. If, 
after the study has begun, c hanges are made to the Statistical Analysis Plan stated below, these deviations 
will be listed with an explanation as to why they occurred in the Statistical Analysis Plan and/or CSR for this study, as appropriate. 
 
The study analyses planned are planned to be performed as defined at the following time points: 
 
• The core analysis will be performed after 195 PFS events have occurred to evaluate the primary and 
secondary objectives of the study, with the exception of OS.  
• The first interim analysis of OS will be performed after approximately 165 OS events (75%) have 
occurred and confirmation of 195 PFS events.   
• The second interim analysis of OS will be performed when 190 OS events (8 6%) have occurred.    
Page 70 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
• The final analysis will be performed at the end of the stu dy, when the required number of OS events 
have occurred.  
 
5.1 Hypotheses  
 
The hypothesis tests described below will be performed on the intent- to-treat population using the IRC 
assessments of disease response.  
 
5.1.1 Primary Hypothesis  
 
The primary hypothesis of thi s study is that the combination of pixantrone + R will result in an 
improvement in PFS compared with treatment with gemcitabine + R in patients with a current diagnosis 
of DLBCL (de novo DLBCL or DLBCL transformed from indolent lymphoma) or follicular grade 3 
lymphoma on the basis of a tissue biopsy who are not currently eligible for high- dose (myeloablative) 
chemotherapy and stem cell transplant and who have relapsed after at least 1 prior chemotherapy regimen.  
 
5.1.2 Secondary Hypotheses  
 
In patients with a current diagnosis of DLBCL (de novo DLBCL or DLBCL transformed from indolent lymphoma) or follicular grade 3 lymphoma on the basis of a tissue biopsy, who are not currently eligible 
for high-dose (myeloablative) chemotherapy and stem cell transplant and who h ave relapsed after at least 
1 prior chemotherapy regimen:   
• The combination of pixantrone + R will result in an improvement in OS compared with treatment 
with gemcitabine +  R. 
• The combination of pixantrone + R will result in a higher ORR compared with trea tment with 
gemcitabine +  R.  
• The combination of pixantrone + R will result in a higher CR rate compared with treatment with gemcitabine +  R. 
 
5.2 Variables/Time Points of Interest  
 
5.2.1 Primary Efficacy Variable 
 
Progression -free survival (PFS)  is defined as the ti me from the date of randomization to the date of 
disease progression or death due to any cause (whichever occurs first). The progression date is the earliest time any progression is observed. Patients with no documented progression or death before the data cutoff 
will be censored at the date of the last adequate radiological assessment.  
 
5.2.2 Secondary Efficacy Variables  
 
Overall survival  (OS) is defined as the time from randomization until death due to any cause. 
 
Overall response rate (ORR) is defined as the p roportion of patients who achieve either a CR or a partial 
response (PR)  without additional therapy. The primary analysis of ORR will be based on disease 
response as determined by the IRC.  
 
Complete response (CR) rate is defined as the proportion of patien ts who achieve a complete response 
without subsequent systemic anticancer therapy, except for rituximab given as maintenance therapy.  
 
Page 71 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
5.2.3 Exploratory Efficacy Variables 
 
Duration of overall response  is defined as the time from first documented response to the first 
documentation of disease progression, relapse or death due to any cause.  
Duration of complete response is defined as the time from first documented complete response to the first documentation of relapse or death due to any cause. 
 
Proportion of patients who receive a stem cell transplant  is defined as the percentage of all patients 
randomized who receive a stem cell transplant after study treatment.  
 
5.2.4 Safety Variables 
 
Safety will be assessed for randomized patients by clinical and/or statistical review of all safety 
parameters, including adverse events and laboratory values. The safety analysis will focus on overall AEs, 
grade 3 and grade 4 AEs, SAEs, treatment- related SAEs and AEs, AEs that lead to treatment 
discontinuation, deaths, and cardiotoxicity as measured by echocardiography and troponin T.  
5.3 Statistical Methods  
 5.3.1 Analysis Populations  
 5.3.1.1  Intent -To-Treat (ITT) Population  
 
The ITT population is defined as all randomized patients. Following the intent- to-treat principle, patients 
will be analyzed according to the treatment to which they were assigned at randomization.  
 
The ITT population is the primary population used for all efficacy analysis.  
5.3.1.2  Histologically Confirmed Population  
 
The histologically confirmed population will include all randomized patients with DLBCL (de novo 
DLBCL or DLBCL transformed from indolent lymphoma) or follicular grade 3 lymphoma per WHO guidelines confirmed by central pathology review.  
 
Patients in this population will be analyzed according to the treatment to which the y were randomized. 
This population will be used for supportive efficacy analyses.  
 
5.3.1.3  Per-Protocol (PP) Population  
 
The PP population is defined as all randomized patients who undergo at least one post baseline disease 
assessment and have no major protocol vi olations. Patients in this population will be analyzed according 
to the treatment that they actually received.  
 
The PP population will be used as a supportive efficacy analysis.  
 
5.3.1.4  Safety Population 
 
The safety population is defined as all randomized patients who receive at least one dose of study drug. 
The safety population will be analyzed according to the treatment actually received. The safety population will be used for all safety analyses.  
Page 72 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
5.3.2 Efficacy Evaluation 
 5.3.2.1  Progression -Free Survival  
 
The primary analysis of PFS will use disease progression assessed by the IRC. The progression date is the earliest time when any progression per Modified IWG criteria is observed. Patients will be censored at the 
last adequate radiological assessment date if they are alive with no documented progression before data 
cutoff. Last adequate radiological assessment is defined as the last radiological assessment or set of 
radiological assessments sufficient to allow IRC disease response assessment per PIX306 Modified IWG 
2007 Revised Response Criteria. Patients who receive subsequent systemic anticancer therapy, except for rituximab given as maintenance therapy, without evidence of progression, will be censored at the last 
adequate radiological assessment date prior to the start of the new therapy.  Table--12 provides the event 
and censoring rules for the primary analysis of PFS.   
Table--12 
Event and Censoring Rules for Progression -Free Survival Analysis  
Situation Date of Progression or Censoring Situation 
Outcome  
No post-baseline disease assessment  Day 1 Censored  
Progression documented  Earliest date when any progression is observed  Event 
No progression Date of last adequate radiologic assessment with 
evidence of no progression  Censored  
Received any subsequent systemic anticancer 
therapy, except for rituximab given as 
maintenance therapy, before progression of 
disease or death  Date of last adequate radiologic assessment prior 
to the start of the subsequent s ystemic anticancer 
therapy, except for rituximab given as 
maintenance therapy  Censored  
Death Date of death if no progression  Event 
Lost to follow -up Date of last adequate radiological assessment 
showing no progression  Censored  
 
The comparison of the treatment effect on PFS will be performed with a log- rank test stratified by IPI 
score (Section 8.1), prior lines of therapy for DLBCL and follicular grade 3 lymphoma, and length of time 
from initiation of therapy for DLBCL or grade 3 follicular lymphoma until first relapse. The Kaplan-
Meier product -limit method will be used to estimate the distribution of PFS. Summary statistics (median, 
95% confidence interval) and PFS curves will be presented by treatment group. 
 
Sensitivity analyses will be performed to evaluate the robustness of the PFS result and will include PFS, 
as determined by investigator assessments, and PFS based on other analysis populations. The detailed 
methodology for these analyses is displayed in the Statistical Analysis Plan.  
 
5.3.2.2  Overall Survival  
 
Overall survival (OS)  is defined as the time from the date of randomization to the date of death due to any 
cause. If the patient is not known to have died, survival will be censored at the date the patient was last 
known to be alive.  The comparison of the treatment effect on OS will be performed with a stratified log-rank test, as described for PFS.  The primary analysis of OS will be performed at the end of the study, 
although two interim analyses of OS are also planned (see Section  5.4 for the details).  
 
Page 73 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
5.3.2.3  Overall Response Rate (ORR) and Complete Response (CR) Rate  
 
ORR will be based on disease response as determined by the IRC. Comparison of the ORRs between the 
two treatment arms will be performed using the exact Cochran -Mantel-Haenszel (CMH) test, controlling 
for IPI score (Section 8.1), number of prior lines of therapy for DLBCL or follicular grade 3 lymphoma, 
and length of time from initial therapy for DLBCL or follicular grade 3 lymphoma until first relapse. The number and percentage of patients achieving a PR or better will be presented. The 95%  confidence 
interval of the difference in response rates between the tw o treatment arms will also be provided. The CR 
rate will be analyzed using the same method as for the ORR.  
 
5.3.2.4  Exploratory Efficacy Variables 
 
Exploratory efficacy variables will be analyzed using descriptive statistics. A 95% confidence interval 
will be calc ulated for each endpoint. The detailed analysis of these secondary endpoints will be discussed 
in the Statistical Analysis Plan.  
 
5.3.2.5  Multiplicity  
 
The hypotheses tests will follow a closed -step-down procedure to ensure the overall type I error at 0.05.  
The tests hierarchy will reflect the importance of the clinical endpoints in the study, as described below:  
− First, the primary hypothesis test for PFS will be performed at the 2-sided 0.05 α- level. 
− If the p-value on PFS is significant, the secondary hypothesis of OS will be tested using an 
overall 0.05 α-level. To be noted that two interim analyses of OS will be carried out using a group 
sequential procedure; a detailed description of these analyses is provided in Section 5.4. 
− If the hypothesis test of OS is achieved, then the secondary hypotheses of ORR, followed by CR, 
will be tested at the remaining α- level. Hypotheses of ORR and CR will be tested only when the 
p-value on OS is significant either at an interim or at the final OS analysis . 
 
5.3.2.6  Subgroup Analyses  
 
Subgroup analyses will be performed for primary and secondary endpoints, as appropriate. The subgroups 
will include the number of prior treatment regimens for DLBCL and follicular grade 3 lymphoma, length 
of time from initiation of therapy for DLBCL or folli cular grade 3 lymphoma until first relapse, and IPI  
score (Section  8.1). The subgroups may also include, but are not limited to, gender, age, race, Ann Arbor 
Stage (Section  8.3), time between first and second -line regimens, the number of prior lines of therapy  for 
DLBCL or follicular grade 3 lymphoma (0 - 1 vs. ≥ 2) and prior SCT. Cox regression model will be 
performed as well. The detailed subgroup analyses will be addressed in the Statistical Analysis Plan.  
 
5.3.3 Safety Evaluation 
 
The assessment of safety will be mainly on the frequency of adverse events and on the number of laboratory values that fall outside of predetermined ranges.  
 Adverse events, including SAEs, in each treatment group will be summarized by presenting the number 
and percentage of patients having any AE, an AE in each body system, and individual events according to 
MedDRA dictionary. CTCAE grades and relatedness to study drug will be summarized, as appropriate.   
Laboratory data will be summarized by presenting shift tables using CTCAE grades. Summary statistics 
of value and change from baseline will be performed for each visit.  
 
Page 74 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
5.3.4 Pharmacokinetics Analysis 
 
The analysis of PK data (collected at particip ating sites) will be performed as described in Section 12 
Addendum: Pharmacokinetics Sub -Study. 
 
5.4 Interim Analysis  
 
No interim analysis is planned for this study for the primary objective prior to the core analys is. 
 The first interim analysis of OS is planned at the time of the core analysis . It is estimated that at the time 
of the core analysis, approximately 165 deaths will have occurred.   The second interim analysis is planned 
to occur when 190 death events are reached.  The purpose of the interim analysis is to stop the study early 
due to superiority of OS. T he 2 OS interim analyses  and reviews will be performed by IDMC. 
 Using group sequential methods, including Rho family alpha spending with a parameter of 7, if the log-
rank test p -value for OS is ≤0.007 (assuming 165 events) , then the study will claim OS superiority for the 
pixantrone + R arm at the first interim analysis. At the second interim analysis, the study will claim OS 
superiority for the pixantrone + R arm  if the p-value is ≤0.017 (assuming 190 events) .  The final stopping 
parameters for both interim analyses will be based on the actual number of events at the time of the data 
cutoff for the analyses.  Table--13 provides the estimated number of deaths, and corresponding stopping 
parameters based on the potential number of events at each analysis.  
 
 
Table--13 
Stopping Parameters Based on the Potential Number of Events  
 Number of Dea ths P-value to Reject H 0 Hazard Ratio  
Interim OS Analysis  #1 165 P ≤ 0.007  0.655 
Interim OS Analysis  #2 190 P ≤ 0.017  0.706 
Final OS Analysis  220 P ≤ 0.048 0.766 
  
5.5 Power and Sample Size Determination  
 
One hundred ninety- five (195) PFS events are required to detect at least a 35% improvement (ie, 
HR = 0.65) in PFS with 85% power and a 2-sided alpha of 0.05. Based on results from a recent study by 
Pettengell et al.
(29), it is assumed that the median PFS for the control group is 2.8 months. 
 Based on updated study projections,  it is estimated that approximately 320 patients are needed  to reach 
the required 195 PFS events that are projected to occur approximately 80 months after randomization of 
the first patient. The actual number of patients enrolled may vary, as actual enroll ment may differ from 
assumptions.  
 
For the secondary endpoint of OS, 220 deaths are planned to have 75% power to detect at least a 30% improvement in OS allowing for 5% drop-offs, or 68% power to detect at least a 28% improvement in 
OS.  Based on the study by Pettengell et al.
(29), it is assumed that the median OS for the control group is 7 
months.  
Page 75 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
6 Ethical Considerations  
 
6.1 Informed Consent  
 
The investigator is responsible for obtaining written informed consent fr om each patient (or the patient’s 
legally authorized representative) before any study -specific screening or other procedures are performed 
and before any study drug is administered.   
Patients meeting the criteria set forth in the protocol will be offered the opportunity to participate in the 
study. To avoid introduction of bias, the investigator must exercise no selectivity with regard to offering eligible patients the opportunity to participate in the study. Potential patients, or the legally authorized representatives of potential patients, will receive a comprehensive explanation of the proposed treatment, 
including the nature of the therapy, alternative therapies available, any known previous adverse reactions, the investigational status of the study dr ug, and other factors that are part of obtaining proper informed 
consent. Patients will be given the opportunity to ask questions of a qualified health care professional trained on the study, as well as adequate time to consider whether they wish to partic ipate. 
 Informed consent will be documented by the use of a written Informed Consent Form that includes all elements required by regulations and the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for  Human Use (ICH) guidelines. The form is to be 
signed and dated by the patient or the patient’s legally authorized representative and by the person who administered the consent process. A copy of the signed form will be given to the person who signed it and 
the original will be maintained with the patient’s medical records. The date and time that informed consent was obtained must be recorded in source documents. The informed consent process must be 
documented at the site in the patient’s file.  
 If an amendment to this protocol changes the schedule, scope, or activity of patient participation or 
increases the potential risk to patients, the protocol amendment and a revised informed consent document must be submitted to the IRB for review and approval before use. Patients currently enrolled in the study 
who could be affected by the protocol amendment must again give consent using the revised document. 
This includes all patients in the Follow -up periods of the study if new information about the study drugs 
or procedures increases the risk patients incur by participation in the treatment period. All patients enrolled after the approval date of the protocol amendment must sign and date the revised informed consent form. 
 
For any subject who is lost to follow-up, the study site will attempt to ascertain survival information via 
public database search. Informed consent to obtain these data will be obtained from subjects at the time of 
enrollment. 
 
6.2 Institutional Review Board/Ethics Committee Approval  
 
An appropriatel y constituted Institutional Review Board (IRB)/Ethics Committee (EC) that complies with 
the requirements of 21 CFR Section 56 and appropriate Good Clinical Practice (GCP) regulations must provide initial and continuing review and approval of this clinical study. Before enrolling any patients, 
investigators must transmit the investigator’s brochure, protocol, and consent form to their IRB/EC for review and approval, and notification of IRB/EC approval must be received by CTI before any 
investigational suppli es will be shipped to the investigator.  
 The investigator will ensure that all changes in the research activity and all unanticipated problems 
involving risks to human subjects are reported promptly to the IRB/EC, and that no changes are made to 
Page 76 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
the protocol without prior sponsor and IRB/EC approval, except when necessary to eliminate apparent 
immediate hazards to human subjects.  
 The investigator must promptly notify the IRB/EC of any SAEs occurring at that site according to 
IRB/EC policies. Copies of all study- related correspondence between the investigator and the IRB/EC 
must be forwarded to CTI by the investigator. The investigator is responsible for submitting periodic 
progress reports to the IRB/EC at intervals appropriate to the degree of patient risk involved in the study, 
but not less than once per year and at the completion or termination of the study. 
 
The FDA considers any direct recruiting advertisements to be part of the informed consent and subject 
selection process and therefore governed by regulations 21 CFR 50.20,50.25, 56.11(a)(3), and 21 CFR 312.7(23). These regulations require that all advertisements for potential research subjects are reviewed 
and approved by an IRB or Independent Ethics Committee (IEC) before publication. In addition, a ny 
recruitment material developed by a site must be reviewed by CTI prior to use. Patient education material that does not mention specific studies or research is generally not subject to these requirements.  
 
6.3 Patient Privacy 
 
CTI and the investigator affir m and uphold the principle of the patient’s right to privacy. CTI and the 
investigator shall comply with applicable privacy laws. To verify compliance with this protocol, CTI or its designee must be able to review the original medical records of patients. Should access to such medical 
records require a waiver or authorization separate from the statement of informed consent, the investigator will obtain such permission in writing from the patient before the patient is entered into the study. 
 
7 Study Administr ation 
 7.1 Good Clinical Practice and Regulatory Requirements  
 
Investigators must agree to conduct this study in accordance with the ICH principles of Good Clinical 
Practice (ICH -E6), CFR parts 50, 56, 312, and 314, and with the Declaration of Helsinki (1989). The 
investigator will conduct all aspects of this study in accordance with all national, state, and local laws of the applicable regulatory agencies.  
 
Where applicable this study must also be conducted in accordance with “directive 2001/20/EC of the 
European Parliament and of the Council of April 4, 2001 on the approximation of the laws, regulations 
and administrative provisions of the Member States relating to the implementation of GCP in the conduct 
of clinical trials on medicinal products for human use.”  
7.2 Quality Assurance Procedures  
 
CTI’s Quality Assurance (QA) department or its designee may conduct audits at the clinical site or other 
study-related facilities and organizations. Audit reports will be retained by CTI’s QA department as part 
of the written record.  
 
7.3 Changes to the Protocol 
 
Significant changes to the protocol must be approved by the sponsor and the appropriate IRB/EC prior to 
implementation, except where immediate implementation is necessary to eliminate an imminent hazard to 
the patient. All protocol amendments must be signed and dated by both the sponsor and the investigator. 
 
Page 77 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
7.4 Site Training and Monitoring Procedures  
 
Before initiation of the study, CTI or designated representatives will review and discuss the following 
items with the inve stigator and clinic staff: the protocol, study procedures, record keeping and 
administrative requirements, drug accountability, AE reporting, GCP guidelines, eCRF completion guidelines, monitoring requirements, and the ability of the site to satisfactorily complete the protocol. A study manual with instructions for study compliance and eCRF completion will also be provided. 
Investigator meetings to train investigators and study coordinators will be held, and eCRF training will be 
reviewed at that time as we ll.  
 Monitoring visits will occur periodically, with frequency dependent on the rate of enrollment and enrolled patients’ progress through the study at each site. The investigator will permit CTI’s representatives to 
monitor the study as frequently as CTI deems necessary to determine that protocol adherence and data 
recording are prompt and satisfactory. CRAs will remotely view eCRF data and contact the site between 
monitoring visits. They will be available to answer questions about any aspect of the conduct of the study.  
 During monitoring visits, the CTI representative will usually review regulatory documentation, eCRFs, 
source documents, and study drug preparation, storage, and accountability. The eCRFs will be reviewed for completeness, adherence to th e provided guidelines, and accuracy compared with the source 
documents. This review includes inspection of data acquired as a requirement for participation in this study and other medical records as required to confirm information contained in the eCRFs is complete, 
timely and accurate. This will include information about medical history, secondary diagnoses, and 
concomitant medications. Source documents must be available during the scheduled monitoring visits at the beginning of the visit. All source data and study records must also be available for inspection by 
representatives of the FDA or other regulatory agencies.  
 
7.5 Record Retention  
 
Investigative sites must retain study records, including source data, copies of eCRFs, and all study 
correspondence, according to local requirements but for a minimum of 2 years after the last market 
approval is received for this product, or for 2 years after all clinical and product development of this 
product has been discontinued. In addition, the investigator will keep a master log of all patients 
participating in the study with sufficient information to allow retrieval of a study patient’s medical record. The investigator must notify CTI or its designee before destroying or moving any records relating to this 
study. 
 
7.6 Financing and Insurance  
 
Financing and insurance issues are addressed in detail in the Clinical Study Agreement.  
 
7.6.1 Financial Disclosure  
 
Each investigator (including the principal investigator and any sub investigator) directly involved in the 
treatment or evaluation of research subjects must disclose certain financial arrangements.  
 
In this context investigator  is defined as all individuals listed on FDA Form 1572—or, for non- IND 
studies performed outside the United States, listed in the signature list —who are directly involved in the 
treatment or evaluation of research subjects. The term also includes the spouse and each dependent child 
of the investigator.  
 
Page 78 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
The following arrangements and interests involving investigators and their spouse and dependent children 
may be disclosed to the FDA: 
 
Any compensation affected by the outcome of clinical studies.  
 Any ownership interest, stock options, or other financial interest, the value of which cannot be readily determined through reference to public prices (generally , interests in a non -publicly traded corporation), 
or any equity interest in a publically traded corporation that exceeds $50,000 during the time the clinical investigator is carrying out the study and for 1 year following completion of the study. 
 
Payments made by the sponsor of a covered study to the investigator or the institution to support activities of the investigator that have a monetary value of more than $25,000, exclusive of the costs of conducting 
the clinical study or other clinical studies, (e g, a grant to fund ongoing research, compensation in the form 
of equipment or retainers for ongoing consultation or honoraria) during the time the investigator is carrying out the study and for 1 year following the completion of the study.  
A financial disc losure statement must be provided to the sponsor for each investigator at a study site 
before the study can commence. Financial disclosure statements must also be provided at the time the 
study is closed and at the 1 -year anniversary of study closure.  
 
7.7 Publication Policy  
 
The publication policy is covered in the clinical study agreements. The investigator agrees to submit all 
manuscripts, abstracts, or other publications to CTI at least 1 month prior to submission for publication. This allows the sponsor to  protect proprietary information and to provide comments based on information 
from other studies that may not yet be available to the investigator.  
 
8 Appendices  
 
8.1 International Prognostic Index (IPI) Score Calculation  
 
For the purposes of this study, baselin e information is used to calculate the IPI.  
 
IPI Pointsa Characteristic 
1 Age > 60 years  
1 [ECOG] Performance Status 2, 3, or 4  
1 NHL Stage III or IV  
1 Elevated LDH  
1 More than 1 extranodal site  
Maximum Possible Score: 5  
Abbreviations:  
ECOG = Eas tern Cooperative Oncology Group LDH = lactate dehydrogenase  NHL = non -Hodgkin lymphoma.  
aThe International Non -Hodgkin's Lymphoma Prognostic Factors Project(30). 
 
Page 79 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
8.2 ECOG Performance Status Grades and Definitions  
 
ECOG PS Gradea Definition  
0 Fully active, able to carry on all predisease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature, eg, light house work, offic e work 
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and 
about more than 50% of waking hours  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours  
4 Completely disabled. C annot carry on any self -care. Totally confined to bed or chair  
5 Dead 
Abbreviations:  
ECOG = Eastern Cooperative Oncology Group PS = performance status.  
aOken MM, et al.(31). 
 
8.3 Ann Arbor Staging System  
 
Ann Arbor Stagea Definition  
I Involvement of a single lymph node or a single extranodal organ or site  
II Involvement of ≥2 lymph node regions on the same side of the diaphragm, or localized 
involvement of an extranodal site or organ (IIE) and ≥1 lymph node regions on the same side 
of the diaphragm  
III Involvement of lymph node regions on both sides of the diaphragm, which may be also 
accompanied by local involvement of an extranodal organ or site (stage IIIE) spleen (Stage 
IIIS) or both (stage IIISE)  
IV Diffuse or disseminated involvement of one or more distant extranodal organs with or 
without associated lymph node involvement  
aCarbone PP, et al.(32). 
 8.4 New York Heart Association Functional Classification  
 
The New York Heart Association (NYHA) functional classification is often used to characterize 
limitation from left ventricular failure. Since 1973 the NYHA has not officially sanctioned the functional 
classification. However, it continues to be used widely and h as a strong association with mortality that is 
independent of left ventricular ejection fraction (LVEF).  
 
NYHA Classa Definition  
I No limitation of physical activity. Ordinary physical activity does not cause undue fatigue or 
dyspnea. 
II Slight limitation of physical activity. Comfortable rest, but ordinary physical activity results 
in fatigue or dyspnea.  
III Marked limitation of physical activity. Comfortable rest, but less than ordinary activity 
causes fatigue or dyspnea.  
IV Unable to carry on any phy sical activity without symptoms. Symptoms are present even at 
rest. If any physical activity is undertaken, symptoms are increased.  
aThe Criteria Committee of the New York Heart Association(33). 
 
Page 80 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
8.5 Anthracycline/Anthracenedione Equivalent Doses  
 
Agent Dose Equivalent to 450 mg/m2 Doxorubicin 
(mg/m2) 
Doxorubicin 450 
Lipo doxorubicin 450 
Daunorubicin 490 
Lipo daunorubicin 818 
Epirubicin  736 
Idarubicin  112.5 
Mitoxantrone  160 
 
To calculate the doxorubicin- equivalent dose, use the following expanded formula for the appropriate 
drugs:  Doxorubicin equivalent dose = A + 0.9184*B + 0.5501*C + 0.6114*D + 4*E + 2.8125*Y, where: 
 
 A is the combined doxorubicin and liposomal doxorubicin dose in mg/m
2 
 B is the daunorubicin dose in mg/m2 
 C is the liposomal daunorubicin dose in mg/m2 
 D is the epirubicin dose in mg/m2 
 E is the idarubicin dose in mg/m2 
 Y is the mitoxantrone dose in mg/m2 
 
8.6 Evaluation of Target and Non-target Lesions 
 
The following calculations and assessments should be performed for scanned lesions at radiologic 
assessment time points as specified in the protocol and for unscheduled CT/MRI assessments.  
 
8.6.1 Baseline Target Lesion Evaluation 
 
1. For each target lesion, identify and measure the longest diameter. From this point forward, this will be 
referred to as the target lesion’s long diameter (LDi). The LDi will be assessed in all subsequent 
target lesion evaluations.  
2. For each target lesion, identify and measure the longest diameter that is perpendicular  to the LDi. 
From this point forward, this will be referred to as the target lesion’s short diameter (SDi).The SDi 
will be assessed in all subsequent target lesion evaluations.  
3. For each target lesion, multiply the LDi × SDi to calculate the PPD. The PPD will be assessed in all 
subsequent target lesion evaluations.  
4. Add the PPDs of the entire group of target lesions to arrive at the Sum of Products of the Perpendicular Diameters (SPD).The SPD will be assessed in all subsequent target lesion evaluations.  
 
8.6.2 All Subsequent  Target Lesion Evaluations 
 
Do all of the calculations (steps 1 -4) in Section 8.6.1. After each step, answer the following questions and 
make the indicated calculations.  
Page 81 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
 
For the LDi and SDi: has the length incr eased, decreased, or has it remained the same?  
• If increased in length, calculate the percentage of increase from the shortest prior length measured at 
baseline or at any other prior evaluation (nadir). 
 
For each target lesion: calculate the PPD (LDi ×  SDi)  
• If increased in size, calculate the percentage of increase from the smallest prior PPD measured at 
baseline or at any other prior evaluation (nadir). 
 
Calculate the SPD (sum of PPDs of all target lesions)  
• If increased in size, calculate the percentage of increase from the smallest prior SPD measured at 
baseline, or at any other prior evaluation (nadir). 
• If decreased in size, calculate the percentage of decrease from baseline.  
• No change, note. 
 
8.6.3 Baseline and Post -Baseline Non-target Lesion Evaluations 
 
Identify the non- target lesions and note their locations. At each post- baseline assessment, visually assess 
change in size and categorize each lesion as one of the following:   
• Absent 
• Decreased  
• Stable 
• Increased  
Page 82 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
9 Investigator Responsibilities, Required Documentation, and Signature  
 
CTI BioPharma Corp. will select the investigator(s) on the basis of their expertise in the field of clinical 
studies in hematologic oncology and in the care and treatment of patients wi th cancer. Investigators will 
also be selected on the appropriateness of the facility to conduct a research study of this nature, and the patient population treated at the institution. The investigator will:  
 
• Obtain Institutional Review Board (IRB) or Inde pendent Ethics Committee (IEC) approval of the 
protocol or amendments to the protocol and Informed Consent Form before initiation of the study, 
and obtain annual Institutional Review Board or Independent Ethics Committee (IEC) renewal, as 
required.  
• Be responsible for ensuring that current FDA and/or ICH- E6 regulations are followed.  
• Select all patients in accordance with the selection criteria outlined in  Section 3. 
• Treat and follow patients as described in this research protocol; complete all case report forms in a 
timely manner, review CRFs for accuracy and completeness, and provide the original clinical source 
documents with a clinical summary to the sponsor's clinical research monitor. 
• Report all adverse events to CTI BioPharma Corp. or designee as required by the protocol.  
• Ensure that investigational drug is kept in a secured, limited access area and stored under proper 
conditions. Ensure that all investigational drug receipt and dispensing is recorded and all drug can be 
accounted for at all times.  
• If participating in the study, will submit to CTI before initiation of the study: 
• FDA Form 1572 and, if applicable, other Ministry of Health-required forms 
• Copies of the medical licenses of principal investigator and subinvestigators  
• Address and a description of all clinical laboratory facilities to be used  
• Laboratory certification and expiration dates 
• Normal ranges and effective date for all required laboratory tests  
• IRB/IEC Appr oval Letter referencing the protocol (and amendments, if applicable) 
• IRB/IEC Membership List: A list of the IEB/EC members, their respective titles or occupations, 
and their institutional affiliations  
• A sample copy of the IRB/IEC-approved Informed Consent 
• Curricula vitae for the principal investigator and all subinvestigators  
• Financial disclosure for the principal investigator and all subinvestigators  
• Protocol signature page signed by the investigator  
 
Investigator Statement and Signature:  
I attest that I h ave read this protocol, understand and agree to the provisions of the protocol, and accept 
the responsibilities listed above in my role as principal investigator for the study. 
 
 
Investigator Signature  Date 
  
Investigator Name, Printed  
 
Page 83 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
10 Document History  
 
Protocol Version Effective Date  
Original December 7, 2010  
Amendment 1  December 9, 2010  
Amendment 2  March 10, 2011  
Amendment 3  August 3, 2011  
Amendment 4  January 5, 2012  
Amendment 5  April 9, 2012 (NA)d June 18, 2012 (NNA)d 
Amendment 6a August 31, 201 2 (NA)d October 17, 2012 (NNA)d 
Amendment 7b None (NA)d September 16, 2013 (NNA)d 
Amendment 8c July 25, 2014  
Amendment 8a  PK e November 10, 2015  
Amendment 9  July 10, 2017  
a The North America and Non -North America versions of Amendment 6 were identical , except for minor formatting differences.  
b Only Non -North America Amendment 6 was updated to Amendment 7; see details in Note to File in the CTMF dated 
25 June 2014. 
c Amendment 8 protocol unifies the previous NA and NNA versions. Changes include those from Amend 6 NA and Amend 7 
NNA.  
d NA = North America, NNA = Non -North America  
e Applicable only to sites performing pharmacokinetics evaluations  
 
Page 84 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
11 References  
 
1. Surveillance Epidemiology and End Results Web site. Cancer Statistics. SEER Stat Fact Sheets: N on-Hodgkin 
Lymphoma.  http://seer.cancer.gov/statfacts/html/nhl.html . Accessed on 21 July 2014.  
2. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975 -2006, National Cancer Institute 
web site, Bethesda, MD:  http://seer.cancer.gov/csr/1975_2006/ , based on November 2008 SEER data 
submission, posted to the SEER web site, 2009.  Accessed on 01 July 2014. 
3. Fisher RI1, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. 
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non -
Hodgkin's lymphoma. N Engl J Med 1993 Apr 8;328(14):1002- 6. 
4. Prichard M, Harris  T, Williams ME, Densmore JJ. Treatment strategies for relapsed and refractory aggressive 
non-Hodgkin's lymphoma. Expert Opin Pharmacother 2009 Apr;10(6):983- 95. 
5. Gisselbrecht C, Glass B, Mounier N, et al. R -ICE versus R -DHAP in relapsed patients with CD20 diffuse large 
B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol 
2009;27(suppl abstr 8509):152. 
6. Center for International Blood & Marrow Transplant Research (CIBMTR) web site, accessed on 01 July 2014: 
http://www.cibmtr.org/pages/index.aspx . 
7. Mordente A1, Meucci E, Silvestrini A, Martorana GE, Giardina B. New developments in anthracycline -induced 
cardiotoxicity. Curr Med Chem. 2009;16(13):1656- 72. 
8. Doxorubi cin Prescribing Information. Pfizer Labs, A Division of Pfizer Inc. Sep 2011.  
9. Sissi C, Moro S, Richter S, Gatto B, Menta E, Spinelli S, Krapcho AP, Zunino F, Palumbo M. DNA -interactive 
anticancer aza- anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action. Mol 
Pharmacol 2001 Jan;59(1):96- 103. 
10. Evison BJ, Bilardi RA, Chiu FC, Pezzoni G, Phillips DR, Cutts SM. CpG methylation potentiates pixantrone 
and doxorubicin- induced DNA damage and is a marker of drug sensitivity. Nucleic Acids Res 2009 
Oct;37(19):6355- 70. 
11. Cavalletti E1, Crippa L, Mainardi P, Oggioni N, Cavagnoli R, Bellini O, Sala F. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs 2007 Jun;25(3):187- 95. 
12. Marcus R, Hagenbeek A. The therapeutic use of rituximab in non -Hodgkin's lymphoma. Eur J Haematol Suppl 
2007 Jan;(67):5- 14. 
13. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Fe uring-Buske M, Radford JA, 
Capdeville R, Diehl V, Reyes F. Rituximab (anti -CD20 monoclonal antibody) for the treatment of patients with 
relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998 Sep 15;92(6):1927- 32. 
14. Tobinai K, Igarashi T, Itoh K, Kobayashi Y, Taniwaki M, Ogura M, Kinoshita T, Hotta T, Aikawa K, Tsushita 
K, Hiraoka A, Matsuno Y, Nakamura S, Mori S, Ohashi Y; IDEC -C2B8 Japan Study Group. Japanese 
multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive 
B-cell lymphoma. Ann Oncol 2004 May;15(5):821- 30. 
15. Decaudin D, Marszak FB, Couturier J, Mathiot C, Martin A, Némati F, Lantz O, Santo Jd, Arnaud P, Bordier V, 
Vincent-Salomon A, Poupon MF. High efficacy of combined rituximab and gemcitabine on Epstein -Barr virus -
associated human B -cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice. Anticancer 
Drugs. 2006 Jul;17(6):685- 95. 
16. Chau I, Watkins D, Cunningham D. Gemcitabine and its combinations in the treatment of malignant lymphoma. Clin Lymphoma. 2002 Sep;3(2):97- 104.  
17. Bernell P , Ohm L. Promising activity of gemcitabine in refractory high -grade non -Hodgkin's lymphoma. Br J 
Haematol. 1998 Apr;101(1):203- 4. 
18. Savage DG1, Rule SA, Tighe M, Garrett TJ, Oster MW, Lee RT, Ruiz J, Heitjan D, Keohan ML, Flamm M, 
Johnson SA. Gemcitabine for relapsed  or resistant lymphoma. Ann Oncol 2000 May;11(5):595- 7. 
Page 85 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
19. Fosså A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, Bonadonna G, Seeber S, 
Nowrousian MR. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non -
Hodgkin's lymphoma. J Clin Oncol 1999 Dec;17(12):3786- 92. 
20. Wenger C1, Stern M, Herrmann R, Rochlitz Ch, Pless M. Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma? Leuk Lymphoma. 2005 Jan;46(1): 71-5. 
21. Rothe A, Schulz H, Elter T, Engert A, Reiser M.  Rituximab monotherapy is effective in patients with poor risk 
refractory aggressive non -Hodgkin's lymphoma.  Haematologica. 2004 Jul;89(7):875- 6. 
22. Palacios A, Navarrete M, Gallur L. Retreatment with Rituximab plus chemotherapy in patients with aggressive lymphoma treated previously with CHOP or CHOP -like combinations plus rituximab. Blood (ASH Annual 
Meeting Abstracts) 2006;108:Abstr 4707.  
23. National Comprehensive Cancer Network Clinical Practice Guidelines (NCCN Guidelines): 
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp . Accessed on 30 June 2014.  
24. Morschhauser F1, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, Rule S, Liberati AM, Milpied N, 
Hess G, Stein H, Kalmus J, Marcus R. Efficacy and safety of yttrium -90 ibritumomab tiuxetan in patients with 
relapsed or refractory diffuse large B -cell lymphoma not appropriate for autologous stem -cell transplantation. 
Blood 2007 Jul 1;110(1):54- 8. 
25. Corazzelli G, Capobianco G, Arcamone M, Ballerini PF, Iannitto E, Russo F, Frigeri F, Becchimanzi C, Marcacci G, De Chiara A, Pinto A. Long -term results of gemcitabine plus oxaliplatin with and without 
rituximab as salvage treatment for transplant -ineligible patients with refractory/relapsing B -cell lymphoma. 
Cancer Chemother Pharmacol. 2009 Oct;64(5):907- 16.  
26. Genentech, Inc., 2010. Rituxan Prescribing Inform ation.  
27. Eli Lilly and Company, 2010. Gemzar Prescribing Information.  
28. Cheson B, Pfistner B, Juweid M, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;26(5):579- 85. 
29. Pettengell R1, Coiffier B, Narayanan G, de Mendoza FH, Digumarti  R, Gomez H, Zinzani PL, Schiller G, 
Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. Pixantrone dimaleate versus other chemotherapeutic agents as a single -agent salvage treatment in patients with  relapsed or refractory 
aggressive non- Hodgkin lymphoma: a phase 3, multicentre, open -label, randomised trial. Lancet Oncol. 2012 
Jul;13(7):696- 706. 
30. A predictive model for aggressive non -Hodgkin's lymphoma. The International Non -Hodgkin's Lymphoma 
Prognostic Factors Project. N Engl  J Med 1993 Sep 30;329(14):987- 94. 
31. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982 Dec;5(6):649- 55. 
32. Carbone PP, Kaplan HS, Musshoff K , Smithers DW, Tubiana M. Report of the Committee on Hodgkin's 
Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860- 1. 
33. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart an d great vessels. 9th Ed., Boston, Mass: Little, Brown & Co; 1994:253- 6. 
 
Page 86 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
12 Addendum: Pharmacokinetics Sub-Study 
 
Previously, the pharmacokinetics (PK) of pixantrone was assessed in patients with malignancy when 
pixantrone wa s given alone or in combination w ith multiple chemotherapeutic agents (see Investigator’s 
Brochure) , but not in combination with rituximab.  This sub-study is designed to provide additional 
information regarding the PK of pixantrone when administered as a single agent in combination with rituximab. 
 
Approximately 20 sites have been selected to participate in this sub-study, and were identified based on 
their qualifications, experience  in collecting samples for PK analysis, and willingness to participate  in the 
sub-study.  The goal is to enroll approximately 20 patients into the PK sub-study. 
  
12.1 Background  
 
As shown in studies to date, clinical PK of pixantrone is linear over a wide dose range.  Pixantrone has a 
large volume of distribution (eg, V
ss, approx. 15–20 L/kg), a high systemic clea rance (CL, approx.  
1 L/h/kg), and a relatively long terminal elimination half -life (t½,z, approx. 20 hours).  Biliary excretion 
appears to be the major route of systemic clearance for pixantrone.  Modest amounts of phase I metabolites were produced by side-chain cyclization and N-dealkylation.  Two monoacetylated 
metabolites have also been observed.  Renal excretion is a minor route of drug elimination (<10%).   
 
A comprehensive population PK analysis was also conducted , using PK data from six phase 1 studi es  
(139 patients) following single or multiple dose administrations.  Covariates that were tested included 
age, sex, body weight, calculated creatinine clearance (CL
CR), concomitant antiemetic medication, total 
bilirubin, race, and body surface area (BSA) .  Across the full dose range in the clinical program, clearance 
was nearly proportional to BSA, suggesting that dosing according to BSA appropriately normalizes 
exposures (see Investigator’s Brochure).  
 
The recommended monotherapy dose of pixantrone is 50 mg/m2 pixantrone base form (equivalent to 85 
mg/m2 pixantrone dimaleate), given on Days 1, 8, and 15 of up to six 28-day cycles.  In the present study 
(PIX306), patients are randomized to the combination of gemcitabine plus rituximab, or pixantrone plus 
rituximab for up to 6 cycles, with rituximab co-administered on Day 1 of each 28- day cycle.   
 
12.2 Objective of Pharmacokinetics Sub -Study  
 
Objective : To characterize the PK profile of pixantrone when co-administered with rituximab.  
 
The PK sub-study of this trial (PIX306) is being conducted to characterize the pharmacokinetics of 
pixantrone in patients also receiving rituximab.  These data will complement the pharmacokinetic results 
collected to date for pixantrone, provide a reference set of pharmacokinetic parameters in patients treated 
with the combinat ion of pixantrone and rituximab and support the assumption that pixantrone PK is not 
influenced by rituximab co- administration .  Rituximab is co-administered with pixantrone on Day 1 of 
each 28-day cycle; therefore, plasma samples for PK analysis (7 samples) will be collected relative to the 
Day 1 dose of pixantrone in one of the six treatment cycles for each participating patient.  
Page 87 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
12.3 Pharmacokinetics Sub-Study Population  
 
PK Sub-Study Inclusion Criteria  
 
• Patient must have been randomized to the PIX306 pixantrone + rituximab arm at a participating 
clinical site. Patients newly randomized or already randomized in the pixantrone group can be 
included.  
• Patients must be willing to participate in the PK sub -study and cooperate with the PK sampling 
schedule, as described in the written consent for participation in the sub -study. 
 Patient enrollment in the PK sub study will commence upon approval of this PIX306 amendment and will 
continue until the sub- study accrual go al of approximately 20 patients is reached or the PIX306 study 
accrual ceases, whichever comes first (see Section  12.6 for discussion of sample size).   
 Patients already randomized at the time this amendment is initiated can also participate in the PK sub -
study, provided that one or more 28-day cycles remain to be completed, and after providing informed consent.   
 
12.4 Pharmacokinetics Sub-Study Assessment  
 
Seven blood samples (up to 10 mL/sample) for PK assessment will be collected into lithium heparinized 
polypropylene tubes per the table in Section 12.4.1 on Day 1 in one of the six treatment cycles.  When possible, complete the PK sampling during cycle 1 or 2. 
 
Patients must have successfully received their dose of rituximab prior to pixantrone infusion for post -
infusion PK samples to be obtained.  
 
12.4.1  PK Sampling  Schedule  
 
Collect PK samples only when rituximab has been administered on Day 1 prior to pixantrone, per  Section 3.4.  The sampling schedule for the study is provided below; plasma samples are to be collected at 
the indicated nominal time points relative to the initiation of the pixantrone infusion .  Refer to Table--14 
for the collection r egimen. 
 
Table--14 Sample Collection Times for Pharmacokinetic Evaluation  
 
Sample 
Number Nominal Sample Time  Collection Window  
1 Prior to start of pixantrone infusion  Within 1 hour of initiation of infusion  
2 1 hour after start o f pixantrone infusion  Within 10 minutes after the end of infusion  
3 1.5 hours after start of pixantrone infusion  ±10 minutes  
4 2 hours after start of pixantrone infusion  ±10 minutes  
5 4 hours after start of pixantrone infusion  ±30 minutes  
6 6 hours aft er start of pixantrone infusion  ±1 hour 
7 24–48 hours after start of pixantrone infusion   
 
Page 88 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
12.4.2  Adverse Events During PK Sampling 
 
Adverse events associated with blood sampling for this PIX306 PK evaluation will be collected and 
reported consistent with Secti on 3.10.1 of the protocol.  
 
12.5 Sample Collection and Handling Procedures  
 
Plasma samples for measurement of pixantrone are to be collected, processed and shipped according to 
the PK Plasma Sample Handling and Collection Manual  (provided separately) .  Samples will be 
subsequently analyzed for pixantrone levels according to a validated bioanalytical assay method.  All samples collected will be shipped to the PK laboratory, even if sampling is incomplete and/or rescheduled.  
 The treatment cycle, nominal sample times, date, and 24 -hour actual collection times for each sample will 
be recorded on the case report form.  The start and end times of the infusion will be separately recorded in the case report form.  
 
Sample Rescheduling  
 
Ideally, PK sampling should occur in the earliest possible treatment cycle.  However, PK sampling should 
be rescheduled or repeated for a subsequent cycle if any of the below events occur:  
 
• Rituximab was not administered prior to pixantrone 
• Pixantrone infusion is not administered per protocol, including, but not limited to, such deviations as 
interrupted infusion, infiltrated infusion, and infusion that does not occur in the protocol- specified 
time frame (1 hour ±10 minutes). 
• Significant and acute changes are noted in predose liver function tests or general medical condition on the day of dosing, as compared to their screening baseline.  In case of study site questions about this 
criterion, the unblinded medical monitor should be consulted for answers and decision- making.  
(Unblinded medical monitor will notify the CTI PIX306 pharmacokineticist in a blinded fashion.)  
• A clinical event occurs that interferes with proper collection of samples.  
 
All samples collected will be shipped to the PK laborato ry, even if sampling is incomplete and/or 
rescheduled.   
12.6 PK Analysis 
 
This amendment is being initiated after a significant number of patients have already been enrolled in the 
PIX 306 study, but before the efficacy and safety results have been analyzed.  The goal is to enroll 
approximately 20 patients receiving pixantrone into the PK sub-study.  This sample size is considered 
clinically reasonable to obtain estimates of PK parameters of pixantrone when co -administered with 
rituximab, to supplement currentl y available PK analyses.  
 The PK sample analysis will be performed by Atlanbio (St. Nazaire, France) using a validated analytical 
method.  Additionally, using the bioanalytical data provided by Atlanbio and clinical covariate data from the study database, Quantitative Solutions (Certara, Princeton, NJ, USA) will be used to supplement the 
population analyses that were previously conducted (see  Section 12.1) and examin e the impact of 
coadministration of rituximab w ith pixantrone on PK parameters in the population model.  
 
Page 89 of 90 
CTI BioPharma Corp.  
PIX306 Protocol Amendment 9 
10 July 2017  
Descriptive statistics (n, mean, standard deviation (SD), median, minimum, maximum) of blood 
concentrations of pixantrone will be performed at each nominal time point. 
 
A population modeling approach will be used to describe the PK of pixantrone. In a first stage, the 
individual concentration-time profiles of patients will be compared to existing data using the model 
previously developed.  This will be done by simulations (Visual Predictive Checks).  Then, in a second stage, the model will be used to generate individual secondary PK parameters (eg, exposure, half -life etc.) 
of patients with relapsed, aggressive B -cell NHL receiving pixantrone in association with rituximab.  To 
do that, for each subje ct, due to the sparse sampling time design (ie, 7 blood samples), a compartmental 
analysis will be first performed on the individual concentration-time data, using the population PK model previously developed, to provide individual predicted PK profiles si mulated with a rich sampling time 
design (step 1).  Second (step 2), a non- compartmental analysis (NCA) will be performed on the predicted 
PK obtained by the Bayesian approach in step 1.  The following parameters will be determined in plasma, as well as ot hers, as deemed appropriate: Cinf (concentration at the end of the infusion), AUC0-24, t1/2, 
z, CL, Ke Vss and Vz.  Descriptive statistics will be performed on the plasma concentrations and on the pharmacokinetic parameters of pixantrone.   
 12.7 Pharmacokine tics Sub-Study Ethical Considerations  
 
This amendment and specific procedures for the PK sub -study will be included in a properly constituted 
supplemental informed consent to be reviewed and approved by the respective Institutional Review Board/Ethics Committee responsible for those sites agreeing to enroll patients into the PK sub-study. 
Informed consent for the sub-study will be obtained only from patients eligible for (randomized to pixantrone plus rituximab treatment arm) and willing to participate in the  PK sub-study.  
  
Page 90 of 90 